{"id":"osimertinib","rwe":[],"_fda":{"id":"b4ae37b4-12de-4824-9b06-833e0f18fd38","set_id":"5e81b4a7-b971-45e1-9c31-29cea8c87ce7","openfda":{"nui":["N0000175605","N0000175082","N0000190114","N0000185506","N0000191266","N0000190113"],"unii":["3C06JJ0Z2O"],"route":["ORAL"],"rxcui":["1721565","1721571","1721581","1721583"],"spl_id":["b4ae37b4-12de-4824-9b06-833e0f18fd38"],"brand_name":["TAGRISSO"],"spl_set_id":["5e81b4a7-b971-45e1-9c31-29cea8c87ce7"],"package_ndc":["0310-1349-30","0310-1350-30","0310-1350-95","0310-1248-30","0310-1251-30"],"product_ndc":["0310-1248","0310-1349","0310-1350","0310-1251"],"generic_name":["OSIMERTINIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["OSIMERTINIB"],"pharm_class_epc":["Kinase Inhibitor [EPC]"],"pharm_class_moa":["Kinase Inhibitors [MoA]","Cytochrome P450 3A Inhibitors [MoA]","Cytochrome P450 3A4 Inducers [MoA]","Cytochrome P450 1A2 Inducers [MoA]","Breast Cancer Resistance Protein Inhibitors [MoA]"],"manufacturer_name":["AstraZeneca Pharmaceuticals LP"],"application_number":["NDA208065"],"is_original_packager":[true]},"version":"35","pregnancy":["8.1 Pregnancy Risk Summary Based on data from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , TAGRISSO can cause fetal harm when administered to a pregnant woman. There are no available data on TAGRISSO use in pregnant women. Administration of osimertinib to pregnant rats was associated with embryolethality and reduced fetal growth at plasma exposures 1.5 times the exposure at the recommended clinical dose (see Data ) . Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data When administered to pregnant rats prior to embryonic implantation through the end of organogenesis (gestation days 2-20) at a dose of 20 mg/kg/day, which produced plasma exposures of approximately 1.5 times the clinical exposure, osimertinib caused post-implantation loss and early embryonic death. When administered to pregnant rats from implantation through the closure of the hard palate (gestation days 6 to 16) at doses of 1 mg/kg/day and above (0.1 times the AUC observed at the recommended clinical dose of 80 mg once daily), an equivocal increase in the rate of fetal malformations and variations was observed in treated litters relative to those of concurrent controls. When administered to pregnant dams at doses of 30 mg/kg/day during organogenesis through lactation Day 6, osimertinib caused an increase in total litter loss and postnatal death. At a dose of 20 mg/kg/day, osimertinib administration during the same period resulted in increased postnatal death as well as a slight reduction in mean pup weight at birth that increased in magnitude between lactation days 4 and 6."],"description":["11 DESCRIPTION Osimertinib is a kinase inhibitor for oral use. The molecular formula for osimertinib mesylate is C 28 H 33 N 7 O 2 •CH 4 O 3 S, and the molecular weight is 596 g/mol. The chemical name is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide mesylate salt. Osimertinib has the following structural formula (as osimertinib mesylate): TAGRISSO tablets contain 40 or 80 mg of osimertinib, equivalent to 47.7 and 95.4 mg of osimertinib mesylate, respectively. Inactive ingredients in the tablet core are mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and sodium stearyl fumarate. The tablet coating consists of polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, ferric oxide yellow, ferric oxide red and ferric oxide black. chem_structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 80 mg tablets: beige, oval and biconvex tablet marked with “AZ 80” on one side and plain on the reverse and are available in bottles of 30 (NDC 0310-1350-30). 40 mg tablets: beige, round and biconvex tablet marked with “AZ 40” on one side and plain on the reverse and are available in bottles of 30 (NDC 0310-1349-30). Store TAGRISSO bottles at 25°C (77°F). Excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]."],"geriatric_use":["8.5 Geriatric Use Monotherapy Of the 1813 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive NSCLC who were treated with TAGRISSO monotherapy, 770 patients were ≥65 years and 207 patients were ≥75 years of age [see Adverse Reactions (6.1) ] . Exploratory analysis suggests a higher incidence of Grade 3 or higher adverse reactions (43% vs 33%) and more frequent dosage modifications for adverse reactions (34% vs 23%) in patients 65 years or older as compared to those younger than 65 years. No overall differences in safety or effectiveness were observed between patients 65 years or older and younger patients. TAGRISSO Following Definitive Platinum-based Chemoradiation Therapy Of the 142 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive, locally advanced unresectable (Stage III) NSCLC treated with TAGRISSO following definitive platinum-based chemoradiation therapy, 62 patients were ≥65 years and 13 patients were ≥75 years of age [see Adverse Reactions (6.1)]. No overall differences in safety or effectiveness were observed between patients 65 years or older and younger patients. TAGRISSO in Combination with Pemetrexed and Platinum-based Chemotherapy Of the 276 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive, locally advanced or metastatic NSCLC treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, 104 patients were ≥65 years and 23 patients were ≥75 years of age [see Adverse Reactions (6.1) ] . Exploratory analysis suggests a higher incidence of Grade 3 or higher adverse reactions (68% vs 61%) and more frequent dosage modifications for adverse reactions (55% vs 43%) in patients 65 years or older as compared to those younger than 65 years. Clinical studies of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of TAGRISSO in pediatric patients have not been established."],"effective_time":"20240925","clinical_studies":["14 CLINICAL STUDIES 14.1 Adjuvant Treatment of Early-Stage EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) The efficacy of TAGRISSO was demonstrated in a randomized, double-blind, placebo-controlled trial (ADAURA [NCT02511106]) for the adjuvant treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC who had complete tumor resection, with or without prior adjuvant chemotherapy. Eligible patients with resectable tumors (stage IB – IIIA according to American Joint Commission on Cancer [AJCC] 7 th edition) were required to have predominantly non-squamous histology and EGFR exon 19 deletions or exon 21 L858R mutations identified prospectively from tumor tissue in a central laboratory by the cobas ® EGFR Mutation Test. Patients with clinically significant uncontrolled cardiac disease, prior history of ILD/pneumonitis, or who received treatment with any EGFR kinase inhibitor were not eligible for the study. Patients were randomized (1:1) to receive TAGRISSO 80 mg orally once daily or placebo following recovery from surgery and standard adjuvant chemotherapy if given. Patients who did not receive adjuvant chemotherapy were randomized within 10 weeks and patients who received adjuvant chemotherapy were randomized within 26 weeks following surgery. Randomization was stratified by mutation type (exon 19 deletions or exon 21 L858R mutations), race (Asian or non-Asian) and pTNM staging (IB or II or IIIA) according to AJCC 7 th edition. Treatment was given for 3 years or until disease recurrence, or unacceptable toxicity. The major efficacy outcome measure was disease-free survival (DFS, defined as reduction in the risk of disease recurrence or death) in patients with stage II – IIIA NSCLC determined by investigator assessment. Additional efficacy outcome measures included DFS in the overall population (patients with stage IB – IIIA NSCLC), and overall survival (OS) in patients with stage II – IIIA NSCLC and in the overall population. A total of 682 patients were randomized to TAGRISSO (n=339) or placebo (n=343). The median age was 63 years (range 30-86 years); 70% were female; 64% were Asian and 72% were never smokers. Baseline World Health Organization (WHO) performance status was 0 (64%) or 1 (36%); 31% had stage IB, 35% II, and 34% IIIA. With regard to EGFR mutation status, 55% were exon 19 deletions and 45% were exon 21 L858R mutations. The majority (60%) of patients received adjuvant chemotherapy prior to randomization (27% IB; 70% II, 79% IIIA). ADAURA demonstrated a statistically significant difference in DFS for patients treated with TAGRISSO compared to patients treated with placebo. The final analysis of OS demonstrated a statistically significant improvement in OS for patients treated with TAGRISSO compared to patients treated with placebo. Median OS was not reached in either arm. In the overall population (IB-IIIA), the median follow-up time was 61.5 months in both treatment arms. Efficacy results from ADAURA are summarized in Table 14 and Figures 1 and 2, respectively. Table 14. Efficacy Results in ADAURA according to Investigator Assessment STAGE II-IIIA POPULATION STAGE IB-IIIA POPULATION Efficacy Parameter TAGRISSO (N=233) PLACEBO (N=237) TAGRISSO (N=339) PLACEBO (N=343) Disease-Free Survival (DFS) DFS events (%) 26 (11) 130 (55) 37 (11) 159 (46) Recurrent disease (%) 26 (11) 129 (54) 37 (11) 157 (46) Deaths (%) 0 1 (0.4) 0 2 (0.6) Median DFS, months (95% CI) NR (38.8, NE) 19.6 (16.6, 24.5) NR (NE, NE) 27.5 (22.0, 35.0) Hazard ratio (95% CI) Stratified by race (Asian vs other races), mutation status (Ex19del vs L858R), and pTNM staging. Pike estimator. 0.17 (0.12, 0.23) 0.20 (0.15, 0.27) p-value Stratified log-rank test. <0.0001 <0.0001 Overall Survival (OS) Number of deaths (%) 35 (15) 65 (27) 42 (12) 82 (24) Hazard Ratio (95% CI) 0.49 (0.33, 0.73) 0.49 (0.34, 0.70) p-value 0.0004 <0.0001 DFS results based on investigator assessment. CI=Confidence Interval; NE=Not Estimable; NR=Not Reached Figure 1. Kaplan-Meier Curves of Disease-Free Survival (Overall Population) by Investigator Assessment in ADAURA Figure 2. Kaplan-Meier Curves of Overall Survival (Overall Population) in ADAURA In an exploratory analysis of site(s) of relapse, the proportion of patients with CNS involvement at the time of disease recurrence was 5 patients (1.5%) on the TAGRISSO arm and 34 patients (10%) on the placebo arm. Figure_1 Figure_2 14.2 Locally Advanced, Unresectable (Stage III) EGFR Mutation Positive NSCLC The efficacy of TAGRISSO was evaluated in the LAURA trial [NCT03521154], a double blind, randomized, placebo-controlled study in adult patients with locally advanced, unresectable stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations whose disease had not progressed during or following definitive platinum-based chemoradiation therapy. Eligible patients were randomized within 42 days prior to study randomization and had a WHO performance status of 0 or 1. Prior to study enrollment, patients received concurrent chemoradiation therapy (cCRT) or sequential chemoradiation therapy (sCRT) regimens, where at least 2 cycles every 3 weeks or 5 doses of weekly platinum-based chemotherapy and definitive radiation were to be completed ≤6 weeks prior to randomization. The study excluded patients who had progressive disease during or following definitive chemoradiation therapy and patients with Grade ≥2 pneumonitis after chemoradiation therapy or any ILD prior to chemoradiation therapy. Patient tumor tissue samples were required to have an EGFR exon 19 deletion or exon 21 L858R mutation, as identified by the cobas® EGFR Mutation Test v2 in a central laboratory or by an FDA-approved test at a CLIA certified or accredited laboratory. Patients were randomized (2:1) to receive either TAGRISSO 80 mg orally once daily or placebo until disease progression or unacceptable toxicity. Randomization was stratified by prior chemoradiation strategy (cCRT vs sCRT), tumor staging prior to chemoradiation (IIIA vs IIIB/IIIC), and by region (China versus rest of the world). Post progression, all patients were offered open label TAGRISSO if, in the opinion of the treating healthcare provider, there was an expected clinical benefit. Tumor assessments were performed every 8 weeks until week 48, and then every 12 weeks. The major efficacy outcome measure was progression free survival (PFS) as assessed by blinded independent central review (BICR). Additional efficacy outcome measures included OS and CNS PFS. A total of 216 patients were randomized (2:1) to TAGRISSO (n=143) or placebo (n=73). The study population characteristics were: median age 63 years (range 36-84 years); 13% ≥75 years old; 61% female; 82% Asian, 14% White, 1.4% American Indian or Alaska Native and 2.3% had reported race as other; 6% were Hispanic or Latino; and 70% were never smokers. Baseline WHO performance status was 0 (51%) or 1 (49%); 35% of patients had stage IIIA, 49% of patients had stage IIIB and 16% of patients had stage IIIC NSCLC; 4% had squamous and 96% had non-squamous histology; 54% had exon 19 deletions and 45% had exon 21 L858R mutations. Prior to randomization, 89% of patients received cCRT and 11% of patients received sCRT. All patients received platinum-based chemotherapy (55% carboplatin-based chemotherapy and 44% cisplatin-based chemotherapy). The median total dose of radiation was 60 Gy for patients in both arms. LAURA demonstrated a statistically significant improvement in PFS for patients randomized to TAGRISSO as compared to placebo. Efficacy results from LAURA are summarized in Table 15, and the Kaplan-Meier curve for PFS is shown in Figure 3. While OS results were immature at the current analysis, with 36% of pre-specified deaths for the final analysis reported, no trend towards a detriment was observed. Table 15. Efficacy Results in LAURA Efficacy Parameter TAGRISSO (N=143) Placebo (N=73) Progression-Free Survival PFS events (%) 57 (40) 63 (86) Progressive disease (%) 53 (37) 62 (85) Death Without documented radiological disease progression. (%) 4 (3) 1 (1) Median PFS in months (95% CI) 39.1 (31.5, NE) 5.6 (3.7, 7.4) Hazard Ratio (95% CI) Stratified by disease stage prior to chemotherapy (IIIA vs IIIB/IIIC). Pike estimator. 0.16 (0.10, 0.24) p-value Stratified log-rank test. <0.001 Overall Response Rate Confirmed responses. ORR, % (95% CI) 54 (45, 62) 26 (17, 38) CI=Confidence Interval, NE=Not Estimable PFS and ORR results as assessed by BICR. Figure 3. Kaplan-Meier Curves of PFS as assessed by BICR in LAURA All patients underwent magnetic resonance imaging (MRI) brain scans at baseline and at each follow-up during the study. In an exploratory analysis of site(s) of relapse, the proportion of patients with new CNS lesions at the time of disease progression was 17/143 patients (12%) on the TAGRISSO arm and 26/73 patients (36%) on the placebo arm. Figure_3.jpg 14.3 Previously Untreated EGFR Mutation-Positive Metastatic NSCLC FLAURA – TAGRISSO Monotherapy The efficacy of TAGRISSO was demonstrated in a randomized, multicenter, double-blind, active-controlled trial (FLAURA [NCT02296125]) in patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive, metastatic NSCLC, who had not received previous systemic treatment for metastatic disease. Patients were required to have measurable disease per RECIST v1.1, a WHO performance status of 0-1, and EGFR exon 19 deletions or exon 21 L858R mutation in tumor prospectively identified by the cobas ® EGFR Mutation Test in a central laboratory or by an investigational assay at a CLIA-certified or accredited laboratory. Patients with CNS metastases not requiring steroids and with stable neurologic status for at least two weeks after completion of definitive surgery or radiotherapy were eligible. Patients were assessed at the investigator’s discretion for CNS metastases if they had a history of, or suspected, CNS metastases at study entry. Patients were randomized (1:1) to receive TAGRISSO 80 mg orally once daily or to receive gefitinib 250 mg orally once daily or erlotinib 150 mg orally once daily until disease progression or unacceptable toxicity. Randomization was stratified by EGFR mutation type (exon 19 deletions or exon 21 L858R mutation) and ethnicity (Asian or non-Asian). Patients randomized to the control arm were offered TAGRISSO at the time of disease progression if tumor samples tested positive for the EGFR T790M mutation. The major efficacy outcome measure was progression-free survival (PFS), as assessed by investigator. Additional efficacy outcome measures included OS and overall response rate (ORR). A total of 556 patients were randomized to TAGRISSO (n=279) or to control (gefitinib n=183; erlotinib n=94). The median age was 64 years (range 26-93 years); 54% were <65 years of age; 63% were female; 62% were Asian and 64% were never smokers. Baseline WHO performance status was 0 (41%) or 1 (59%); 5% had Stage IIIb and 95% had Stage IV; and 7% received prior systemic cytotoxic chemotherapy as neoadjuvant or adjuvant therapy. With regard to EGFR tumor testing, 63% were exon 19 deletions and 37% were exon 21 L858R; 5 patients (<1%) also had a concomitant de novo T790M mutation. EGFR mutation status was confirmed centrally using the cobas ® EGFR Mutation Test in 90% of patients. At the time of the final data cut-off, of those randomized to TAGRISSO and to investigator’s choice erlotinib or gefitinib arm, 133 (48%) and 180 (65%) patients had received at least one subsequent treatment, respectively. Out of the 180 patients randomized to erlotinib or gefitinib who received subsequent treatment, 85 (47%) patients received TAGRISSO as first subsequent therapy. FLAURA demonstrated a statistically significant improvement in PFS for patients randomized to TAGRISSO as compared to erlotinib or gefitinib (see Table 16 and Figure 4). The final analysis of overall survival demonstrated a statistically significant improvement in overall survival in patients randomized to TAGRISSO compared to erlotinib or gefitinib (see Table 17 and Figure 5). Table 16. Efficacy Results in FLAURA according to Investigator Assessment Efficacy Parameter TAGRISSO (N=279) EGFR TKI (gefitinib or erlotinib) (N=277) Progression-Free Survival (PFS) PFS events (%) 136 (49) 206 (74) Progressive disease (%) 125 (45) 192 (69) Death Without documented radiological disease progression. (%) 11 (4) 14 (5) Median PFS in months (95% CI) 18.9 (15.2, 21.4) 10.2 (9.6, 11.1) Hazard Ratio (95% CI) Stratified by ethnicity (Asian vs Other races) and mutation status (Ex19del vs L858R). , Pike estimator. 0.46 (0.37, 0.57) p-value , Stratified log-rank test. <0.0001 Overall Survival (OS) Number of deaths (%) 155 (56) 166 (60) Median OS in months (95% CI) 38.6 (34.5, 41.8) 31.8 (26.6, 36.0) Hazard Ratio (95% CI) , 0.80 (0.64, 1.00) p-value , 0.0462 Overall Response Rate (ORR) Confirmed responses. ORR, % (95% CI) 77 (71, 82) 69 (63, 74) Complete response, % 2 1 Partial response, % 75 68 Duration of Response (DoR) Median in months (95% CI) 17.6 (13.8, 22.0) 9.6 (8.3, 11.1) Figure 4. Kaplan-Meier Curves of PFS by Investigator Assessment in FLAURA In a supportive analysis of PFS according to blinded independent central review (BICR), median PFS was 17.7 months in the TAGRISSO arm compared to 9.7 months in the EGFR TKI comparator arm (HR=0.45; 95% CI: 0.36, 0.57). Figure 5. Kaplan-Meier Curves of Overall Survival in FLAURA Of 556 patients, 200 patients (36%) had baseline brain scans reviewed by BICR; this included 106 patients in the TAGRISSO arm and 94 patients in the investigator choice of EGFR TKI arm. Of these 200 patients, 41 had measurable CNS lesions per RECIST v1.1. Results of pre-specified exploratory analyses of CNS ORR and duration of response (DoR) by BICR in the subset of patients with measurable CNS lesions at baseline are summarized in Table 17. Table 17. CNS ORR and DOR by BICR in Patients with Measurable CNS Lesions at Baseline in FLAURA TAGRISSO N=22 EGFR TKI (gefitinib or erlotinib) N=19 CNS Tumor Response Assessment According to RECIST v1.1. Based on confirmed response. CNS ORR, % (95% CI) 77 (55, 92) 63 (38, 84) Complete response, % 18 0 CNS Duration of Response Based on patients with response only; DoR defined as the time from the date of first documented response (complete response or partial response) until progression or death event. Number of responders 17 12 Response Duration ≥6 months, % 88 50 Response Duration ≥12 months, % 47 33 Figure_4 Figure_5.jpg 14.4 Previously Untreated EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC FLAURA2 – TAGRISSO in Combination with Pemetrexed and Platinum-based Chemotherapy The efficacy of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]) in patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive locally advanced or metastatic NSCLC, who had not received previous systemic treatment for advanced disease. Patients were required to have measurable disease per RECIST v1.1, a WHO performance status of 0-1, and EGFR exon 19 deletions or exon 21 L858R mutations as identified by the cobas ® EGFR Mutation Test v2 performed prospectively in tissue samples in a central laboratory or by a local test performed in a CLIA-certified or accredited laboratory. Patients were randomized (1:1) to one of the following treatment arms: • TAGRISSO (80 mg) orally once daily with pemetrexed (500 mg/m 2 ) and investigator’s choice of cisplatin (75 mg/m2) or carboplatin (AUC5) administered intravenously on Day 1 of 21-day cycles for 4 cycles, followed by TAGRISSO (80 mg) orally once daily and pemetrexed (500 mg/m 2 ) administered intravenously every 3 weeks • TAGRISSO (80 mg) orally once daily Randomization was stratified by race (Chinese/Asian, Other races except-Chinese/Asian or other races), WHO performance status (0 or 1), and method for tissue testing (central or local). Patients received study therapy until intolerance to therapy, or the investigator determined that the patient was no longer experiencing clinical benefit. Progression-free survival, as assessed by investigator per RECIST 1.1 was the primary efficacy outcome measure. Overall survival was a key secondary outcome measure. Additional efficacy outcome measures included ORR and DoR. A total of 557 patients were randomized to either TAGRISSO in combination with pemetrexed and platinum-based chemotherapy (n=279) or TAGRISSO monotherapy (n=278). The median age was 61 years (range 26-85 years); 39% were ≥65 years and 8% were ≥75 years of age; 61% were female; 64% were Asian and 66% were never smokers. Baseline WHO PS was 0 (37%) or 1 (63%); 4% had locally advanced and 96% had metastatic NSCLC; and 1.8% received prior systemic cytotoxic chemotherapy as neoadjuvant or adjuvant therapy. With regard to EGFR tumor testing, 61% of tumors had exon 19 deletions and 38% had exon 21 L858R mutations; 0.7% of patients had tumors with both exon 19 deletions and exon 21 L858R. EGFR mutation status was centrally confirmed using the cobas ® EGFR Mutation Test v2 in 96% of patients. FLAURA2 demonstrated a statistically significant improvement in PFS for patients randomized to TAGRISSO in combination with pemetrexed and platinum-based chemotherapy as compared to TAGRISSO monotherapy (see Table 18 and Figure 6). While OS results were immature at the current analysis, with 45% of pre-specified deaths for the final analysis reported, no trend towards a detriment was observed. Table 18. Efficacy Results in FLAURA2 according to Investigator Assessment Efficacy Parameter TAGRISSO with pemetrexed and platinum-based chemotherapy (N=279) TAGRISSO (N=278) Progression-Free Survival (PFS) PFS and ORR results by BICR were consistent with those reported via investigator assessment. PFS events (%) 120 (43) 166 (60) Progressive disease (%) 95 (34) 158 (57) Death Without documented radiological disease progression (%) 25 (9) 8 (2.9) Median PFS in months (95% CI) 25.5 (24.7, NE) 16.7 (14.1, 21.3) Hazard Ratio (95% CI) Stratified by race (Chinese/Asian, -Other races except Chinese/Asian vs other races), WHO performance status (0 or 1) and method of tissue testing (central or local). Pike estimator. 0.62 (0.49, 0.79) p-value Stratified log-rank test. <0.0001 Overall Response Rate (ORR) Confirmed responses. ORR, % (95% CI) 77 (71, 82) 69 (63, 74) Complete response, % 0.4 0.4 Partial response, % 76 68 Duration of Response (DoR) Median in months (95% CI) 24.9 (22.1, NE) 17.9 (15.2, 20.9) NE=Not Estimable; NR=Not Reached Figure 6. Kaplan-Meier Curves of PFS by Investigator Assessment in FLAURA2 All patients had available baseline brain scans reviewed by BICR using modified RECIST; 78/557 (14%) patients had CNS measurable lesions. Results of pre-specified exploratory analyses of CNS ORR and DoR by BICR are summarized in Table 19. Table 19. Exploratory Analysis – CNS Efficacy by BICR in Patients with CNS Metastases on a Baseline Brain Scan in FLAURA2 Efficacy Parameter CNS Measurable Lesions TAGRISSO with pemetrexed and platinum-based chemotherapy (N=40) TAGRISSO (N=38) CNS Tumor Response Assessment According to RECIST v1.1. Based on confirmed response. CNS ORR, % (95% CI) 80 (64, 91) 76 (60, 89) Complete response, % 48 16 Partial response, % 33 61 CNS Duration of Response Based on patients with response only; DoR defined as the time from the date of first documented response (complete response or partial response) until progression or death event. Number of responders 32 29 Response Duration ≥6 months, % 75 50 Response Duration ≥12 months, % 65 34 Figure_6.jpg 14.5 Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC The efficacy of TAGRISSO was demonstrated in a randomized, multicenter open-label, active-controlled trial in patients with metastatic EGFR T790M mutation-positive NSCLC who had progressed on prior systemic therapy, including an EGFR TKI (AURA3) [NCT02151981]. All patients were required to have EGFR T790M mutation-positive NSCLC identified by the cobas ® EGFR Mutation Test performed in a central laboratory prior to randomization. A total of 419 patients were randomized 2:1 to receive TAGRISSO (n=279) or platinum-based doublet chemotherapy (n=140). Randomization was stratified by ethnicity (Asian vs non-Asian). Patients in the TAGRISSO arm received TAGRISSO 80 mg orally once daily until intolerance to therapy, disease progression, or investigator determination that the patient was no longer benefiting from treatment. Patients in the chemotherapy arm received pemetrexed 500 mg/m 2 with carboplatin AUC5 or pemetrexed 500 mg/m 2 with cisplatin 75 mg/m 2 on Day 1 of every 21-day cycle for up to 6 cycles. Patients whose disease had not progressed after four cycles of platinum-based chemotherapy could have received pemetrexed maintenance therapy (pemetrexed 500 mg/m 2 on Day 1 of every 21-day cycle). The major efficacy outcome measure was PFS according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) by investigator assessment. Additional efficacy outcome measures included ORR, DoR, and OS. Patients randomized to the chemotherapy arm who had radiological progression according to both investigator and BICR were permitted to cross over to receive treatment with TAGRISSO. The baseline demographic and disease characteristics of the overall trial population were: median age 62 years (range: 20-90 years), ≥75 years old (15%), female (64%), White (32%), Asian (65%), never smoker (68%), WHO performance status 0 or 1 (100%). Fifty-four percent (54%) of patients had extra-thoracic visceral metastases, including 34% with central nervous system (CNS) metastases (including 11% with measurable CNS metastases) and 23% with liver metastases. Forty-two percent (42%) of patients had metastatic bone disease. In AURA3, there was a statistically significant improvement in PFS in the patients randomized to TAGRISSO compared to chemotherapy (see Table 20 and Figure 7). No statistically significant difference was observed between the treatment arms at final OS analysis. At the time of the final OS analysis, 99 patients (71%) randomized to chemotherapy had crossed over to TAGRISSO treatment. Table 20. Efficacy Results According to Investigator Assessment in AURA3 Efficacy Parameter TAGRISSO (N=279) Chemotherapy (N=140) Progression-Free Survival Number of events (%) 140 (50) 110 (79) Progressive disease (%) 129 (46) 104 (74) Death Without documented radiological disease progression. (%) 11 (4) 6 (4) Median PFS in months (95% CI) 10.1 (8.3, 12.3) 4.4 (4.2, 5.6) Hazard Ratio (95% CI Stratified by ethnicity (Asian vs other races). Pike estimator. ) 0.30 (0.23,0.41) p-value Stratified log-rank test. <0.001 Overall Survival Number of deaths (%) 188 (67) 93 (66) Median OS in months (95% CI) 26.8 (23.5, 31.5) 22.5 (20.2, 28.8) Hazard Ratio (95% CI) 0.87 (0.67, 1.12) p-value 0.277 Overall Response Rate Confirmed responses. ORR, % (95% CI) 65 (59, 70) 29 (21, 37) Complete response, % 1 1 Partial response, % 63 27 p-value Logistic regression analysis. <0.001 Duration of Response (DoR) Median in months (95% CI) 11.0 (8.6, 12.6) 4.2 (3.0, 5.9) Figure 7. Kaplan-Meier Curves of PFS by Investigator Assessment in AURA3 In a supportive analysis of PFS according to BICR, median PFS was 11 months in the TAGRISSO arm compared to 4.2 months in the chemotherapy arm (HR 0.28; 95% CI: 0.20, 0.38). Of 419 patients, 205 (49%) had baseline brain scans reviewed by BICR; this included 134 (48%) patients in the TAGRISSO arm and 71 (51%) patients in the chemotherapy arm. Assessment of CNS efficacy by RECIST v1.1 was performed in the subgroup of 46/419 (11%) patients identified by BICR to have measurable CNS lesions on a baseline brain scan. Results are summarized in Table 21. Table 21. CNS ORR and DoR by BICR in Patients with Measurable CNS Lesions at Baseline in AURA3 TAGRISSO N=30 Chemotherapy N=16 CNS Tumor Response Assessment According to RECIST v 1.1. Based on confirmed response. CNS ORR, % (95% CI) 57 (37, 75) 25 (7, 52) Complete response, % 7 0 Duration of CNS Response Based on patients with response only; DoR defined as the time from the date of first documented response (complete response or partial response) until progression or death event. Number of responders 17 4 Response Duration ≥6 months, % 47 0 Response Duration ≥9 months, % 12 0 Figure_7.jpg"],"pharmacodynamics":["12.2 Pharmacodynamics Based on an analysis of dose-exposure response relationships over the dose range of 20 mg (0.25 times the recommended dose) to 240 mg (3 times the recommended dose), no apparent relationship between osimertinib exposure and overall response rate, duration of response and progression-free survival was identified; however, there were limited data available at the 20 mg dose. Over the same dose range, increased exposure led to increased probability of adverse reactions, specifically rash, diarrhea and ILD. Cardiac Electrophysiology The QTc interval prolongation potential of osimertinib was assessed in 210 patients who received TAGRISSO 80 mg daily in AURA2. A central tendency analysis of the QTcF data at steady-state demonstrated that the maximum mean change from baseline was 16.2 msec (upper bound of two-sided 90% confidence interval (CI) 17.6 msec). A pharmacokinetic/pharmacodynamic analysis in AURA2 suggested a concentration-dependent QTc interval prolongation of 14 msec (upper bound of two-sided 90% CI: 16 msec) at a dose of TAGRISSO 80 mg."],"pharmacokinetics":["12.3 Pharmacokinetics The area under the plasma concentration-time curve (AUC) and maximal plasma concentration (C max ) of osimertinib increased dose proportionally over 20 to 240 mg dose range (i.e., 0.25 to 3 times the recommended dosage) after oral administration and exhibited linear pharmacokinetics (PK). Administration of TAGRISSO orally once daily resulted in approximately 3-fold accumulation with steady-state exposures achieved after 15 days of dosing. At steady state, the C max to C min (minimal concentration) ratio was 1.6-fold. The pharmacokinetics in patients treated with osimertinib in combination with pemetrexed and platinum-based chemotherapy are similar to those in patients treated with osimertinib monotherapy. Absorption The median time to C max of osimertinib was 6 hours (range 3-24 hours). Following administration of a 20 mg TAGRISSO tablet with a high-fat, high-calorie meal (containing approximately 58 grams of fat and 1000 calories), the C max and AUC of osimertinib were comparable to that under fasting conditions. Distribution The mean volume of distribution at steady-state (V ss /F) of osimertinib was 918 L. Plasma protein binding of osimertinib was 95%. PET brain imaging studies in healthy volunteers and in patients with brain metastases show that osimertinib is distributed to the brain following intravenous injection of a micro dose of 11 C-labeled osimertinib. Elimination Osimertinib plasma concentrations decreased with time and a population estimated mean half-life of osimertinib was 48 hours, and oral clearance (CL/F) was 14.3 (L/h). Metabolism The main metabolic pathways of osimertinib were oxidation (predominantly CYP3A) and dealkylation in vitro . Two pharmacologically active metabolites (AZ7550 and AZ5104) have been identified in the plasma after TAGRISSO oral administration. The geometric mean exposure (AUC) of each metabolite (AZ5104 and AZ7550) was approximately 10% of the exposure of osimertinib at steady-state. Excretion Osimertinib is primarily eliminated in the feces (68%) and to a lesser extent in the urine (14%). Unchanged osimertinib accounted for approximately 2% of the elimination. Specific Populations No clinically significant differences in the pharmacokinetics of osimertinib were observed based on age, sex, ethnicity, body weight, baseline albumin, line of therapy, smoking status, renal function (creatinine clearance (CLcr) ≥15 mL/min by Cockcroft-Gault), or hepatic impairment (Child-Pugh A and B, or total bilirubin ≤ ULN and AST > ULN or total bilirubin between 1 to 3 times ULN and any AST). The pharmacokinetics of osimertinib in patients with end-stage renal disease (CLcr <15 mL/min) or severe hepatic impairment (total bilirubin 3 to 10 times ULN and any AST) are unknown [see Use in Specific Populations (8.6) and (8.7) ] . Drug Interaction Studies Effect of Other Drugs on TAGRISSO in Clinical Pharmacokinetic Studies Strong CYP3A Inducers: The steady-state AUC of osimertinib was reduced by 78% in patients when co-administered with rifampin (600 mg daily for 21 days) [see Drug Interactions (7.1) ]. Strong CYP3A Inhibitors: Co-administering TAGRISSO with 200 mg itraconazole twice daily (a strong CYP3A4 inhibitor) had no clinically significant effect on the exposure of osimertinib (AUC increased by 24% and C max decreased by 20%). Gastric Acid Reducing Agents: The exposure of osimertinib was not affected by concurrent administration of a single 80 mg TAGRISSO tablet following 40 mg omeprazole administration for 5 days. Effect of Osimertinib on Other Drugs in Clinical Pharmacokinetic Studies BCRP substrates: Co-administering TAGRISSO with rosuvastatin (a BCRP substrate) increased rosuvastatin AUC by 35% and C max by 72% [see Drug Interactions (7.2) ] . P-gp substrates: Co-administering TAGRISSO with fexofenadine (a P-gp substrate) increased fexofenadine AUC and C max by 56% and 76% after a single dose and 27% and 25% at steady state, respectively. CYP3A4 substrates: Co-administering TAGRISSO with simvastatin (a CYP3A4 substrate) had no clinically significant effect on the exposure of simvastatin. In Vitro Studies CYP450 Metabolic Pathways: Osimertinib does not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 and 2E1. Osimertinib induced CYP1A2 enzymes. Transporter Systems: Osimertinib is a substrate of P-glycoprotein and BCRP and is not a substrate of OATP1B1 and OATP1B3. Osimertinib is an inhibitor of BCRP and does not inhibit OAT1, OAT3, OATP1B1, OATP1B3, MATE1, MATE2K and OCT2."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: • Interstitial Lung Disease/Pneumonitis [see Error! Hyperlink reference not valid. ] • QTc Interval Prolongation [see Error! Hyperlink reference not valid. ] • Cardiomyopathy [see Error! Hyperlink reference not valid. ] • Keratitis [see Error! Hyperlink reference not valid. ] • Erythema multiforme, Stevens-Johnson syndrome, and Toxic epidermal necrolysis [see Error! Hyperlink reference not valid. ] • Cutaneous Vasculitis [see Error! Hyperlink reference not valid. ] • Aplastic Anemia [see Error! Hyperlink reference not valid. ] Most common (≥20%) adverse reactions, including laboratory abnormalities, were: • TAGRISSO monotherapy: leukopenia, lymphopenia, thrombocytopenia, anemia, diarrhea, rash, musculoskeletal pain, neutropenia, nail toxicity, dry skin, stomatitis, and fatigue. ( 6.1 ) • TAGRISSO monotherapy following platinum-based chemoradiation therapy: lymphopenia, leukopenia, ILD/pneumonitis, thrombocytopenia, neutropenia, rash, diarrhea, nail toxicity, musculoskeletal pain, cough and COVID-19. ( 6.1 ) • TAGRISSO in combination with pemetrexed and platinum-based chemotherapy: leukopenia, thrombocytopenia, neutropenia, lymphopenia, rash, diarrhea, stomatitis, nail toxicity, dry skin, and increased blood creatinine. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or www.TAGRISSO.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data in the WARNINGS AND PRECAUTIONS section reflect exposure to TAGRISSO in 1813 patients with EGFR mutation-positive NSCLC who received TAGRISSO monotherapy at the recommended dose of 80 mg orally once daily until disease progression or unacceptable toxicity in four randomized, controlled trials [ADAURA (n=337), FLAURA (n=338), FLAURA2 (monotherapy arm; n=275), and AURA3 (n=279)] [see Clinical Studies (14) ] , two single arm trials [AURA Extension (n=201) {NCT01802632} and AURA2 (n=210)]{NCT02094261}, and one dose-finding study, AURA1 (n=173). Among 1813 patients who received TAGRISSO monotherapy, 82% were exposed for 6 months or longer and 67% were exposed for greater than one year. In this pooled safety population, the most common adverse reactions in ≥20% of 1813 patients who received TAGRISSO monotherapy were diarrhea (47%), rash (46%), musculoskeletal pain (38%), nail toxicity (34%), dry skin (32%), stomatitis (24%), and fatigue (21%). The most common laboratory abnormalities in ≥20% of 1813 patients who received TAGRISSO monotherapy were leukopenia (65%), lymphopenia (64%), thrombocytopenia (53%), anemia (52%), and neutropenia (36%). In addition to the 1813 patients, certain subsections in the WARNINGS AND PRECAUTIONS describe adverse reactions observed with exposure to TAGRISSO monotherapy (80 mg orally once daily until disease progression or unacceptable toxicity) following definitive platinum-based chemoradiation therapy (n=143) in the LAURA study. The data described below reflect exposure to TAGRISSO (80 mg daily) in 337 patients with EGFR mutation-positive resectable NSCLC, 143 patients with EGFR mutation-positive locally advanced, unresectable (stage III) NSCLC, and 833 patients with EGFR mutation-positive locally advanced or metastatic NSCLC in five randomized, controlled trials [ADAURA (n=337), LAURA (n=143), FLAURA (n=279), FLAURA2 (monotherapy arm; n=275), and AURA3 (n=279)]. The data also reflect exposure to TAGRISSO at the recommended dose of 80 mg daily given in combination with pemetrexed and platinum-based chemotherapy in 276 patients with EGFR mutation-positive locally advanced or metastatic NSCLC in one randomized controlled trial [FLAURA2 (n=276)]. Patients with a history of interstitial lung disease, drug induced interstitial disease or radiation pneumonitis that required steroid treatment, serious arrhythmia or baseline QTc interval greater than 470 msec on electrocardiogram were excluded from enrollment in these studies. Adjuvant Treatment of EGFR Mutation-Positive NSCLC - Monotherapy The safety of TAGRISSO was evaluated in ADAURA, a randomized, double-blind, placebo-controlled trial for the adjuvant treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC who had complete tumor resection, with or without prior adjuvant chemotherapy. At time of DFS analysis, the median duration of exposure to TAGRISSO was 22.5 months. Serious adverse reactions were reported in 16% of patients treated with TAGRISSO. The most common serious adverse reaction (≥1%) was pneumonia (1.5%). Adverse reactions leading to dose reductions occurred in 9% of patients treated with TAGRISSO. The most frequent adverse reactions leading to dose reductions or interruptions were diarrhea (4.5%), stomatitis (3.9%), nail toxicity (1.8%) and rash (1.8%). Adverse reactions leading to permanent discontinuation occurred in 11% of patients treated with TAGRISSO. The most frequent adverse reactions leading to discontinuation of TAGRISSO were interstitial lung disease (2.7%), and rash (1.2%). Tables 4 and 5 summarize common adverse reactions and laboratory abnormalities which occurred in ADAURA. Table 4. Adverse Reactions Occurring in ≥10% of Patients Receiving TAGRISSO in ADAURA NCI CTCAE v4.0. Adverse Reaction TAGRISSO (N=337) PLACEBO (N=343) All Grades (%) Grade 3 or higher All events were grade 3. (%) All Grades (%) Grade 3 or higher (%) Gastrointestinal Disorders Diarrhea Includes diarrhea, colitis, enterocolitis, enteritis. 47 2.4 20 0.3 Stomatitis Includes aphthous ulcer, cheilitis, gingival ulceration, glossitis, tongue ulceration, stomatitis and mouth ulceration. 32 1.8 7 0 Abdominal Pain Includes abdominal discomfort, abdominal pain, abdominal lower pain, abdominal upper pain, epigastric discomfort, hepatic pain. 12 0.3 7 0 Skin Disorders Rash Includes rash, rash generalized, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, rash pruritic, rash vesicular, rash follicular, erythema, folliculitis, acne, dermatitis, dermatitis acneiform, dermatitis bullous, dermatitis exfoliative generalized, drug eruption, eczema, eczema asteatotic, lichen planus, skin erosion, pustule. 40 0.6 19 0 Nail toxicity Includes nail bed disorder, nail bed inflammation, nail bed infection, nail discoloration, nail pigmentation, nail disorder, nail toxicity, nail dystrophy, nail infection, nail ridging, onychalgia, onychoclasis, onycholysis, onychomadesis, onychomalacia, paronychia. 37 0.9 3.8 0 Dry skin Includes dry skin, skin fissures, xerosis, eczema, xeroderma. 29 0.3 7 0 Pruritus Includes pruritus, pruritus generalized, eyelid pruritus. 19 0 9 0 Respiratory, Thoracic and Mediastinal Disorders Cough Includes cough, productive cough, upper-airway cough syndrome. 19 0 19 0 Musculoskeletal and Connective Tissue Disorders Musculoskeletal Pain Includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain in extremity, and spinal pain. 18 0.3 25 0.3 Infection and Infestation Disorders Nasopharyngitis 14 0 10 0 Upper respiratory tract infection 13 0.6 10 0 Urinary Tract Infection Includes cystitis, urinary tract infection, and urinary tract infection bacterial. 10 0.3 7 0 General Disorders and Administration Site Conditions Fatigue Includes asthenia, fatigue. 13 0.6 9 0.3 Metabolism and Nutrition Disorders Decreased appetite 13 0.6 3.8 0 Nervous System Disorders Dizziness Includes dizziness, vertigo, and vertigo positional. 10 0 9 0 Clinically relevant adverse reactions in ADAURA in <10% of patients receiving TAGRISSO were alopecia (6%), epistaxis (6%), interstitial lung disease (3%), palmar-plantar erythrodysesthesia syndrome (1.8%), skin hyperpigmentation (1.8%), urticaria (1.5%), keratitis (0.6%), QTc interval prolongation (0.6%), and erythema multiforme (0.3%). QTc interval prolongation represents the incidence of patients who had a QTcF prolongation >500 msec. Table 5. Laboratory Abnormalities Worsening from Baseline in ≥20% of Patients in ADAURA Laboratory Abnormality NCI CTCAE v4.0 Based on the number of patients with available follow-up laboratory data. TAGRISSO (N=337) PLACEBO (N=343) All Grades (%) Grade 3 or Grade 4 (%) All Grades (%) Grade 3 or Grade 4 (%) Hematology Leukopenia 54 0 25 0 Thrombocytopenia 47 0 7 0.3 Lymphopenia 44 3.4 14 0.9 Anemia 30 0 12 0.3 Neutropenia 26 0.6 10 0.3 Chemistry Hyperglycemia 25 2.3 30 0.9 Hypermagnesemia 24 1.3 14 1.5 Hyponatremia 20 1.8 16 1.5 Laboratory abnormalities in ADAURA that occurred in <20% of patients receiving TAGRISSO was increased blood creatinine (10%). Locally Advanced, Unresectable (Stage III) EGFR Mutation Positive NSCLC The safety of TAGRISSO was evaluated in LAURA, a double blind, randomized (2:1), placebo controlled study conducted in 216 patients with EGFR exon 19 deletions or exon 21 L858R mutation positive, locally advanced, unresectable (stage III) NSCLC, who had not progressed during or following definitive platinum based chemoradiation therapy. Among patients who received TAGRISSO, 81% were exposed for 6 months or longer and 74% were exposed for one year or longer. Serious adverse reactions were reported in 38% of patients treated with TAGRISSO. The most common serious adverse reactions (≥1%) included ILD/pneumonitis (13%), pneumonia (6%) and gastroenteritis (1.4%). Fatal adverse reactions occurred in 1.4% of patients who received TAGRISSO due to pneumonia (0.7%) and ILD/pneumonitis (0.7%). Permanent discontinuation of TAGRISSO due to an adverse reaction occurred in 13% of patients. The adverse reactions resulting in permanent discontinuation of TAGRISSO in > 1 patient were ILD/pneumonitis (7%) and pneumonia (1.4%). Dosage interruptions of TAGRISSO due to an adverse reaction occurred in 56% of patients. The adverse reactions requiring dosage interruption in ≥2% of patients were ILD/pneumonitis (35%), pneumonia (6%), COVID-19 (4.2%), neutropenia (2.1%), and QTc interval prolongation (2.1%). Dose reductions of TAGRISSO due to an adverse reaction occurred in 8% of patients. The most common adverse reactions, including laboratory abnormalities worsening from baseline, were lymphopenia, leukopenia, ILD/pneumonitis, thrombocytopenia, neutropenia, rash, diarrhea, nail toxicity, musculoskeletal pain, cough, and COVID-19. Tables 6 and 7 summarize common adverse reactions and laboratory abnormalities which occurred in LAURA. Table 6. Adverse Reactions in ≥10% of Patients Receiving TAGRISSO in LAURA NCI CTCAE v5.0 Adverse Reaction TAGRISSO (N=143) Placebo (N=73) Any Grade (%) Grade 3 or 4(%) Any Grade (%) Grade 3 or 4 (%) Respiratory, Thoracic and Mediastinal Disorders ILD/pneumonitis Includes radiation pneumonitis, radiation lung fibrosis, pneumonitis, interstitial lung disease (ILD), pulmonary fibrosis. 56 3.5 38 0 Cough Includes cough, productive cough. 20 0 15 0 Skin Disorders Rash Includes rash, maculo-papular rash, pustular rash, pruritic rash, folliculitis, papule, dermatitis, acneiform dermatitis, atopic dermatitis, eczema, asteatotic eczema, acne, urticaria. 39 0.7 19 0 Nail toxicity Includes nail bed disorder, nail disorder, nail discoloration, nail infection, onychoclasis, paronychia. 23 0 1.4 0 Dry skin Includes dry skin, skin fissures, senile xerosis, xeroderma. 17 0.7 5 0 Pruritus 13 0 7 0 Gastrointestinal Disorders Diarrhea Includes diarrhea, enteritis. 36 2.1 14 0 Stomatitis Includes stomatitis, aphthous ulceration, mouth ulceration. 15 0 5 0 Musculoskeletal and Connective Tissue Disorders Musculoskeletal pain Includes musculoskeletal chest pain, myalgia, arthritis, arthralgia, back pain, bone pain, musculoskeletal pain, neck pain, pain in extremity, spinal osteoarthritis. 20 0.7 26 0 Infection and Infestation Disorders COVID-19 Includes COVID-19 and COVID-19 pneumonia. 20 0.7 10 0 Pneumonia Includes pneumonia, aspiration pneumonia, viral pneumonia, Pneumocystis jiroveci pneumonia, Haemophilus pneumonia, lower respiratory tract infection. 15 3.5 10 5 Metabolism and Nutrition Disorders Decreased appetite 15 0.7 5 0 Clinically relevant adverse reactions in LAURA in <10% of patients receiving TAGRISSO were dyspnea (8%), urinary tract infection (8%), alopecia (1.4%), urticaria (1.4%), epistaxis (0.7%), keratitis (0.7%), and QTc interval prolongation (0.7%). QTc interval prolongation represents the incidence of patients who had a QTc prolongation >500 msec. Table 7. Laboratory Abnormalities Worsening from Baseline in ≥20% of Patients in LAURA Laboratory Abnormality NCI CTCAE v5.0 Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (TAGRISSO arm: 142 and placebo arm: 72). TAGRISSO (N=143) Placebo (N=73) All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Hematology Lymphopenia 70 3.5 40 1.4 Leukopenia 66 2.8 24 0 Thrombocytopenia 51 1.4 8 1.4 Neutropenia 42 2.1 15 1.4 A clinically relevant laboratory abnormality in LAURA that occurred in <20% of patients receiving TAGRISSO was increased blood creatinine (19%). Previously Untreated EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer - Monotherapy The safety of TAGRISSO was evaluated in FLAURA, a multicenter international double-blind randomized (1:1) active‑controlled trial conducted in 556 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive, unresectable or metastatic NSCLC who had not received previous systemic treatment for advanced disease. The median duration of exposure to TAGRISSO was 16.2 months. Serious adverse reactions were reported in 4% of patients treated with TAGRISSO; the most common serious adverse reactions (≥1%) were pneumonia (2.9%), ILD/pneumonitis (2.1%), and pulmonary embolism (1.8%). Dose reductions occurred in 2.9% of patients treated with TAGRISSO. The most frequent adverse reactions leading to dose reductions or interruptions were prolongation of the QT interval as assessed by ECG (4.3%), diarrhea (2.5%), and lymphopenia (1.1%). Adverse reactions leading to permanent discontinuation occurred in 13% of patients treated with TAGRISSO. The most frequent adverse reaction leading to discontinuation of TAGRISSO was ILD/pneumonitis (3.9%). Tables 8 and 9 summarize common adverse reactions and laboratory abnormalities which occurred in FLAURA. Table 8. Adverse Reactions Occurring in ≥10% of Patients Receiving TAGRISSO in FLAURA NCI CTCAE v4.0 Adverse Reaction TAGRISSO (N=279) EGFR TKI comparator (gefitinib or erlotinib) (N=277) Any Grade (%) Grade 3 or higher (%) Any Grade (%) Grade 3 or higher (%) Gastrointestinal Disorders Diarrhea One grade 5 (fatal) event was reported (diarrhea) for EGFR TKI comparator. 58 2.2 57 2.5 Stomatitis Includes stomatitis and mouth ulceration. 32 0.7 22 1.1 Nausea 14 0 19 0 Constipation 15 0 13 0 Vomiting 11 0 11 1.4 Skin Disorders Rash Includes rash, rash generalized, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, rash pruritic, rash vesicular, rash follicular, erythema, folliculitis, acne, dermatitis, dermatitis acneiform, drug eruption, skin erosion, pustule. 58 1.1 78 7 Dry skin Includes dry skin, skin fissures, xerosis, eczema, xeroderma. 36 0.4 36 1.1 Nail toxicity Includes nail bed disorder, nail bed inflammation, nail bed infection, nail discoloration, nail pigmentation, nail disorder, nail toxicity, nail dystrophy, nail infection, nail ridging, onychalgia, onychoclasis, onycholysis, onychomadesis, onychomalacia, paronychia. 35 0.4 33 0.7 Pruritus Includes pruritus, pruritus generalized, eyelid pruritus. 17 0.4 17 0 General Disorders and Administration Site Conditions Fatigue Includes fatigue, asthenia. 21 1.4 15 1.4 Pyrexia 10 0 4 0.4 Metabolism and Nutrition Disorders Decreased appetite 20 2.5 19 1.8 Respiratory, Thoracic and Mediastinal Disorders Cough 17 0 15 0.4 Dyspnea 13 0.4 7 1.4 Neurologic Disorders Headache 12 0.4 7 0 Cardiac Disorders Prolonged QT Interval Includes prolonged QT interval reported as adverse reaction. 10 2.2 4 0.7 Infection and Infestation Disorders Upper Respiratory Tract Infection 10 0 7 0 Clinically relevant adverse reactions in FLAURA in <10% of patients receiving TAGRISSO were alopecia (7%), epistaxis (6%), interstitial lung disease (3.9%), urticaria (2.2%), palmar-plantar erythrodysesthesia syndrome (1.4%), QTc interval prolongation (1.1%), keratitis (0.4%), and skin hyperpigmentation (0.4%). QTc interval prolongation represents the incidence of patients who had a QTcF prolongation >500 msec. Table 9. Laboratory Abnormalities Worsening from Baseline in ≥20% of Patients in FLAURA Laboratory Abnormality NCI CTCAE v4.0 Each test incidence, except for hyperglycemia, is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (TAGRISSO range: 267 - 273 and EGFR TKI comparator range: 256 - 268). TAGRISSO (N=279) EGFR TKI comparator (gefitinib or erlotinib) (N=277) All Grades (%) Grade 3 or Grade 4 (%) All Grades (%) Grade 3 or Grade 4 (%) Hematology Lymphopenia 63 6 36 4.2 Anemia 59 0.7 47 0.4 Thrombocytopenia 51 0.7 12 0.4 Neutropenia 41 3 10 0 Chemistry Hyperglycemia Hyperglycemia is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: TAGRISSO (179) and EGFR comparator (191). 37 0 31 0.5 Hypermagnesemia 30 0.7 11 0.4 Hyponatremia 26 1.1 27 1.5 Increased AST 22 1.1 43 4.1 Increased ALT 21 0.7 52 8 Hypokalemia 16 0.4 22 1.1 Hyperbilirubinemia 14 0 29 1.1 A clinically relevant laboratory abnormality in FLAURA that occurred in <20% of patients receiving TAGRISSO was increased blood creatinine (9%). Previously Untreated EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer – TAGRISSO in Combination with Pemetrexed and Platinum-based Chemotherapy The safety of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy was evaluated in FLAURA2, a multicenter international open-label, randomized (1:1), active-controlled trial conducted in 557 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive, locally advanced or metastatic NSCLC who had not received previous systemic treatment for advanced disease. The median duration of exposure to TAGRISSO in combination with pemetrexed and platinum-based chemotherapy was 22.3 months and the median duration of exposure to TAGRISSO monotherapy was 19.3 months. Serious adverse reactions were reported in 38% of patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; the most frequently reported serious adverse reactions (≥2%) in the combination arm were anemia (3.3%), COVID-19 (2.5%), pneumonia (2.5%), febrile neutropenia (2.2%), thrombocytopenia (2.2%), and pulmonary embolism (2.2%). Fatal adverse reactions occurred in 7% of patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy including pulmonary embolism (1.1%), pneumonia (1.1%) and cardiomyopathy (1.1%). Dosage interruptions of TAGRISSO, when given with pemetrexed and platinum-based chemotherapy, due to an adverse reaction occurred in 44% of patients. Adverse reactions which required dosage interruption in ≥ 2% of patients included anemia (4.7%), neutropenia (4.3%), diarrhea (3.6%), febrile neutropenia (3.3%) and thrombocytopenia (2.9%). Permanent discontinuation of TAGRISSO when given in combination with pemetrexed and platinum-based chemotherapy due to an adverse reaction occurred in 11% of patients. Adverse reactions which resulted in permanent discontinuation of TAGRISSO in ≥1% of patients included ILD/pneumonitis (2.9%), pneumonia (1.4%), and decreased ejection fraction (1.1%). Adverse reactions leading to dose reduction of TAGRISSO occurred in 10% of patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy. The most frequently reported adverse reactions leading to dose reduction of TAGRISSO in the combination arm in ≥1% of patients were diarrhea (1.1%) and rash (1.1%). Tables 10 and 11 summarize common adverse reactions and laboratory abnormalities which occurred in FLAURA2. Table 10. Adverse Reactions Occurring in ≥10% of Patients Receiving TAGRISSO in FLAURA2 NCI CTCAE v5.0 Adverse Reaction TAGRISSO with Pemetrexed and Platinum-based Chemotherapy (N=276) TAGRISSO (N=275) Any Grade (%) Grade 3 or higher (%) Any Grade (%) Grade 3 or higher (%) Skin Disorders Rash Includes rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, rash pruritic, rash vesicular, rash follicular, erythema, folliculitis, acne, dermatitis, dermatitis acneiform, drug eruption, skin erosion, pustule. 49 2.5 44 1.5 Nail toxicity Includes nail bed disorder, nail bed inflammation, nail bed infection, nail discoloration, nail pigmentation, nail disorder, nail toxicity, nail dystrophy, nail infection, nail ridging, onychalgia, onychoclasis, onycholysis, onychomadesis, onychomalacia, paronychia. 27 0.7 32 0.4 Dry skin Includes dry skin, skin fissures, xerosis, eczema, xeroderma. 24 0 31 0 Pruritus Includes pruritus, eyelid pruritus. 8 0 11 0 Gastrointestinal Disorders Diarrhea 43 2.9 41 0.4 Stomatitis Includes stomatitis and mouth ulceration. 31 0.4 21 0.4 Clinically relevant adverse reactions in FLAURA2 in <10% of patients receiving TAGRISSO in combination with pemetrexed and platinum-based chemotherapy were alopecia (9%), epistaxis (7%), palmar-plantar erythrodysesthesia syndrome (5%), interstitial lung disease (3.3%), skin hyperpigmentation (2.5%), QTc interval prolongation (1.8%), erythema multiforme (1.4%), urticaria (1.4%), and keratitis (0.7%). QTc interval prolongation represents the incidence of patients who had a QTcF prolongation >500 msec. Table 11. Laboratory Abnormalities Worsening from Baseline in ≥20% of Patients in FLAURA2 NCI CTCAE v5.0 Findings based on test results presented as CTCAE grade shifts. Laboratory Abnormality Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (TAGRISSO with pemetrexed and platinum-based chemotherapy arm: 275 and TAGRISSO monotherapy arm: 275). TAGRISSO with Pemetrexed and Platinum-based Chemotherapy (N=276) TAGRISSO (N=275) All Grades (%) Grade 3 or Grade 4 (%) All Grades (%) Grade 3 or Grade 4 (%) Hematology Leukopenia 88 20 53 3.3 Thrombocytopenia 85 16 44 1.8 Neutropenia 85 36 40 4.7 Lymphopenia 78 16 55 7 Chemistry Blood creatinine increased 22 0.4 8 0 Previously Treated EGFR T790M Mutation-Positive Metastatic Non-Small Cell Lung Cancer – Monotherapy The safety of TAGRISSO was evaluated in AURA3, a multicenter international open label randomized (2:1) controlled trial conducted in 419 patients with unresectable or metastatic EGFR T790M mutation-positive NSCLC who had progressive disease following first line EGFR TKI treatment. A total of 279 patients received TAGRISSO 80 mg orally once daily until intolerance to therapy, disease progression, or investigator determination that the patient was no longer benefiting from treatment. A total of 136 patients received pemetrexed plus either carboplatin or cisplatin every three weeks for up to 6 cycles; patients without disease progression after 4 cycles of chemotherapy could continue maintenance pemetrexed until disease progression, unacceptable toxicity, or investigator determination that the patient was no longer benefiting from treatment. Left Ventricular Ejection Fraction (LVEF) was evaluated at screening and every 12 weeks. The median duration of treatment was 8.1 months for patients treated with TAGRISSO and 4.2 months for chemotherapy-treated patients. The trial population characteristics were: median age 62 years, age less than 65 (58%), female (64%), Asian (65%), never smokers (68%), and ECOG PS 0 or 1 (100%). Serious adverse reactions were reported in 18% of patients treated with TAGRISSO and 26% in the chemotherapy group. No single serious adverse reaction was reported in 2% or more patients treated with TAGRISSO. One patient (0.4%) treated with TAGRISSO experienced a fatal adverse reaction (ILD/pneumonitis). Dose reductions occurred in 2.9% of patients treated with TAGRISSO. The most frequent adverse reactions leading to dose reductions or interruptions were prolongation of the QT interval as assessed by ECG (1.8%), neutropenia (1.1%), and diarrhea (1.1%). Adverse reactions resulting in permanent discontinuation of TAGRISSO occurred in 7% of patients treated with TAGRISSO. The most frequent adverse reaction leading to discontinuation of TAGRISSO was ILD/pneumonitis (3%). Tables 12 and 13 summarize common adverse reactions and laboratory abnormalities which occurred in TAGRISSO-treated patients in AURA3. Table 12. Adverse Reactions Occurring in ≥10% of Patients Receiving TAGRISSO in AURA3 NCI CTCAE v4.0. Adverse Reaction TAGRISSO (N=279) Chemotherapy (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) (N=136) All Grades No grade 4 events were reported. (%) Grade 3/4 (%) All Grades (%) Grade 3/4 (%) Gastrointestinal Disorders Diarrhea 41 1.1 11 1.5 Nausea 16 0.7 49 3.7 Stomatitis Includes stomatitis and mouth ulceration. 19 0 15 1.5 Constipation 14 0 35 0 Vomiting 11 0.4 20 2.2 Skin Disorders Rash Includes rash, rash generalized, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, erythema, folliculitis, acne, dermatitis, acneiform dermatitis, pustule. 34 0.7 6 0 Dry skin Includes dry skin, eczema, skin fissures, xerosis. 23 0 4.4 0 Nail toxicity Includes nail disorders, nail bed disorders, nail bed inflammation, nail bed tenderness, nail discoloration, nail disorder, nail dystrophy, nail infection, nail ridging, nail toxicity, onychalgia, onychoclasis, onycholysis, onychomadesis, paronychia. 22 0 1.5 0 Pruritus Includes pruritus, pruritus generalized, eyelid pruritus. 13 0 5 0 General Disorders and Administration Site Conditions Fatigue Includes fatigue, asthenia. 22 1.8 40 5.1 Metabolism and Nutrition Disorders Decreased appetite 18 1.1 36 2.9 Respiratory, Thoracic and Mediastinal Disorders Cough 17 0 14 0 Musculoskeletal and Connective Tissue Disorders Back pain 10 0.4 9 0.7 Clinically relevant adverse reactions in AURA3 in <10% of patients receiving TAGRISSO were epistaxis (5%), interstitial lung disease (3.9%), alopecia (3.6%), urticaria (2.9%), palmar-plantar erythrodysesthesia syndrome (1.8%), QTc interval prolongation (1.4%), keratitis (1.1%), and erythema multiforme (0.7%), and skin hyperpigmentation (0.4%). QTc interval prolongation represents the incidence of patients who had a QTcF prolongation >500 msec. Table 13. Laboratory Abnormalities Worsening from Baseline in ≥20% of Patients in AURA3 Laboratory Abnormality NCI CTCAE v4.0 Each test incidence, except for hyperglycemia, is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (TAGRISSO 279, Chemotherapy comparator 131). TAGRISSO (N=279) Chemotherapy (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) (N=131) All Grades (%) Grade 3 or Grade 4 (%) All Grades (%) Grade 3 or Grade 4 (%) Hematology Anemia 43 0 79 3.1 Lymphopenia 63 8 61 10 Thrombocytopenia 46 0.7 48 7 Neutropenia 27 2.2 49 12 Chemistry Hypermagnesemia 27 1.8 9 1.5 Hyponatremia 26 2.2 36 1.5 Hyperglycemia Hyperglycemia is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (TAGRISSO 270, Chemotherapy 5; fasting glucose was not a protocol requirement for patients in the chemotherapy arm). 20 0 NA NA Hypokalemia 9 1.4 18 1.5 NA=Not Applicable Clinically relevant laboratory abnormalities in AURA3 that occurred in <20% of patients receiving TAGRISSO included increased blood creatinine (7%). Other Clinical Trials Experience The following adverse reaction has been reported following administration of TAGRISSO: increased blood creatine phosphokinase. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of TAGRISSO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. o Skin and subcutaneous tissue: Erythema multiforme major (EMM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), cutaneous vasculitis, erythema dyschromicum perstans o Blood and lymphatic system disorders: Aplastic anemia"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Strong CYP3A Inducers : Avoid concomitant use. If not possible, increase TAGRISSO to 160 mg daily in patients receiving a strong CYP3A4 inducer. ( 2.5 , 7.1 ) 7.1 Effect of Other Drugs on Osimertinib Strong CYP3A Inducers Co-administering TAGRISSO with a strong CYP3A4 inducer decreased the exposure of osimertinib compared to administering TAGRISSO alone [see Clinical Pharmacology (12.3) ] . Decreased osimertinib exposure may lead to reduced efficacy. Avoid co-administering TAGRISSO with strong CYP3A inducers. Increase the TAGRISSO dosage when co-administering with a strong CYP3A4 inducer if concurrent use is unavoidable [see Dosage and Administration (2.5) ] . No dose adjustments are required when TAGRISSO is used with moderate and/or weak CYP3A inducers. 7.2 Effect of Osimertinib on Other Drugs Co-administering TAGRISSO with a breast cancer resistant protein (BCRP) or P-glycoprotein (P-gp) substrate increased the exposure of the substrate compared to administering it alone [see Clinical Pharmacology (12.3) ] . Increased BCRP or P-gp substrate exposure may increase the risk of exposure-related toxicity. Monitor for adverse reactions of the BCRP or P-gp substrate, unless otherwise instructed in its approved labeling, when co-administered with TAGRISSO. 7.3 Drugs That Prolong the QTc Interval The effect of co-administering medicinal products known to prolong the QTc interval with TAGRISSO is unknown. When feasible, avoid concomitant administration of drugs known to prolong the QTc interval with known risk of Torsades de pointes. If not feasible to avoid concomitant administration of such drugs, conduct periodic ECG monitoring [see Error! Hyperlink reference not valid. and Clinical Pharmacology (12.2) ]."],"mechanism_of_action":["12.1 Mechanism of Action Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) at approximately 9-fold lower concentrations than wild-type. Two pharmacologically-active metabolites (AZ7550 and AZ5104 circulating at approximately 10% of the parent) with similar inhibitory profiles to osimertinib have been identified in the plasma after oral administration of osimertinib. AZ7550 showed a similar potency to osimertinib, while AZ5104 showed greater potency against exon 19 deletion and T790M mutants (approximately 8-fold) and wild-type (approximately 15-fold) EGFR. In vitro , osimertinib also inhibited the activity of HER2, HER3, HER4, ACK1, and BLK at clinically relevant concentrations. In cultured cells and animal tumor implantation models, osimertinib exhibited anti-tumor activity against NSCLC lines harboring EGFR-mutations (T790M/L858R, L858R, T790M/exon 19 deletion, and exon 19 deletion) and, to a lesser extent, wild-type EGFR amplifications. Osimertinib distributed to the brain in multiple animal species (monkey, rat, and mouse) with brain to plasma AUC ratios of approximately 2 following oral dosing. These data are consistent with observations of tumor regression and increased survival in osimertinib- versus control-treated animals in a pre-clinical mutant-EGFR intracranial mouse metastasis xenograft model (PC9; exon 19 deletion)."],"recent_major_changes":["Indications and Usage ( 1.2 ) 09/2024 Indications and Usage ( 1.4 ) 02/2024 Dosage and Administration, Patient Selection ( 2.2 ) 09/2024 Dosage and Administration, Recommended Dosage and Administration ( 2.3 ) 09/2024 Dosage and Administration, Dosage Modifications ( 2.5 ) 09/2024 Warnings and Precautions, Interstitial Lung Disease/Pneumonitis ( Error! Hyperlink reference not valid. ) 09/2024 Warnings and Precautions, QTc Interval Prolongation ( Error! Hyperlink reference not valid. ) 09/2024 Warnings and Precautions, Cardiomyopathy ( Error! Hyperlink reference not valid. ) 09/2024 Warnings and Precautions, Keratitis ( Error! Hyperlink reference not valid. ) 09/2024 Warnings and Precautions, Aplastic Anemia ( Error! Hyperlink reference not valid. ) 02/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) at approximately 9-fold lower concentrations than wild-type. Two pharmacologically-active metabolites (AZ7550 and AZ5104 circulating at approximately 10% of the parent) with similar inhibitory profiles to osimertinib have been identified in the plasma after oral administration of osimertinib. AZ7550 showed a similar potency to osimertinib, while AZ5104 showed greater potency against exon 19 deletion and T790M mutants (approximately 8-fold) and wild-type (approximately 15-fold) EGFR. In vitro , osimertinib also inhibited the activity of HER2, HER3, HER4, ACK1, and BLK at clinically relevant concentrations. In cultured cells and animal tumor implantation models, osimertinib exhibited anti-tumor activity against NSCLC lines harboring EGFR-mutations (T790M/L858R, L858R, T790M/exon 19 deletion, and exon 19 deletion) and, to a lesser extent, wild-type EGFR amplifications. Osimertinib distributed to the brain in multiple animal species (monkey, rat, and mouse) with brain to plasma AUC ratios of approximately 2 following oral dosing. These data are consistent with observations of tumor regression and increased survival in osimertinib- versus control-treated animals in a pre-clinical mutant-EGFR intracranial mouse metastasis xenograft model (PC9; exon 19 deletion). 12.2 Pharmacodynamics Based on an analysis of dose-exposure response relationships over the dose range of 20 mg (0.25 times the recommended dose) to 240 mg (3 times the recommended dose), no apparent relationship between osimertinib exposure and overall response rate, duration of response and progression-free survival was identified; however, there were limited data available at the 20 mg dose. Over the same dose range, increased exposure led to increased probability of adverse reactions, specifically rash, diarrhea and ILD. Cardiac Electrophysiology The QTc interval prolongation potential of osimertinib was assessed in 210 patients who received TAGRISSO 80 mg daily in AURA2. A central tendency analysis of the QTcF data at steady-state demonstrated that the maximum mean change from baseline was 16.2 msec (upper bound of two-sided 90% confidence interval (CI) 17.6 msec). A pharmacokinetic/pharmacodynamic analysis in AURA2 suggested a concentration-dependent QTc interval prolongation of 14 msec (upper bound of two-sided 90% CI: 16 msec) at a dose of TAGRISSO 80 mg. 12.3 Pharmacokinetics The area under the plasma concentration-time curve (AUC) and maximal plasma concentration (C max ) of osimertinib increased dose proportionally over 20 to 240 mg dose range (i.e., 0.25 to 3 times the recommended dosage) after oral administration and exhibited linear pharmacokinetics (PK). Administration of TAGRISSO orally once daily resulted in approximately 3-fold accumulation with steady-state exposures achieved after 15 days of dosing. At steady state, the C max to C min (minimal concentration) ratio was 1.6-fold. The pharmacokinetics in patients treated with osimertinib in combination with pemetrexed and platinum-based chemotherapy are similar to those in patients treated with osimertinib monotherapy. Absorption The median time to C max of osimertinib was 6 hours (range 3-24 hours). Following administration of a 20 mg TAGRISSO tablet with a high-fat, high-calorie meal (containing approximately 58 grams of fat and 1000 calories), the C max and AUC of osimertinib were comparable to that under fasting conditions. Distribution The mean volume of distribution at steady-state (V ss /F) of osimertinib was 918 L. Plasma protein binding of osimertinib was 95%. PET brain imaging studies in healthy volunteers and in patients with brain metastases show that osimertinib is distributed to the brain following intravenous injection of a micro dose of 11 C-labeled osimertinib. Elimination Osimertinib plasma concentrations decreased with time and a population estimated mean half-life of osimertinib was 48 hours, and oral clearance (CL/F) was 14.3 (L/h). Metabolism The main metabolic pathways of osimertinib were oxidation (predominantly CYP3A) and dealkylation in vitro . Two pharmacologically active metabolites (AZ7550 and AZ5104) have been identified in the plasma after TAGRISSO oral administration. The geometric mean exposure (AUC) of each metabolite (AZ5104 and AZ7550) was approximately 10% of the exposure of osimertinib at steady-state. Excretion Osimertinib is primarily eliminated in the feces (68%) and to a lesser extent in the urine (14%). Unchanged osimertinib accounted for approximately 2% of the elimination. Specific Populations No clinically significant differences in the pharmacokinetics of osimertinib were observed based on age, sex, ethnicity, body weight, baseline albumin, line of therapy, smoking status, renal function (creatinine clearance (CLcr) ≥15 mL/min by Cockcroft-Gault), or hepatic impairment (Child-Pugh A and B, or total bilirubin ≤ ULN and AST > ULN or total bilirubin between 1 to 3 times ULN and any AST). The pharmacokinetics of osimertinib in patients with end-stage renal disease (CLcr <15 mL/min) or severe hepatic impairment (total bilirubin 3 to 10 times ULN and any AST) are unknown [see Use in Specific Populations (8.6) and (8.7) ] . Drug Interaction Studies Effect of Other Drugs on TAGRISSO in Clinical Pharmacokinetic Studies Strong CYP3A Inducers: The steady-state AUC of osimertinib was reduced by 78% in patients when co-administered with rifampin (600 mg daily for 21 days) [see Drug Interactions (7.1) ]. Strong CYP3A Inhibitors: Co-administering TAGRISSO with 200 mg itraconazole twice daily (a strong CYP3A4 inhibitor) had no clinically significant effect on the exposure of osimertinib (AUC increased by 24% and C max decreased by 20%). Gastric Acid Reducing Agents: The exposure of osimertinib was not affected by concurrent administration of a single 80 mg TAGRISSO tablet following 40 mg omeprazole administration for 5 days. Effect of Osimertinib on Other Drugs in Clinical Pharmacokinetic Studies BCRP substrates: Co-administering TAGRISSO with rosuvastatin (a BCRP substrate) increased rosuvastatin AUC by 35% and C max by 72% [see Drug Interactions (7.2) ] . P-gp substrates: Co-administering TAGRISSO with fexofenadine (a P-gp substrate) increased fexofenadine AUC and C max by 56% and 76% after a single dose and 27% and 25% at steady state, respectively. CYP3A4 substrates: Co-administering TAGRISSO with simvastatin (a CYP3A4 substrate) had no clinically significant effect on the exposure of simvastatin. In Vitro Studies CYP450 Metabolic Pathways: Osimertinib does not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 and 2E1. Osimertinib induced CYP1A2 enzymes. Transporter Systems: Osimertinib is a substrate of P-glycoprotein and BCRP and is not a substrate of OATP1B1 and OATP1B3. Osimertinib is an inhibitor of BCRP and does not inhibit OAT1, OAT3, OATP1B1, OATP1B3, MATE1, MATE2K and OCT2."],"indications_and_usage":["1 INDICATIONS AND USAGE TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.1 , 2.2 ) • the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.2 , 2.2 ) • the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.3 , 2.2 ) • in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.4 , 2.2 ) • the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy. ( 1.5 , 2.2 ) 1.1 Adjuvant Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC TAGRISSO is indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2)]. 1.3 First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC TAGRISSO is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ]. 1.4 First-line Treatment of EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC TAGRISSO in combination with pemetrexed and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ]. 1.5 Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy [see Dosage and Administration (2.2) ] ."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Interstitial Lung Disease (ILD)/Pneumonitis: Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. For patients receiving TAGRISSO who have not received recent definite platinum-based chemoradiation therapy, permanently discontinue TAGRISSO in patients diagnosed with ILD/Pneumonitis. For patients who received recent definitive platinum-based chemoradiation therapy with Grade 1 ILD/pneumonitis continue TAGRISSO or interrupt and restart, as appropriate. Permanently discontinue TAGRISSO in patients diagnosed with Grade ≥2 ILD/pneumonitis. ( 2.5 , Error! Hyperlink reference not valid. ) • QTc Interval Prolongation: Monitor electrocardiograms and electrolytes in patients who have a history or predisposition for QTc prolongation, or those who are taking medications that are known to prolong the QTc interval. Withhold, then restart at a reduced dose or permanently discontinue TAGRISSO based on severity. ( 2.5 , Error! Hyperlink reference not valid. ) • Cardiomyopathy: Occurred in 3.8% of patients. Conduct cardiac monitoring, including left ventricular ejection fraction (LVEF) assessment in patients with cardiac risk factors. ( 2.5 , Error! Hyperlink reference not valid. ) • Keratitis: Promptly refer patients with signs and symptoms of keratitis to an ophthalmologist for evaluation. ( Error! Hyperlink reference not valid. ) • Erythema Multiforme Major, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis: Withhold TAGRISSO if erythema multiforme major (EMM), Stevens-Johnson syndrome (SJS), or toxic epidermal necrolysis (TEN) is suspected and permanently discontinue if confirmed. ( 2.5 , Error! Hyperlink reference not valid. ) • Cutaneous Vasculitis: Withhold TAGRISSO if cutaneous vasculitis is suspected, evaluate for systemic involvement, and consider dermatology consultation. If no other etiology can be identified, consider permanent discontinuation based on severity. ( Error! Hyperlink reference not valid. ) • Aplastic Anemia: Withhold TAGRISSO if aplastic anemia is suspected and permanently discontinue TAGRISSO if confirmed. ( 2.5 , Error! Hyperlink reference not valid. ) • Embryo-Fetal Toxicity: TAGRISSO can cause fetal harm. Advise females of potential risk to the fetus and to use effective contraception during treatment with TAGRISSO and for 6 weeks after last dose. Advise males to use effective contraception for 4 months after the last dose of TAGRISSO. ( Error! Hyperlink reference not valid. , 8.1 , 8.3 ) 5.1 Interstitial Lung Disease/Pneumonitis TAGRISSO can cause severe and fatal ILD/pneumonitis. Across clinical trials, interstitial lung disease (ILD)/pneumonitis occurred in 4% of the 1813 patients treated with TAGRISSO monotherapy who had not received recent definitive chemoradiation therapy; 0.4% of cases were fatal. ILD/Pneumonitis with TAGRISSO in Combination with Pemetrexed and Platinum-based Chemotherapy In the FLAURA2 study, ILD/pneumonitis occurred in 3.3% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 0.4% of cases were fatal. ILD/Pneumonitis Following Definitive Platinum-based Chemoradiation Therapy In the LAURA study, following definitive platinum-based chemoradiation therapy, ILD/pneumonitis, including radiation pneumonitis, occurred in 80 of the 143 patients (56%) who received TAGRISSO monotherapy and 28 of the 73 patients (38%) who received placebo. There was one fatal case (0.7%), 3.5% Grade 3, 34% Grade 2, and 18% Grade 1 adverse reactions of ILD/pneumonitis in TAGRISSO-treated patients. For TAGRISSO-treated patients, ILD/pneumonitis led to permanent discontinuation of TAGRISSO in 7% of patients and dosage interruptions of TAGRISSO in 35% of patients. Among the 46 patients who were rechallenged with TAGRISSO, 11% had recurrence of ILD/pneumonitis. In the 80 TAGRISSO-treated patients, ILD/pneumonitis resolved in 40%, resolved with sequelae in 1.3%, were resolving in 16%, did not resolve in 41%, and resulted in death in 1.3%. For patients receiving TAGRISSO who have not received recent definitive platinum-based chemoradiation therapy, withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening or respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Permanently discontinue TAGRISSO if ILD/pneumonitis is confirmed [see Dosage and Administration (2.5) and Adverse Reactions (6.1) ]. For patients who have received recent definitive platinum-based chemoradiation therapy with Grade 1 ILD/pneumonitis continue TAGRISSO or interrupt and restart, as appropriate. Permanently discontinue TAGRISSO in patients diagnosed with Grade ≥2 ILD/pneumonitis [see Dosage and Administration (2.5) and Adverse Reactions (6.1) ]. 5.2 QTc Interval Prolongation TAGRISSO can cause heart rate-corrected QT (QTc) interval prolongation. Of the 1813 patients treated with TAGRISSO monotherapy in clinical trials, 1.1% were found to have a QTc >500 msec, and 4.3% of patients had an increase from baseline QTc >60 msec [see Clinical Pharmacology (12.2) ]. Of the 276 patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy in the FLAURA2 study, 1.8% were found to have a QTc >500 msec, and 10.5% of patients had an increase from baseline QTc >60 msec. No QTc-related arrhythmias were reported. Clinical trials of TAGRISSO did not enroll patients with baseline QTc of >470 msec. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia [see Dosage and Administration (2.5) ]. 5.3 Cardiomyopathy TAGRISSO can cause cardiomyopathy, including cardiac failure, chronic cardiac failure, congestive heart failure, pulmonary edema or decreased ejection fraction. Across clinical trials, cardiomyopathy occurred in 3.8% of the 1813 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. In the FLAURA2 study, cardiomyopathy occurred in 9% of the 276 patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy; 1.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10 percentage points from baseline and to less than 50% LVEF occurred in 4.2% of 1557 patients who had baseline and at least one follow-up LVEF assessment. In the ADAURA study, 1.5% (5/325) of patients treated with TAGRISSO experienced LVEF decreases greater than or equal to 10 percentage points and a drop to less than 50%. In the LAURA study, following platinum-based chemoradiation therapy, 3% (4/135) of patients treated with TAGRISSO and no patients treated with placebo experienced LVEF decreases greater than or equal to 10 percentage points and a drop to less than 50%. In the FLAURA2 study, 8% (21/262) of patients treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, who had baseline and at least one follow-up LVEF assessment, experienced LVEF decreases greater than or equal to 10 percentage points and a drop to less than 50%. For patients who will be receiving TAGRISSO monotherapy, conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors. For patients who will be receiving TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in all patients. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO [see Dosage and Administration (2.5) ]. 5.4 Keratitis Keratitis was reported in 0.6% of 1813 patients treated with TAGRISSO monotherapy in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist. 5.5 Erythema Multiforme Major, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis Postmarketing cases consistent with erythema multiforme major (EMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in patients receiving TAGRISSO [see Postmarketing (6.2) ] . Withhold TAGRISSO if EMM, SJS, or TEN is suspected and permanently discontinue if confirmed. 5.6 Cutaneous Vasculitis Postmarketing cases of cutaneous vasculitis including leukocytoclastic vasculitis, urticarial vasculitis, and IgA vasculitis have been reported in patients receiving TAGRISSO [see Postmarketing (6.2) ] . Withhold TAGRISSO if cutaneous vasculitis is suspected, evaluate for systemic involvement, and consider dermatology consultation. If no other etiology can be identified, consider permanent discontinuation of TAGRISSO based on severity. 5.7 Aplastic Anemia Aplastic anemia has been reported in patients treated with TAGRISSO in clinical trials (0.06% of 1813) and postmarketing [see Postmarketing (6.2) ] . Some cases had a fatal outcome. Inform patients of the signs and symptoms of aplastic anemia including but not limited to, new or persistent fevers, bruising, bleeding, and pallor. If aplastic anemia is suspected, withhold TAGRISSO and obtain a hematology consultation. If aplastic anemia is confirmed, permanently discontinue TAGRISSO [see Dosage and Administration (2.5) ] . Perform complete blood count with differential before starting TAGRISSO, periodically throughout treatment, and more frequently if indicated. 5.8 Embryo-Fetal Toxicity Based on data from animal studies and its mechanism of action, TAGRISSO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, osimertinib caused post-implantation fetal loss when administered during early development at a dose exposure 1.5 times the exposure at the recommended clinical dose. When males were treated prior to mating with untreated females, there was an increase in preimplantation embryonic loss at plasma exposures of approximately 0.5 times those observed at the recommended dose of 80 mg once daily. Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the last dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the last dose [see Use in Specific Populations (8.1 and 8.3) ]."],"clinical_studies_table":["<table ID=\"_RefID0EKWDI\" width=\"100%\"><caption>Table 14. Efficacy Results in ADAURA according to Investigator Assessment</caption><col width=\"26%\"/><col width=\"21%\"/><col width=\"18%\"/><col width=\"17%\"/><col width=\"18%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">STAGE II-IIIA POPULATION</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">STAGE IB-IIIA POPULATION</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=233)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">PLACEBO</content> <content styleCode=\"bold\">(N=237)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=339)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">PLACEBO</content> <content styleCode=\"bold\">(N=343)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Disease-Free Survival (DFS)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>DFS events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>26 (11)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>130 (55)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37 (11)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>159 (46)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Recurrent disease (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>26 (11)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>129 (54)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37 (11)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>157 (46)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Deaths (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1 (0.4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2 (0.6)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Median DFS, months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NR (38.8, NE)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19.6 (16.6, 24.5)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NR (NE, NE)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27.5 (22.0, 35.0)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hazard ratio (95% CI)<footnote ID=\"_Ref59356104\">Stratified by race (Asian vs other races), mutation status (Ex19del vs L858R), and pTNM staging.</footnote><footnote ID=\"_Ref178934609\">Pike estimator.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.17 (0.12, 0.23)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.20 (0.15, 0.27)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>p-value<footnoteRef IDREF=\"_Ref59356104\"/><footnote ID=\"_Ref178934665\">Stratified log-rank test.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;0.0001</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;0.0001</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Overall Survival (OS)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Number of deaths (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>35 (15)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>65 (27)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>42 (12)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>82 (24)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hazard Ratio (95% CI)<footnoteRef IDREF=\"_Ref59356104\"/><footnoteRef IDREF=\"_Ref178934609\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.49 (0.33, 0.73)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.49 (0.34, 0.70)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>p-value<footnoteRef IDREF=\"_Ref59356104\"/><footnoteRef IDREF=\"_Ref178934665\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.0004</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;0.0001</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Botrule \" valign=\"top\"><paragraph>DFS results based on investigator assessment.</paragraph><paragraph>CI=Confidence Interval; NE=Not Estimable; NR=Not Reached</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EZBAK\" width=\"100%\"><caption>Table 15. Efficacy Results in LAURA</caption><col width=\"44%\"/><col width=\"28%\"/><col width=\"28%\"/><thead><tr><th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Efficacy Parameter</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=143)</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N=73)</content></th></tr></thead><tbody><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Progression-Free Survival</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>PFS events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>57 (40)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>63 (86)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Progressive disease (%)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>53 (37)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>62 (85)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Death<footnote ID=\"_Ref191017086\">Without documented radiological disease progression.</footnote> (%)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4 (3)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1 (1)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Median PFS in months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>39.1 (31.5, NE)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5.6 (3.7, 7.4)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hazard Ratio (95% CI)<footnote ID=\"_Ref178937608\">Stratified by disease stage prior to chemotherapy (IIIA vs IIIB/IIIC).</footnote><footnote ID=\"_Ref178937620\">Pike estimator.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.16 (0.10, 0.24)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>p-value<footnoteRef IDREF=\"_Ref178937608\"/><footnote ID=\"_Ref178937722\">Stratified log-rank test.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>&lt;0.001</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Overall Response Rate</content><footnote ID=\"_Ref178937779\">Confirmed responses.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>ORR, % (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>54 (45, 62)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>26 (17, 38)</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Botrule \" valign=\"middle\"><paragraph>CI=Confidence Interval, NE=Not Estimable</paragraph><paragraph>PFS and ORR results as assessed by BICR.</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0ESIAK\" width=\"100%\"><caption>Table 16. Efficacy Results in FLAURA according to Investigator Assessment</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><thead><tr><th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Efficacy Parameter</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=279)</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">EGFR TKI</content> <content styleCode=\"bold\">(gefitinib or erlotinib)</content> <content styleCode=\"bold\">(N=277)</content></th></tr></thead><tbody><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Progression-Free Survival (PFS)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>PFS events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>136 (49)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>206 (74)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Progressive disease (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>125 (45)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>192 (69)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Death<footnote ID=\"_Ref191017118\">Without documented radiological disease progression.</footnote> (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>11 (4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>14 (5)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Median PFS in months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>18.9 (15.2, 21.4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>10.2 (9.6, 11.1)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hazard Ratio (95% CI)<footnote ID=\"_Ref178945416\">Stratified by ethnicity (Asian vs Other races) and mutation status (Ex19del vs L858R).</footnote><sup>, </sup><footnote ID=\"_Ref178945492\">Pike estimator.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.46 (0.37, 0.57)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>p-value<footnoteRef IDREF=\"_Ref178945416\"/><sup>, </sup><footnote ID=\"_Ref178945456\">Stratified log-rank test.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>&lt;0.0001</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Overall Survival (OS)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Number of deaths (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>155 (56)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>166 (60)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Median OS in months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>38.6 (34.5, 41.8)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>31.8 (26.6, 36.0)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hazard Ratio (95% CI)<footnoteRef IDREF=\"_Ref178945416\"/><sup>, </sup><footnoteRef IDREF=\"_Ref178945492\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.80 (0.64, 1.00)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>p-value<footnoteRef IDREF=\"_Ref178945416\"/><sup>, </sup><footnoteRef IDREF=\"_Ref178945456\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.0462</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Overall Response Rate (ORR)</content><footnote ID=\"_Ref178945400\">Confirmed responses.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>ORR, % (95% CI)<footnoteRef IDREF=\"_Ref178945416\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>77 (71, 82)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>69 (63, 74)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Complete response, %</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Partial response, %</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>75</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>68</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Duration of Response (DoR)</content><footnoteRef IDREF=\"_Ref178945400\"/></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Median in months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>17.6 (13.8, 22.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>9.6 (8.3, 11.1)</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EMSAK\" width=\"100%\"><caption>Table 17. CNS ORR and DOR by BICR in Patients with Measurable CNS Lesions at Baseline in FLAURA</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr styleCode=\"Toprule\"><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">TAGRISSO</content></paragraph><paragraph>N=22</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">EGFR TKI</content></paragraph><paragraph><content styleCode=\"bold\">(gefitinib or erlotinib)</content></paragraph><paragraph>N=19</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">CNS Tumor Response Assessment</content><footnote ID=\"_Ref59361977\">According to RECIST v1.1.</footnote><footnote ID=\"_Ref183610807\">Based on confirmed response.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>CNS ORR, % (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>77 (55, 92)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>63 (38, 84)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Complete response, %</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">CNS Duration of Response</content><footnote ID=\"_Ref191027007\">Based on patients with response only; DoR defined as the time from the date of first documented response (complete response or partial response) until progression or death event.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Number of responders</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Response Duration &#x2265;6 months, %</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>88</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>50</paragraph></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> Response Duration &#x2265;12 months, %</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>33</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EIYAK\" width=\"100%\"><caption>Table 18. Efficacy Results in FLAURA2 according to Investigator Assessment</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><thead><tr><th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Efficacy Parameter</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO with pemetrexed and platinum-based chemotherapy</content> <content styleCode=\"bold\">(N=279)</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=278)</content></th></tr></thead><tbody><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Progression-Free Survival (PFS)</content><footnote ID=\"_Ref158999012\">PFS and ORR results by BICR were consistent with those reported via investigator assessment.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>PFS events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>120 (43)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>166 (60)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Progressive disease (%)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>95 (34)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>158 (57)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Death<footnote ID=\"_Ref178938619\">Without documented radiological disease progression</footnote> (%)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>25 (9)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>8 (2.9)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Median PFS in months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>25.5 (24.7, NE)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>16.7 (14.1, 21.3)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hazard Ratio (95% CI)<footnote ID=\"_Ref178938679\">Stratified by race (Chinese/Asian, -Other races except Chinese/Asian vs other races), WHO performance status (0 or 1) and method of tissue testing (central or local).</footnote><footnote ID=\"_Ref183611160\">Pike estimator.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.62 (0.49, 0.79)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>p-value<footnoteRef IDREF=\"_Ref178938679\"/><footnote ID=\"_Ref178938738\">Stratified log-rank test.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>&lt;0.0001</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Overall Response Rate (ORR)</content><footnote ID=\"_Ref183611211\">Confirmed responses.</footnote><footnoteRef IDREF=\"_Ref158999012\"/></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>ORR, % (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>77 (71, 82)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>69 (63, 74)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Complete response, %</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Partial response, %</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>76</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>68</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Duration of Response (DoR)</content><footnoteRef IDREF=\"_Ref183611211\"/></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Median in months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>24.9 (22.1, NE)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>17.9 (15.2, 20.9)</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Botrule \" valign=\"top\"><paragraph>NE=Not Estimable; NR=Not Reached</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EJABK\" width=\"100%\"><caption>Table 19. Exploratory Analysis &#x2013; CNS Efficacy by BICR in Patients with CNS Metastases on a Baseline Brain Scan in FLAURA2</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Efficacy Parameter</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">CNS Measurable Lesions</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">TAGRISSO with pemetrexed and platinum-based chemotherapy</content> <content styleCode=\"bold\">(N=40)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=38)</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">CNS Tumor Response Assessment</content><footnote ID=\"_Ref178938929\">According to RECIST v1.1.</footnote><footnote ID=\"_Ref183611541\">Based on confirmed response.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>CNS ORR, % (95% CI) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>80 (64, 91)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>76 (60, 89)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Complete response, %</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>16</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Partial response, %</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>61</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">CNS Duration of Response</content><footnoteRef IDREF=\"_Ref183611541\"/><footnote ID=\"_Ref183611608\">Based on patients with response only; DoR defined as the time from the date of first documented response (complete response or partial response) until progression or death event.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Number of responders</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>29</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Response Duration &#x2265;6 months, %</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>75</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>50</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"unordered\"><item><caption> </caption>Response Duration &#x2265;12 months, %</item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>34</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0ECHBK\" width=\"100%\"><caption>Table 20. Efficacy Results According to Investigator Assessment in AURA3</caption><col width=\"49%\"/><col width=\"32%\"/><col width=\"19%\"/><thead><tr><th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Efficacy Parameter</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=279)</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Chemotherapy</content> <content styleCode=\"bold\">(N=140)</content></th></tr></thead><tbody><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Progression-Free Survival</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>140 (50)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>110 (79)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Progressive disease (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>129 (46)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>104 (74)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Death<footnote ID=\"_Ref178946997\">Without documented radiological disease progression.</footnote>(%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>11 (4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>6 (4)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Median PFS in months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>10.1 (8.3, 12.3)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4.4 (4.2, 5.6)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hazard Ratio (95% CI<footnote ID=\"_Ref178946974\">Stratified by ethnicity (Asian vs other races).</footnote><footnote ID=\"_Ref178946983\">Pike estimator.</footnote>)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.30 (0.23,0.41)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>p-value<footnoteRef IDREF=\"_Ref178946974\"/><footnote ID=\"_Ref178947035\">Stratified log-rank test.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>&lt;0.001</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Overall Survival</content></paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Number of deaths (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>188 (67)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>93 (66)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Median OS in months (95% CI) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>26.8 (23.5, 31.5)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>22.5 (20.2, 28.8)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hazard Ratio (95% CI)<footnoteRef IDREF=\"_Ref178946974\"/><footnoteRef IDREF=\"_Ref178946983\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.87 (0.67, 1.12)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>p-value<footnoteRef IDREF=\"_Ref178946974\"/><footnoteRef IDREF=\"_Ref178947035\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.277</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Overall Response Rate</content><footnote ID=\"_Ref178947170\">Confirmed responses.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>ORR, % (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>65 (59, 70)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>29 (21, 37)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Complete response, %</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Partial response, %</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>27</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>p-value<footnoteRef IDREF=\"_Ref178946974\"/><footnote ID=\"_Ref178947273\">Logistic regression analysis.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>&lt;0.001</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Duration of Response (DoR)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Median in months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>11.0 (8.6, 12.6)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>4.2 (3.0, 5.9)</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0ELRBK\" width=\"100%\"><caption>Table 21. CNS ORR and DoR by BICR in Patients with Measurable CNS Lesions at Baseline in AURA3</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr styleCode=\"Toprule\"><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">TAGRISSO</content></paragraph><paragraph><content styleCode=\"bold\">N=30</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Chemotherapy</content></paragraph><paragraph><content styleCode=\"bold\">N=16</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">CNS Tumor Response Assessment</content><footnote ID=\"_Ref59363361\">According to RECIST v 1.1.</footnote><footnote ID=\"_Ref178946710\">Based on confirmed response.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>CNS ORR, % (95% CI) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>57 (37, 75)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>25 (7, 52)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Complete response, %</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Duration of CNS Response</content><footnoteRef IDREF=\"_Ref178946710\"/><footnote ID=\"_Ref178946731\">Based on patients with response only; DoR defined as the time from the date of first documented response (complete response or partial response) until progression or death event.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Number of responders</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Response Duration &#x2265;6 months, %</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Response Duration &#x2265;9 months, %</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility A 2-year carcinogenicity was conducted in male and female rats at oral osimertinib doses of 1, 3, and 10 mg/kg/day. Osimertinib increased the incidences of hemangioma and combined hemangioma/hemangiosarcoma in the mesenteric lymph node and whole body at 10 mg/kg/day (0.2 times the human exposure based on AUC at the clinical dose of 80 mg once daily). Administration of osimertinib to male and female rasH2 transgenic mice by oral gavage daily for 26 weeks did not result in an increased incidence of neoplasms at doses up to 10 mg/kg/day. Osimertinib did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in mouse lymphoma cells or in the rat in vivo micronucleus assay. Based on studies in animals, male fertility may be impaired by treatment with TAGRISSO. Degenerative changes were present in the testes in rats and dogs exposed to osimertinib for 1 month or more with evidence of reversibility in the rat. Following administration of osimertinib to rats for approximately 10 weeks at a dose of 40 mg/kg, at exposures 0.5 times the AUC observed at the recommended clinical dose of 80 mg once daily, there was a reduction in male fertility, demonstrated by increased pre-implantation loss in untreated females mated to treated males. Based on studies in animals, female fertility may be impaired by treatment with TAGRISSO. In repeat dose toxicity studies, histological evidence of anestrus, corpora lutea degeneration in the ovaries and epithelial thinning in the uterus and vagina were seen in rats exposed to osimertinib for 1 month or more at exposures 0.3 times the AUC observed at the recommended clinical dose of 80 mg once daily. Findings in the ovaries seen following 1 month of dosing exhibited evidence of reversibility. In a female fertility study in rats, administration of osimertinib from 2 weeks prior to mating through Day 8 of gestation at a dose of 20 mg/kg/day (approximately 1.5 times the C max at the recommended dose of 80 mg once daily) had no effects on estrous cycling or the number of females becoming pregnant, but caused early embryonic deaths. These findings showed evidence of reversibility when females were mated 1 month after treatment discontinuation. 13.2 Animal Toxicology and/or Pharmacology Administration of osimertinib resulted in histological findings of lens fiber degeneration in the 2-year rat carcinogenicity study at ≥3 mg/kg/day (exposures 0.2 times the human exposure based on AUC). These findings were consistent with the ophthalmoscopic observation of lens opacities, which were first noted from week 52 and showed a gradual increase in incidence and severity with increased duration of dosing."],"adverse_reactions_table":["<table ID=\"_RefID0EZGBG\" width=\"100%\"><caption>Table 4. Adverse Reactions Occurring in &#x2265;10% of Patients Receiving TAGRISSO in ADAURA<footnote ID=\"_Ref178942629\">NCI CTCAE v4.0.</footnote></caption><col width=\"28%\"/><col width=\"28%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"14%\"/><thead><tr><th align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Adverse Reaction</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=337)</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">PLACEBO</content> <content styleCode=\"bold\">(N=343)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">(%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or higher</content><footnote ID=\"_Ref178864506\">All events were grade 3.</footnote> <content styleCode=\"bold\">(%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">(%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or higher</content><footnoteRef IDREF=\"_Ref178864506\"/> <content styleCode=\"bold\">(%)</content></th></tr></thead><tbody><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Diarrhea<footnote ID=\"_Ref178864540\">Includes diarrhea, colitis, enterocolitis, enteritis.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Stomatitis<footnote ID=\"_Ref178864588\">Includes aphthous ulcer, cheilitis, gingival ulceration, glossitis, tongue ulceration, stomatitis and mouth ulceration.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Abdominal Pain<footnote ID=\"_Ref178864607\">Includes abdominal discomfort, abdominal pain, abdominal lower pain, abdominal upper pain, epigastric discomfort, hepatic pain.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Skin Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Rash<footnote ID=\"_Ref178864626\">Includes rash, rash generalized, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, rash pruritic, rash vesicular, rash follicular, erythema, folliculitis, acne, dermatitis, dermatitis acneiform, dermatitis bullous, dermatitis exfoliative generalized, drug eruption, eczema, eczema asteatotic, lichen planus, skin erosion, pustule.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Nail toxicity<footnote ID=\"_Ref178864645\">Includes nail bed disorder, nail bed inflammation, nail bed infection, nail discoloration, nail pigmentation, nail disorder, nail toxicity, nail dystrophy, nail infection, nail ridging, onychalgia, onychoclasis, onycholysis, onychomadesis, onychomalacia, paronychia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dry skin<footnote ID=\"_Ref178864664\">Includes dry skin, skin fissures, xerosis, eczema, xeroderma.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pruritus<footnote ID=\"_Ref178864682\">Includes pruritus, pruritus generalized, eyelid pruritus.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Respiratory, Thoracic and Mediastinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Cough<footnote ID=\"_Ref178864703\">Includes cough, productive cough, upper-airway cough syndrome.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Musculoskeletal and Connective Tissue Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Musculoskeletal Pain<footnote ID=\"_Ref178864725\">Includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain in extremity, and spinal pain.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Infection and Infestation Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Nasopharyngitis</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Upper respiratory tract infection</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Urinary Tract Infection<footnote ID=\"_Ref178864760\">Includes cystitis, urinary tract infection, and urinary tract infection bacterial.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General Disorders and Administration Site Conditions</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Fatigue<footnote ID=\"_Ref178864782\">Includes asthenia, fatigue.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism and Nutrition Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Nervous System Disorders</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Dizziness<footnote ID=\"_Ref178865034\">Includes dizziness, vertigo, and vertigo positional.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EXYBG\" width=\"100%\"><caption>Table 5. Laboratory Abnormalities Worsening from Baseline in &#x2265;20% of Patients in ADAURA</caption><col width=\"28%\"/><col width=\"28%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"15%\"/><thead><tr><th align=\"left\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><content styleCode=\"bold\">Laboratory Abnormality</content><footnote ID=\"_Ref59203742\">NCI CTCAE v4.0</footnote><footnote ID=\"_Ref59203775\">Based on the number of patients with available follow-up laboratory data.</footnote></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=337)</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">PLACEBO</content> <content styleCode=\"bold\">(N=343)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">All Grades (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or Grade 4 (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">(%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or Grade 4</content> <content styleCode=\"bold\">(%)</content></th></tr></thead><tbody><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Leukopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>54</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Thrombocytopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Lymphopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>44</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.9</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Anemia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Neutropenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Chemistry </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hyperglycemia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.9</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypermagnesemia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Hyponatremia</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0ERCAI\" width=\"100%\"><caption>Table 6. Adverse Reactions in &#x2265;10% of Patients Receiving TAGRISSO in LAURA<footnote ID=\"_Ref178865479\">NCI CTCAE v5.0</footnote></caption><col width=\"28%\"/><col width=\"28%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"15%\"/><thead><tr><th align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Adverse Reaction</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=143)</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N=73)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Any Grade (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or 4(%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Any Grade (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or 4</content> <content styleCode=\"bold\">(%)</content></th></tr></thead><tbody><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Respiratory, Thoracic and Mediastinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>ILD/pneumonitis<footnote ID=\"_Ref178865748\">Includes radiation pneumonitis, radiation lung fibrosis, pneumonitis, interstitial lung disease (ILD), pulmonary fibrosis.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Cough<footnote ID=\"_Ref178865772\">Includes cough, productive cough.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Skin Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Rash<footnote ID=\"_Ref178865822\">Includes rash, maculo-papular rash, pustular rash, pruritic rash, folliculitis, papule, dermatitis, acneiform dermatitis, atopic dermatitis, eczema, asteatotic eczema, acne, urticaria.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Nail toxicity<footnote ID=\"_Ref178865863\">Includes nail bed disorder, nail disorder, nail discoloration, nail infection, onychoclasis, paronychia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dry skin<footnote ID=\"_Ref178865985\">Includes dry skin, skin fissures, senile xerosis, xeroderma.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pruritus</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Diarrhea<footnote ID=\"_Ref178866019\">Includes diarrhea, enteritis.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Stomatitis<footnote ID=\"_Ref178866037\">Includes stomatitis, aphthous ulceration, mouth ulceration.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal and Connective Tissue Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Musculoskeletal pain<footnote ID=\"_Ref178866062\">Includes musculoskeletal chest pain, myalgia, arthritis, arthralgia, back pain, bone pain, musculoskeletal pain, neck pain, pain in extremity, spinal osteoarthritis.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Infection and Infestation Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>COVID-19<footnote ID=\"_Ref178866151\">Includes COVID-19 and COVID-19 pneumonia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pneumonia<footnote ID=\"_Ref178866167\">Includes pneumonia, aspiration pneumonia, viral pneumonia, Pneumocystis jiroveci pneumonia, Haemophilus pneumonia, lower respiratory tract infection.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism and Nutrition Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EXQAI\" width=\"100%\"><caption>Table 7. Laboratory Abnormalities Worsening from Baseline in &#x2265;20% of Patients in LAURA</caption><col width=\"28%\"/><col width=\"28%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"15%\"/><thead><tr><th align=\"left\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><content styleCode=\"bold\">Laboratory Abnormality</content><footnote ID=\"_Ref178866594\">NCI CTCAE v5.0</footnote><footnote ID=\"_Ref178866613\">Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (TAGRISSO arm: 142 and placebo arm: 72).</footnote></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=143)</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(N=73)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">All Grades (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or 4</content> <content styleCode=\"bold\">(%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">All Grades </content> <content styleCode=\"bold\">(%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or 4</content> <content styleCode=\"bold\">(%)</content></th></tr></thead><tbody><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Lymphopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Leukopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>66</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Thrombocytopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Neutropenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1.4</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0ECXAI\" width=\"100%\"><caption>Table 8. Adverse Reactions Occurring in &#x2265;10% of Patients Receiving TAGRISSO in FLAURA<footnote ID=\"_Ref178929742\">NCI CTCAE v4.0</footnote></caption><col width=\"30%\"/><col width=\"20%\"/><col width=\"18%\"/><col width=\"14%\"/><col width=\"18%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">TAGRISSO</content></paragraph><paragraph><content styleCode=\"bold\">(N=279)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">EGFR TKI comparator</content></paragraph><paragraph><content styleCode=\"bold\">(gefitinib or erlotinib)</content></paragraph><paragraph><content styleCode=\"bold\">(N=277)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Grade </content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3 or higher (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Any Grade (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3 or higher (%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Diarrhea<footnote ID=\"_Ref178930444\">One grade 5 (fatal) event was reported (diarrhea) for EGFR TKI comparator.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>58</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Stomatitis<footnote ID=\"_Ref178930462\">Includes stomatitis and mouth ulceration.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Skin Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Rash<footnote ID=\"_Ref178930518\">Includes rash, rash generalized, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, rash pruritic, rash vesicular, rash follicular, erythema, folliculitis, acne, dermatitis, dermatitis acneiform, drug eruption, skin erosion, pustule.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>58</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>78</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dry skin<footnote ID=\"_Ref178930534\">Includes dry skin, skin fissures, xerosis, eczema, xeroderma.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Nail toxicity<footnote ID=\"_Ref178930551\">Includes nail bed disorder, nail bed inflammation, nail bed infection, nail discoloration, nail pigmentation, nail disorder, nail toxicity, nail dystrophy, nail infection, nail ridging, onychalgia, onychoclasis, onycholysis, onychomadesis, onychomalacia, paronychia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pruritus<footnote ID=\"_Ref178930589\">Includes pruritus, pruritus generalized, eyelid pruritus.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General Disorders and Administration Site Conditions</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Fatigue<footnote ID=\"_Ref178930765\">Includes fatigue, asthenia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pyrexia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism and Nutrition Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.8</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Respiratory, Thoracic and Mediastinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Cough</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dyspnea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.4</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Neurologic Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cardiac Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Prolonged QT Interval<footnote ID=\"_Ref178930931\">Includes prolonged QT interval reported as adverse reaction.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Infection and Infestation Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Upper Respiratory Tract Infection</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EZJBI\" width=\"100%\"><caption>Table 9. Laboratory Abnormalities Worsening from Baseline in &#x2265;20% of Patients in FLAURA</caption><col width=\"25%\"/><col width=\"25%\"/><col width=\"16%\"/><col width=\"17%\"/><col width=\"17%\"/><tbody><tr styleCode=\"Toprule\"><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Laboratory Abnormality</content><footnote ID=\"_Ref523916562\">NCI CTCAE v4.0</footnote><footnote ID=\"_Ref178931228\">Each test incidence, except for hyperglycemia, is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (TAGRISSO range: 267 - 273 and EGFR TKI comparator range: 256 - 268).</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">TAGRISSO</content></paragraph><paragraph><content styleCode=\"bold\">(N=279)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">EGFR TKI comparator</content></paragraph><paragraph><content styleCode=\"bold\">(gefitinib or erlotinib)</content></paragraph><paragraph><content styleCode=\"bold\">(N=277)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3 or </content></paragraph><paragraph><content styleCode=\"bold\">Grade 4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3</content></paragraph><paragraph><content styleCode=\"bold\">or Grade 4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Lymphopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4.2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Anemia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>59</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>47</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Thrombocytopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Neutropenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Chemistry</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hyperglycemia<footnote ID=\"_Ref178931251\">Hyperglycemia is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: TAGRISSO (179) and EGFR comparator (191).</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypermagnesemia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hyponatremia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Increased AST</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>43</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4.1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Increased ALT</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>52</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hypokalemia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.1</paragraph></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Hyperbilirubinemia</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1.1</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EOWBI\" width=\"100%\"><caption>Table 10. Adverse Reactions Occurring in &#x2265;10% of Patients Receiving TAGRISSO in FLAURA2<footnote ID=\"_Ref158984528\">NCI CTCAE v5.0</footnote></caption><col width=\"28%\"/><col width=\"28%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"15%\"/><thead><tr><th align=\"left\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><content styleCode=\"bold\">Adverse Reaction</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO with Pemetrexed and Platinum-based Chemotherapy (N=276)</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=275)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Any Grade (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or higher</content> <content styleCode=\"bold\">(%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Any Grade (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or higher</content> <content styleCode=\"bold\">(%)</content></th></tr></thead><tbody><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Skin Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Rash<footnote ID=\"_Ref178931857\">Includes rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, rash pruritic, rash vesicular, rash follicular, erythema, folliculitis, acne, dermatitis, dermatitis acneiform, drug eruption, skin erosion, pustule.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>44</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Nail toxicity<footnote ID=\"_Ref178931881\">Includes nail bed disorder, nail bed inflammation, nail bed infection, nail discoloration, nail pigmentation, nail disorder, nail toxicity, nail dystrophy, nail infection, nail ridging, onychalgia, onychoclasis, onycholysis, onychomadesis, onychomalacia, paronychia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Dry skin<footnote ID=\"_Ref178931896\">Includes dry skin, skin fissures, xerosis, eczema, xeroderma.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Pruritus<footnote ID=\"_Ref178931934\">Includes pruritus, eyelid pruritus.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>43</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Stomatitis<footnote ID=\"_Ref178931949\">Includes stomatitis and mouth ulceration.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EO5BI\" width=\"100%\"><caption>Table 11. Laboratory Abnormalities Worsening from Baseline in &#x2265;20% of Patients in FLAURA2<footnote ID=\"_Ref158987615\">NCI CTCAE v5.0</footnote><footnote ID=\"_Ref178932111\">Findings based on test results presented as CTCAE grade shifts.</footnote></caption><col width=\"28%\"/><col width=\"28%\"/><col width=\"15%\"/><col width=\"15%\"/><col width=\"15%\"/><thead><tr><th align=\"left\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><content styleCode=\"bold\">Laboratory Abnormality</content><footnote ID=\"_Ref178932140\">Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (TAGRISSO with pemetrexed and platinum-based chemotherapy arm: 275 and TAGRISSO monotherapy arm: 275).</footnote></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO with Pemetrexed and Platinum-based Chemotherapy (N=276)</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">TAGRISSO</content> <content styleCode=\"bold\">(N=275)</content></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">All Grades (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or Grade 4</content> <content styleCode=\"bold\">(%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">All Grades</content> <content styleCode=\"bold\">(%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grade 3 or Grade 4</content> <content styleCode=\"bold\">(%)</content></th></tr></thead><tbody><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Leukopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>88</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>53</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Thrombocytopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>85</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>44</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Neutropenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>85</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4.7</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Lymphopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>78</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Chemistry</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Blood creatinine increased</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EXFCI\" width=\"100%\"><caption>Table 12. Adverse Reactions Occurring in &#x2265;10% of Patients Receiving TAGRISSO in AURA3<footnote ID=\"_Ref25566854\">NCI CTCAE v4.0.</footnote></caption><col width=\"34%\"/><col width=\"33%\"/><col width=\"10%\"/><col width=\"12%\"/><col width=\"11%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">TAGRISSO</content></paragraph><paragraph><content styleCode=\"bold\">(N=279)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Chemotherapy</content></paragraph><paragraph><content styleCode=\"bold\">(Pemetrexed/Cisplatin or</content></paragraph><paragraph><content styleCode=\"bold\">Pemetrexed/Carboplatin)</content></paragraph><paragraph><content styleCode=\"bold\">(N=136)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">All Grades</content><footnote ID=\"_Ref178932813\">No grade 4 events were reported.</footnote></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Grade 3/4</content><footnoteRef IDREF=\"_Ref178932813\"/></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">All Grades</content><footnoteRef IDREF=\"_Ref178932813\"/><content styleCode=\"bold\"> (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Grade 3/4</content><footnoteRef IDREF=\"_Ref178932813\"/></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.7</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Stomatitis<footnote ID=\"_Ref178932860\">Includes stomatitis and mouth ulceration.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.2</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Skin Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Rash<footnote ID=\"_Ref178932874\">Includes rash, rash generalized, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, erythema, folliculitis, acne, dermatitis, acneiform dermatitis, pustule.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Dry skin<footnote ID=\"_Ref178932888\">Includes dry skin, eczema, skin fissures, xerosis.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Nail toxicity<footnote ID=\"_Ref178932902\">Includes nail disorders, nail bed disorders, nail bed inflammation, nail bed tenderness, nail discoloration, nail disorder, nail dystrophy, nail infection, nail ridging, nail toxicity, onychalgia, onychoclasis, onycholysis, onychomadesis, paronychia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Pruritus<footnote ID=\"_Ref178932914\">Includes pruritus, pruritus generalized, eyelid pruritus.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General Disorders and Administration Site Conditions</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Fatigue<footnote ID=\"_Ref178932923\">Includes fatigue, asthenia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5.1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism and Nutrition Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.9</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Respiratory, Thoracic and Mediastinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Cough</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal and Connective Tissue Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Back pain</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.7</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EFVCI\" width=\"100%\"><caption>Table 13. Laboratory Abnormalities Worsening from Baseline in &#x2265;20% of Patients in AURA3</caption><col width=\"31%\"/><col width=\"30%\"/><col width=\"14%\"/><col width=\"13%\"/><col width=\"13%\"/><tbody><tr><td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Laboratory Abnormality</content><footnote ID=\"_Ref523916862\">NCI CTCAE v4.0</footnote><footnote ID=\"_Ref178934212\">Each test incidence, except for hyperglycemia, is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (TAGRISSO 279, Chemotherapy comparator 131).</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">TAGRISSO</content></paragraph><paragraph><content styleCode=\"bold\">(N=279)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Chemotherapy (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin)</content></paragraph><paragraph><content styleCode=\"bold\">(N=131)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3 or Grade 4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grade 3 or Grade 4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hematology</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Anemia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>43</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>79</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Lymphopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Thrombocytopenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Neutropenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12 </paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Chemistry</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Hypermagnesemia<footnoteRef IDREF=\"_Ref178934212\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Hyponatremia<footnoteRef IDREF=\"_Ref178934212\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Hyperglycemia<footnote ID=\"_Ref178934303\">Hyperglycemia is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (TAGRISSO 270, Chemotherapy 5; fasting glucose was not a protocol requirement for patients in the chemotherapy arm).</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Hypokalemia<footnoteRef IDREF=\"_Ref178934212\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph>NA=Not Applicable</paragraph></td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Interstitial Lung Disease/Pneumonitis • Inform patients of the risks of severe or fatal ILD, including pneumonitis. Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms [see Error! Hyperlink reference not valid. ] . QTc Interval Prolongation • Inform patients of symptoms that may be indicative of significant QTc prolongation including dizziness, lightheadedness, and syncope. Advise patients to report these symptoms and to inform their physician about the use of any heart or blood pressure medications [see Error! Hyperlink reference not valid. ] . Cardiomyopathy • Inform patients that TAGRISSO can cause cardiomyopathy. Advise patients to immediately report any signs or symptoms of heart failure to their healthcare provider [see Error! Hyperlink reference not valid. ] . Keratitis • Advise patients to contact their healthcare provider immediately if they develop eye symptoms (eye inflammation, lacrimation, light sensitivity, eye pain, red eye or changes in vision) [see Error! Hyperlink reference not valid. ] . Erythema Multiforme Major, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis • Inform patients of signs and symptoms that may be indicative of EMM, SJS, or TEN. Advise patients to contact their healthcare provider immediately if they develop target lesions or severe blistering or peeling of skin [see Error! Hyperlink reference not valid. ] . Cutaneous Vasculitis • Inform patients of signs and symptoms that may be indicative of cutaneous vasculitis. Advise patients to contact their healthcare provider immediately if they develop multiple, non-blanching red papules on their forearms, lower legs, or buttocks or large hives on their trunk that do not go away within 24 hours and develop a bruised appearance [see Error! Hyperlink reference not valid. ] . Aplastic Anemia • Inform patients of signs and symptoms of aplastic anemia including but not limited to new or persistent fevers, bruising, bleeding, pallor, infection, tiredness or weakness. Advise patients to contact their healthcare provider immediately if signs and symptoms suggestive of aplastic anemia develop [see Error! Hyperlink reference not valid. ] . Embryo-Fetal Toxicity • Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider if they become pregnant or if pregnancy is suspected, while taking TAGRISSO [see Error! Hyperlink reference not valid. and Use in Specific Populations (8.1) ] . Females and Males of Reproductive Potential • Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the last dose [see Use in Specific Populations (8.3) ] . • Advise males to use effective contraception during treatment and for 4 months after the last dose of TAGRISSO [see Use in Specific Populations (8.3) ] . Lactation • Advise women not to breastfeed during treatment with TAGRISSO and for 2 weeks after the last dose [see Use in Specific Populations (8.2) ] . Distributed by: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 TAGRISSO is a registered trademark of the AstraZeneca group of companies. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 09/2024 ©AstraZeneca 2024 Patient Medication Information PATIENT INFORMATION TAGRISSO ® (tuh-GRISS-oh) (osimertinib) tablets What is the most important information I should know about TAGRISSO? TAGRISSO may cause serious side effects, including: • Lung problems. TAGRISSO may cause severe lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever. • Heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your healthcare provider should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint. • Eye problems. TAGRISSO may cause eye problems. Tell your healthcare provider right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO. • Skin problems. TAGRISSO may cause skin problems. Tell your healthcare provider right away if you develop skin reactions that look like rings (target lesions), severe blistering or peeling of the skin. • Inflammation of the blood vessels in your skin . TAGRISSO may cause blood vessel problems in your skin. Tell your healthcare provider right away if you develop purple spots or redness of the skin that does not fade in color when pressed (non-blanching) on your lower arms, lower legs, or buttocks or large hives on the main part of your body (trunk) that do not go away within 24 hours and look bruised. Blood and bone marrow problems . TAGRISSO may cause a condition where your bone marrow cannot make enough new blood cells (aplastic anemia), and which may lead to death. Your healthcare provider will monitor your blood cell counts before you start and during treatment with TAGRISSO. Tell your healthcare provider right away if you develop any signs or symptoms of blood and bone marrow problems, including: • a new fever or fever that does not go away (temperature 100.4°F or higher) • easy bruising or bleeding that will not stop • unusually pale skin • infection • tiredness • weakness See “What are the possible side effects of TAGRISSO?” for more information about side effects. What is TAGRISSO? TAGRISSO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s): • to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery, or • when your lung cancer has spread to nearby tissues (locally advanced) that is unable to be removed (unresectable) by surgery and has responded or stabilized following chemotherapy and radiation treatment, or • as your first treatment when your lung cancer has spread to other parts of the body (metastatic), or • in combination with pemetrexed and platinum-based chemotherapy, as your first treatment when your lung cancer has spread to nearby tissues (locally advanced) or to other parts of the body (metastatic). • when your lung cancer has spread to other parts of the body (metastatic), and you have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working. Your healthcare provider will perform a test to make sure that TAGRISSO is right for you. It is not known if TAGRISSO is safe and effective in children. Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you: • have lung or breathing problems other than your lung cancer. • have heart problems, including a condition called long QTc syndrome. • have problems with your electrolytes, such as sodium, potassium, calcium, or magnesium. • have a history of eye problems. • are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant. • Females who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO. • Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO. • are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine. Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you: • have lung or breathing problems other than your lung cancer. • have heart problems, including a condition called long QTc syndrome. • have problems with your electrolytes, such as sodium, potassium, calcium, or magnesium. • have a history of eye problems. • are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant. • Females who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO. • Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO. • are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine. How should I take TAGRISSO? • Take TAGRISSO exactly as your healthcare provider tells you to take it. • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TAGRISSO if you have side effects. • Take TAGRISSO 1 time each day. • You can take TAGRISSO with or without food. • If you miss a dose of TAGRISSO, do not make up for the missed dose. Take your next dose at your regular time. • If you cannot swallow TAGRISSO tablets whole: • Place your dose of TAGRISSO in a container that contains 60 mL (2 ounces) of water. Do not use carbonated water or any other liquids. • Stir the TAGRISSO tablet and water until the TAGRISSO tablet is in small pieces (the tablet will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture. • Drink the TAGRISSO and water mixture right away. • Add 120 mL to 240 mL (4 to 8 ounces) of water into the container and drink to make sure that you take your full dose of TAGRISSO. • If you have a nasogastric (NG) tube: • Follow the same instructions for mixing TAGRISSO tablets in a container that contains 15 mL of water. Do not use carbonated water or any other liquids. • Stir the TAGRISSO tablets and water until the TAGRISSO tablets are in small pieces (the tablets will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture. • Add another 15 mL of water into the container to make sure no pieces of TAGRISSO tablet remain. • Give the TAGRISSO tablet and water mixture using the NG tube manufacturer instructions within 30 minutes. Add another 30 mL of water into the syringe and give the water and any remaining TAGRISSO through the NG tube to make sure that all of the medicine is given. Repeat this step until no pieces remain in the syringe. This will help to ensure that the full prescribed dose of the TAGRISSO is given. What are the possible side effects of TAGRISSO? TAGRISSO may cause serious side effects: • See “What is the most important information I should know about TAGRISSO?” The most common side effects of TAGRISSO when given alone include: low white blood cell counts low platelet counts low red blood cell counts (anemia) diarrhea rash muscle, bone, or joint pain changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail dry skin mouth sores tiredness The most common side effects of TAGRISSO when given alone after treatment with platinum-based chemotherapy and radiation treatment include: l ow white blood cell counts lung problems low platelet counts rash diarrhea changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail Cough COVID-19 The most common side effects of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy include: low white blood cell counts low platelet counts rash diarrhea mouth sores changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail dry skin increase of a substance in the blood called creatinine Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TAGRISSO. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store TAGRISSO? • Store TAGRISSO at room temperature between 68°F to 77°F (20°C to 25°C). • Safely throw away medicine that is out of date or that you no longer need. Keep TAGRISSO and all medicines out of the reach of children. General information about the safe and effective use of TAGRISSO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAGRISSO for a condition for which it was not prescribed. Do not give TAGRISSO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAGRISSO that is written for health professionals. What are the ingredients in TAGRISSO? Active ingredient: osimertinib Inactive ingredients: mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate. Tablet coating contains: polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, ferric oxide yellow, ferric oxide red and ferric oxide black. Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850 © AstraZeneca 2024 For more information, go to www.Tagrisso.com or call 1-800-236-9933. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 09/2024"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Adjuvant treatment of early-stage NSCLC: 80 mg orally once daily, with or without food, until disease recurrence, or unacceptable toxicity, or for up to 3 years. ( 2.3 ) Locally advanced, unresectable (stage III) NSCLC: Following platinum-based chemoradiation therapy, 80 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. ( 2.3 ) Metastatic NSCLC: 80 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. ( 2.3 ) Locally advanced or metastatic NSCLC: 80 mg orally once daily administered in combination with pemetrexed and platinum-based chemotherapy, with or without food, until disease progression or unacceptable toxicity due to TAGRISSO. ( 2.3 ) 2.1 Recommended Evaluation and Testing Before Initiating TAGRISSO TAGRISSO Monotherapy • Before initiating TAGRISSO monotherapy in patients with cardiac risk factors, conduct cardiac monitoring, including assessment of left ventricular ejection fraction (LVEF) [see Error! Hyperlink reference not valid. ] . • Before initiating TAGRISSO, perform complete blood count with differential [see Error! Hyperlink reference not valid. ] . TAGRISSO in Combination with Pemetrexed and Platinum-based Chemotherapy • Before initiating TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, conduct cardiac monitoring in all patients , including assessment of left ventricular ejection fraction (LVEF) [see Error! Hyperlink reference not valid. ] . • Before initiating TAGRISSO, perform complete blood count with differential [see Error! Hyperlink reference not valid. ] . 2.2 Patient Selection Table 1 below presents the patient selection criteria for treatment with TAGRISSO. Table : Patient Selection Select patients for treatment with TAGRISSO based on the presence of a mutation as detected by an FDA-approved test. Indication Treatment Regimen Required Mutation Source for Testing Adjuvant Treatment of EGFR Mutation-Positive NSCLC [see Indications and Usage (1.1) ] TAGRISSO monotherapy EGFR exon 19 deletions or exon 21 L858R mutations Tumor Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC [see Indications and Usage (1.2) ] Following completion of platinum-based chemoradiation therapy, TAGRISSO monotherapy EGFR exon 19 deletions or exon 21 L858R mutations Tumor First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC [see Indications and Usage (1.3) ] TAGRISSO monotherapy EGFR exon 19 deletions or exon 21 L858R mutations Plasma or tumor First-line Treatment of EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC [see Indications and Usage (1.4) ] TAGRISSO in combination with pemetrexed and platinum-based chemotherapy EGFR exon 19 deletions or exon 21 L858R mutations Plasma or tumor Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC [see Indications and Usage (1.5) ] TAGRISSO monotherapy EGFR T790M Mutation Plasma or tumor Information on FDA-approved tests for the detection of EGFR mutations is available at http://www.fda.gov/companiondiagnostics . 2.3 Recommended Dosage and Administration Recommended Dosage Table 2 provides the recommended dosage of TAGRISSO by indication. Table 2. Recommended Dosage of TAGRISSO Indication Recommended Dosage of TAGRISSO Duration of Treatment Adjuvant Treatment of EGFR Mutation-Positive NSCLC 80 mg tablet orally once daily with or without food For a total of 3 years or until disease recurrence or unacceptable toxicity Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC Following platinum-based chemoradiation therapy, 80 mg tablet orally once daily with or without food Until disease progression or unacceptable toxicity First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC 80 mg tablet orally once daily with or without food Until disease progression or unacceptable toxicity First-line Treatment of EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC 80 mg tablet orally once daily with or without food in combination with pemetrexed and platinum-based chemotherapy Refer to the Prescribing Information for pemetrexed and cisplatin or carboplatin for the respective dosing information. Until disease progression or unacceptable toxicity due to TAGRISSO Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC 80 mg tablet orally once daily with or without food Until disease progression or unacceptable toxicity Administration Administer TAGRISSO 80 mg tablet orally once daily with or without food. Tablets may be dispersed in water for patients who have difficulty swallowing, or for nasogastric tube administration [see Dosage and Administration (2.4) ]. Missed Dose If a dose of TAGRISSO is missed, do not make up the missed dose and take the next dose as scheduled. 2.4 Administration to Patients Who Have Difficulty Swallowing Solids Disperse TAGRISSO tablet in 60 mL (2 ounces) of non-carbonated water only. Stir until tablet is dispersed into small pieces (the tablet will not completely dissolve) and swallow immediately. Do not crush, heat, or ultrasonicate during preparation. Rinse the container with 120 mL to 240 mL (4 to 8 ounces) of water and immediately drink. If administration via nasogastric tube is required, disperse the TAGRISSO tablet as above in 15 mL of non-carbonated water, and then use an additional 15 mL of water to transfer any residues to the syringe. The resulting 30 mL liquid should be administered as per the nasogastric tube instructions with appropriate water flushes (approximately 30 mL). Repeat this step until no pieces remain in the syringe. This will help to ensure that the full prescribed dose of the TAGRISSO is given. The dispersion and residues should be administered within 30 minutes of the addition of the tablets to water. 2.5 Dosage Modifications for Adverse Reactions The recommended dose reductions for adverse reactions are provided in Table 3. Table 3. Recommended Dosage Modifications for TAGRISSO Target Organ Adverse Reaction Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0). Dosage Modification Pulmonary (Patients who have not received recent definitive platinum-based chemoradiation therapy) [see Error! Hyperlink reference not valid. ] Any Grade Interstitial lung disease (ILD)/Pneumonitis Permanently discontinue TAGRISSO. Pulmonary (Patients who have received recent definitive platinum-based chemoradiation therapy) [see Error! Hyperlink reference not valid. ] Grade 1 ILD/Pneumonitis Withhold or continue TAGRISSO, as clinically indicated. Grade ≥2 ILD/Pneumonitis Permanently discontinue TAGRISSO. Cardiac [see Error! Hyperlink reference not valid. 2, Error! Hyperlink reference not valid. ] QTc QTc = QT interval corrected for heart rate interval greater than 500 msec on at least 2 separate ECGs ECGs = Electrocardiograms Withhold TAGRISSO until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec, then resume at 40 mg dose. QTc interval prolongation with signs/symptoms of life-threatening arrhythmia Permanently discontinue TAGRISSO. Symptomatic congestive heart failure Permanently discontinue TAGRISSO. Cutaneous [see Error! Hyperlink reference not valid. ] Erythema Multiforme Major (EMM), Stevens-Johnson syndrome (SJS), and Toxic Epidermal Necrolysis (TEN) Withhold TAGRISSO if suspected and permanently discontinue if confirmed. Blood and bone marrow [see Error! Hyperlink reference not valid. ] Aplastic anemia Withhold TAGRISSO if aplastic anemia is suspected and permanently discontinue if confirmed. Other [see Adverse Reactions (6.1) ] Adverse reaction of Grade 3 or greater severity Withhold TAGRISSO for up to 3 weeks. If improvement to Grade 0-2 within 3 weeks Resume at 80 mg or 40 mg daily. If no improvement within 3 weeks Permanently discontinue TAGRISSO. Dosage Modifications for Combination Therapy When TAGRISSO is administered in combination with pemetrexed and platinum-based chemotherapy, modify the dose of any one of the treatments for the management of adverse reactions, as appropriate. For TAGRISSO dose modification instructions, see Table 3. Withhold, reduce the dose or permanently discontinue pemetrexed, cisplatin or carboplatin according to their respective Prescribing Information. Drug Interactions Strong CYP3A4 Inducers Avoid concomitant use of strong CYP3A4 inducers with TAGRISSO. If concurrent use is unavoidable, increase TAGRISSO dosage to 160 mg daily when co-administering with a strong CYP3A inducer. Resume TAGRISSO at 80 mg 3 weeks after discontinuation of the strong CYP3A4 inducer [see Drug Interactions (7) and Clinical Pharmacology (12.3) ] ."],"spl_product_data_elements":["TAGRISSO osimertinib OSIMERTINIB OSIMERTINIB MANNITOL MICROCRYSTALLINE CELLULOSE SODIUM STEARYL FUMARATE POLYVINYL ALCOHOL, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL 3350 TALC FERRIC OXIDE YELLOW FERRIC OXIDE RED FERROSOFERRIC OXIDE LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED beige biconvex AZ;40 TAGRISSO osimertinib OSIMERTINIB OSIMERTINIB MANNITOL MICROCRYSTALLINE CELLULOSE SODIUM STEARYL FUMARATE POLYVINYL ALCOHOL, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL 3350 TALC FERRIC OXIDE YELLOW FERRIC OXIDE RED FERROSOFERRIC OXIDE LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED beige biconvex AZ;80 TAGRISSO osimertinib OSIMERTINIB OSIMERTINIB MANNITOL MICROCRYSTALLINE CELLULOSE SODIUM STEARYL FUMARATE POLYVINYL ALCOHOL, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL 3350 TALC FERRIC OXIDE YELLOW FERRIC OXIDE RED FERROSOFERRIC OXIDE LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED beige biconvex AZ;40 TAGRISSO osimertinib OSIMERTINIB OSIMERTINIB MANNITOL MICROCRYSTALLINE CELLULOSE SODIUM STEARYL FUMARATE POLYVINYL ALCOHOL, UNSPECIFIED TITANIUM DIOXIDE POLYETHYLENE GLYCOL 3350 TALC FERRIC OXIDE YELLOW FERRIC OXIDE RED FERROSOFERRIC OXIDE LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED beige biconvex AZ;80"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS 80 mg tablets: beige, oval and biconvex tablet marked with “AZ 80” on one side and plain on the reverse. 40 mg tablets: beige, round and biconvex tablet marked with “AZ 40” on one side and plain on the reverse. Tablets: 80 mg and 40 mg. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Do not breastfeed. (8.2 ) 8.1 Pregnancy Risk Summary Based on data from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , TAGRISSO can cause fetal harm when administered to a pregnant woman. There are no available data on TAGRISSO use in pregnant women. Administration of osimertinib to pregnant rats was associated with embryolethality and reduced fetal growth at plasma exposures 1.5 times the exposure at the recommended clinical dose (see Data ) . Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data When administered to pregnant rats prior to embryonic implantation through the end of organogenesis (gestation days 2-20) at a dose of 20 mg/kg/day, which produced plasma exposures of approximately 1.5 times the clinical exposure, osimertinib caused post-implantation loss and early embryonic death. When administered to pregnant rats from implantation through the closure of the hard palate (gestation days 6 to 16) at doses of 1 mg/kg/day and above (0.1 times the AUC observed at the recommended clinical dose of 80 mg once daily), an equivocal increase in the rate of fetal malformations and variations was observed in treated litters relative to those of concurrent controls. When administered to pregnant dams at doses of 30 mg/kg/day during organogenesis through lactation Day 6, osimertinib caused an increase in total litter loss and postnatal death. At a dose of 20 mg/kg/day, osimertinib administration during the same period resulted in increased postnatal death as well as a slight reduction in mean pup weight at birth that increased in magnitude between lactation days 4 and 6. 8.2 Lactation Risk Summary There are no data on the presence of osimertinib or its active metabolites in human milk, the effects of osimertinib on the breastfed infant or on milk production. Administration to rats during gestation and early lactation was associated with adverse effects, including reduced growth rates and neonatal death [see Use in Specific Populations (8.1) ] . Because of the potential for serious adverse reactions in breastfed infants from osimertinib, advise women not to breastfeed during treatment with TAGRISSO and for 2 weeks after the last dose. 8.3 Females and Males of Reproductive Potential Based on animal data, TAGRISSO can cause malformations, embryo lethality, and postnatal death at doses resulting in exposures 1.5 times or less the human exposure at the clinical dose of 80 mg daily [see Use in Specific Populations (8.1) ]. Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the last dose [see Use in Specific Populations (8.1) ] . Males Advise male patients with female partners of reproductive potential to use effective contraception during and for 4 months following the last dose of TAGRISSO [see Nonclinical Toxicology (13.1) ] . Infertility Based on animal studies, TAGRISSO may impair fertility in females and males of reproductive potential. The effects on female fertility showed a trend toward reversibility. It is not known whether the effects on male fertility are reversible [see Nonclinical Toxicology (13.1) ] . 8.4 Pediatric Use The safety and effectiveness of TAGRISSO in pediatric patients have not been established. 8.5 Geriatric Use Monotherapy Of the 1813 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive NSCLC who were treated with TAGRISSO monotherapy, 770 patients were ≥65 years and 207 patients were ≥75 years of age [see Adverse Reactions (6.1) ] . Exploratory analysis suggests a higher incidence of Grade 3 or higher adverse reactions (43% vs 33%) and more frequent dosage modifications for adverse reactions (34% vs 23%) in patients 65 years or older as compared to those younger than 65 years. No overall differences in safety or effectiveness were observed between patients 65 years or older and younger patients. TAGRISSO Following Definitive Platinum-based Chemoradiation Therapy Of the 142 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive, locally advanced unresectable (Stage III) NSCLC treated with TAGRISSO following definitive platinum-based chemoradiation therapy, 62 patients were ≥65 years and 13 patients were ≥75 years of age [see Adverse Reactions (6.1)]. No overall differences in safety or effectiveness were observed between patients 65 years or older and younger patients. TAGRISSO in Combination with Pemetrexed and Platinum-based Chemotherapy Of the 276 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive, locally advanced or metastatic NSCLC treated with TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, 104 patients were ≥65 years and 23 patients were ≥75 years of age [see Adverse Reactions (6.1) ] . Exploratory analysis suggests a higher incidence of Grade 3 or higher adverse reactions (68% vs 61%) and more frequent dosage modifications for adverse reactions (55% vs 43%) in patients 65 years or older as compared to those younger than 65 years. Clinical studies of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. 8.6 Renal Impairment No dose adjustment is recommended in patients with creatinine clearance (CLcr) 15 - 89 mL/min, as estimated by Cockcroft-Gault. There is no recommended dose of TAGRISSO for patients with end-stage renal disease (CLcr <15 mL/min) [see Clinical Pharmacology (12.3) ]. 8.7 Hepatic Impairment No dose adjustment is recommended in patients with mild to moderate hepatic impairment (Child-Pugh A and B or total bilirubin ≤ ULN and AST > ULN or total bilirubin 1 to 3 times ULN and any AST). There is no recommended dose for TAGRISSO for patients with severe hepatic impairment (total bilirubin between 3 to 10 times ULN and any AST) [see Clinical Pharmacology (12.3) ] ."],"information_for_patients_table":["<table width=\"101.04%\"><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PATIENT INFORMATION</content> <content styleCode=\"bold\">TAGRISSO<sup>&#xAE;</sup></content>(tuh-GRISS-oh) <content styleCode=\"bold\">(osimertinib)</content> <content styleCode=\"bold\">tablets</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is the most important information I should know about TAGRISSO?</content></paragraph><paragraph><content styleCode=\"bold\">TAGRISSO may cause serious side effects, including:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Lung problems.</content> TAGRISSO may cause severe lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Heart problems, including heart failure.</content> TAGRISSO may cause heart problems that may lead to death. Your healthcare provider should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Eye problems. </content>TAGRISSO may cause eye problems. Tell your healthcare provider right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Skin problems. </content>TAGRISSO may cause skin problems. Tell your healthcare provider right away if you develop skin reactions that look like rings (target lesions), severe blistering or peeling of the skin.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Inflammation of the blood vessels in your skin</content>. TAGRISSO may cause blood vessel problems in your skin. Tell your healthcare provider right away if you develop purple spots or redness of the skin that does not fade in color when pressed (non-blanching) on your lower arms, lower legs, or buttocks or large hives on the main part of your body (trunk) that do not go away within 24 hours and look bruised.</item></list><paragraph><content styleCode=\"bold\">Blood and bone marrow problems</content>. TAGRISSO may cause a condition where your bone marrow cannot make enough new blood cells (aplastic anemia), and which may lead to death. Your healthcare provider will monitor your blood cell counts before you start and during treatment with TAGRISSO. <content styleCode=\"bold\">Tell your healthcare provider right away</content> if you develop any signs or symptoms of blood and bone marrow problems, including:</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>a new fever or fever that does not go away (temperature 100.4&#xB0;F or higher)</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>easy bruising or bleeding that will not stop</item><item><caption>&#x2022;</caption>unusually pale skin</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>infection</item><item><caption>&#x2022;</caption>tiredness</item><item><caption>&#x2022;</caption>weakness</item></list></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>See <content styleCode=\"bold\">&#x201C;What are the possible side effects of TAGRISSO?&#x201D; </content>for more information about side effects.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is TAGRISSO?</content></paragraph><paragraph>TAGRISSO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s):</paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery, <content styleCode=\"bold\">or</content></item><item><caption>&#x2022;</caption>when your lung cancer has spread to nearby tissues (locally advanced) that is unable to be removed (unresectable) by surgery and has responded or stabilized following chemotherapy and radiation treatment, <content styleCode=\"bold\">or</content></item><item><caption>&#x2022;</caption>as your first treatment when your lung cancer has spread to other parts of the body (metastatic), <content styleCode=\"bold\">or</content></item><item><caption>&#x2022;</caption>in combination with pemetrexed and platinum-based chemotherapy, as your first treatment when your lung cancer has spread to nearby tissues (locally advanced) or to other parts of the body (metastatic).</item><item><caption>&#x2022;</caption>when your lung cancer has spread to other parts of the body (metastatic), and you have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working.</item></list><paragraph>Your healthcare provider will perform a test to make sure that TAGRISSO is right for you.</paragraph><paragraph>It is not known if TAGRISSO is safe and effective in children.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>have lung or breathing problems other than your lung cancer.</item><item><caption>&#x2022;</caption>have heart problems, including a condition called long QTc syndrome.</item><item><caption>&#x2022;</caption>have problems with your electrolytes, such as sodium, potassium, calcium, or magnesium.</item><item><caption>&#x2022;</caption>have a history of eye problems.</item><item><caption>&#x2022;</caption>are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Females</content> who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Males</content> who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO.</item><item><caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time.</item></list><paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>have lung or breathing problems other than your lung cancer.</item><item><caption>&#x2022;</caption>have heart problems, including a condition called long QTc syndrome.</item><item><caption>&#x2022;</caption>have problems with your electrolytes, such as sodium, potassium, calcium, or magnesium.</item><item><caption>&#x2022;</caption>have a history of eye problems.</item><item><caption>&#x2022;</caption>are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Females</content> who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Males</content> who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO.</item><item><caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time.</item></list><paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I take TAGRISSO?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Take TAGRISSO exactly as your healthcare provider tells you to take it.</item><item><caption>&#x2022;</caption>Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TAGRISSO if you have side effects.</item><item><caption>&#x2022;</caption>Take TAGRISSO 1 time each day.</item><item><caption>&#x2022;</caption>You can take TAGRISSO with or without food.</item><item><caption>&#x2022;</caption>If you miss a dose of TAGRISSO, do not make up for the missed dose. Take your next dose at your regular time.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">If you cannot swallow TAGRISSO tablets whole:</content></item><item><caption>&#x2022;</caption>Place your dose of TAGRISSO in a container that contains 60 mL (2 ounces) of water. Do not use carbonated water or any other liquids.</item><item><caption>&#x2022;</caption>Stir the TAGRISSO tablet and water until the TAGRISSO tablet is in small pieces (the tablet will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture.</item><item><caption>&#x2022;</caption>Drink the TAGRISSO and water mixture right away.</item><item><caption>&#x2022;</caption>Add 120 mL to 240 mL (4 to 8 ounces) of water into the container and drink to make sure that you take your full dose of TAGRISSO.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">If you have a nasogastric (NG) tube:</content></item><item><caption>&#x2022;</caption>Follow the same instructions for mixing TAGRISSO tablets in a container that contains 15 mL of water. <content styleCode=\"bold\">Do not</content> use carbonated water or any other liquids.</item><item><caption>&#x2022;</caption>Stir the TAGRISSO tablets and water until the TAGRISSO tablets are in small pieces (the tablets will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture.</item><item><caption>&#x2022;</caption>Add another 15 mL of water into the container to make sure no pieces of TAGRISSO tablet remain.</item><item><caption>&#x2022;</caption>Give the TAGRISSO tablet and water mixture using the NG tube manufacturer instructions within 30 minutes.</item></list><paragraph>Add another 30 mL of water into the syringe and give the water and any remaining TAGRISSO through the NG tube to make sure that all of the medicine is given. Repeat this step until no pieces remain in the syringe. This will help to ensure that the full prescribed dose of the TAGRISSO is given.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the possible side effects of TAGRISSO?</content></paragraph><paragraph><content styleCode=\"bold\">TAGRISSO may cause serious side effects:</content></paragraph><paragraph><content styleCode=\"bold\">&#x2022; See &#x201C;What is the most important information I should know about TAGRISSO?&#x201D;</content></paragraph><paragraph><content styleCode=\"bold\">The most common side effects of TAGRISSO when given alone include:</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>low white blood cell counts</paragraph><paragraph>low platelet counts</paragraph><list listType=\"unordered\"><item><caption> </caption>low red blood cell counts (anemia)</item></list><paragraph>diarrhea</paragraph><paragraph>rash</paragraph></td><td valign=\"top\"><paragraph>muscle, bone, or joint pain</paragraph><paragraph>changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail</paragraph></td><td styleCode=\"Rrule \" valign=\"top\"><paragraph>dry skin</paragraph><paragraph>mouth sores</paragraph><paragraph>tiredness</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">The most common side effects of TAGRISSO when given alone after treatment with platinum-based chemotherapy and radiation treatment include:</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"bold\">l</content>ow white blood cell counts</item></list><paragraph>lung problems</paragraph><paragraph>low platelet counts</paragraph><paragraph>rash</paragraph><paragraph>diarrhea</paragraph></td><td valign=\"top\"><paragraph>changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail</paragraph></td><td styleCode=\"Rrule \" valign=\"top\"><paragraph>Cough</paragraph><paragraph>COVID-19</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">The most common side effects of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy include:</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>low white blood cell counts</paragraph><paragraph>low platelet counts</paragraph><paragraph>rash</paragraph><paragraph>diarrhea</paragraph><paragraph>mouth sores</paragraph></td><td valign=\"top\"><paragraph>changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail</paragraph></td><td styleCode=\"Rrule \" valign=\"top\"><paragraph>dry skin</paragraph><paragraph>increase of a substance in the blood called creatinine</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</paragraph><paragraph>These are not all the possible side effects of TAGRISSO. For more information, ask your healthcare provider or pharmacist.</paragraph><paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I store TAGRISSO?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Store TAGRISSO at room temperature between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item><item><caption>&#x2022;</caption>Safely throw away medicine that is out of date or that you no longer need.</item></list><paragraph><content styleCode=\"bold\">Keep TAGRISSO and all medicines out of the reach of children.</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of TAGRISSO.</content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAGRISSO for a condition for which it was not prescribed. Do not give TAGRISSO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAGRISSO that is written for health professionals.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the ingredients in TAGRISSO?</content></paragraph><paragraph><content styleCode=\"bold\">Active ingredient:</content> osimertinib</paragraph><paragraph><content styleCode=\"bold\">Inactive ingredients:</content> mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate. Tablet coating contains: polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, ferric oxide yellow, ferric oxide red and ferric oxide black.</paragraph><paragraph>Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850</paragraph><paragraph>&#xA9; AstraZeneca 2024</paragraph><paragraph>For more information, go to <linkHtml href=\"http://www.Tagrisso.com\">www.Tagrisso.com</linkHtml> or call 1-800-236-9933.</paragraph></td></tr></tbody></table>"],"patient_medication_information":["Patient Medication Information PATIENT INFORMATION TAGRISSO ® (tuh-GRISS-oh) (osimertinib) tablets What is the most important information I should know about TAGRISSO? TAGRISSO may cause serious side effects, including: • Lung problems. TAGRISSO may cause severe lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever. • Heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your healthcare provider should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint. • Eye problems. TAGRISSO may cause eye problems. Tell your healthcare provider right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO. • Skin problems. TAGRISSO may cause skin problems. Tell your healthcare provider right away if you develop skin reactions that look like rings (target lesions), severe blistering or peeling of the skin. • Inflammation of the blood vessels in your skin . TAGRISSO may cause blood vessel problems in your skin. Tell your healthcare provider right away if you develop purple spots or redness of the skin that does not fade in color when pressed (non-blanching) on your lower arms, lower legs, or buttocks or large hives on the main part of your body (trunk) that do not go away within 24 hours and look bruised. Blood and bone marrow problems . TAGRISSO may cause a condition where your bone marrow cannot make enough new blood cells (aplastic anemia), and which may lead to death. Your healthcare provider will monitor your blood cell counts before you start and during treatment with TAGRISSO. Tell your healthcare provider right away if you develop any signs or symptoms of blood and bone marrow problems, including: • a new fever or fever that does not go away (temperature 100.4°F or higher) • easy bruising or bleeding that will not stop • unusually pale skin • infection • tiredness • weakness See “What are the possible side effects of TAGRISSO?” for more information about side effects. What is TAGRISSO? TAGRISSO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s): • to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery, or • when your lung cancer has spread to nearby tissues (locally advanced) that is unable to be removed (unresectable) by surgery and has responded or stabilized following chemotherapy and radiation treatment, or • as your first treatment when your lung cancer has spread to other parts of the body (metastatic), or • in combination with pemetrexed and platinum-based chemotherapy, as your first treatment when your lung cancer has spread to nearby tissues (locally advanced) or to other parts of the body (metastatic). • when your lung cancer has spread to other parts of the body (metastatic), and you have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working. Your healthcare provider will perform a test to make sure that TAGRISSO is right for you. It is not known if TAGRISSO is safe and effective in children. Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you: • have lung or breathing problems other than your lung cancer. • have heart problems, including a condition called long QTc syndrome. • have problems with your electrolytes, such as sodium, potassium, calcium, or magnesium. • have a history of eye problems. • are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant. • Females who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO. • Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO. • are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine. Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you: • have lung or breathing problems other than your lung cancer. • have heart problems, including a condition called long QTc syndrome. • have problems with your electrolytes, such as sodium, potassium, calcium, or magnesium. • have a history of eye problems. • are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant. • Females who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO. • Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO. • are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine. How should I take TAGRISSO? • Take TAGRISSO exactly as your healthcare provider tells you to take it. • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TAGRISSO if you have side effects. • Take TAGRISSO 1 time each day. • You can take TAGRISSO with or without food. • If you miss a dose of TAGRISSO, do not make up for the missed dose. Take your next dose at your regular time. • If you cannot swallow TAGRISSO tablets whole: • Place your dose of TAGRISSO in a container that contains 60 mL (2 ounces) of water. Do not use carbonated water or any other liquids. • Stir the TAGRISSO tablet and water until the TAGRISSO tablet is in small pieces (the tablet will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture. • Drink the TAGRISSO and water mixture right away. • Add 120 mL to 240 mL (4 to 8 ounces) of water into the container and drink to make sure that you take your full dose of TAGRISSO. • If you have a nasogastric (NG) tube: • Follow the same instructions for mixing TAGRISSO tablets in a container that contains 15 mL of water. Do not use carbonated water or any other liquids. • Stir the TAGRISSO tablets and water until the TAGRISSO tablets are in small pieces (the tablets will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture. • Add another 15 mL of water into the container to make sure no pieces of TAGRISSO tablet remain. • Give the TAGRISSO tablet and water mixture using the NG tube manufacturer instructions within 30 minutes. Add another 30 mL of water into the syringe and give the water and any remaining TAGRISSO through the NG tube to make sure that all of the medicine is given. Repeat this step until no pieces remain in the syringe. This will help to ensure that the full prescribed dose of the TAGRISSO is given. What are the possible side effects of TAGRISSO? TAGRISSO may cause serious side effects: • See “What is the most important information I should know about TAGRISSO?” The most common side effects of TAGRISSO when given alone include: low white blood cell counts low platelet counts low red blood cell counts (anemia) diarrhea rash muscle, bone, or joint pain changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail dry skin mouth sores tiredness The most common side effects of TAGRISSO when given alone after treatment with platinum-based chemotherapy and radiation treatment include: l ow white blood cell counts lung problems low platelet counts rash diarrhea changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail Cough COVID-19 The most common side effects of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy include: low white blood cell counts low platelet counts rash diarrhea mouth sores changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail dry skin increase of a substance in the blood called creatinine Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TAGRISSO. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store TAGRISSO? • Store TAGRISSO at room temperature between 68°F to 77°F (20°C to 25°C). • Safely throw away medicine that is out of date or that you no longer need. Keep TAGRISSO and all medicines out of the reach of children. General information about the safe and effective use of TAGRISSO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAGRISSO for a condition for which it was not prescribed. Do not give TAGRISSO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAGRISSO that is written for health professionals. What are the ingredients in TAGRISSO? Active ingredient: osimertinib Inactive ingredients: mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate. Tablet coating contains: polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, ferric oxide yellow, ferric oxide red and ferric oxide black. Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850 © AstraZeneca 2024 For more information, go to www.Tagrisso.com or call 1-800-236-9933. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 09/2024"],"dosage_and_administration_table":["<table ID=\"_RefID0EECAG\" width=\"100%\"><caption>Table : Patient Selection</caption><col width=\"29%\"/><col width=\"26%\"/><col width=\"23%\"/><col width=\"21%\"/><tbody><tr styleCode=\"Toprule\"><td colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Select patients for treatment with TAGRISSO based on the presence of a mutation as detected by an FDA-approved test.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Indication</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Treatment Regimen</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Required Mutation</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Source for Testing</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Adjuvant Treatment of EGFR Mutation-Positive NSCLC<content styleCode=\"italics\"> [see <linkHtml href=\"#_RefID_bc9aa7ef-83d4-477c-a303-860173393\">Indications and Usage (1.1)</linkHtml>]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>TAGRISSO monotherapy</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>EGFR exon 19 deletions or exon 21 L858R mutations</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Tumor</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC [see </content><linkHtml href=\"#_RefID_71d5ba15-244e-413c-a253-1521487b6\">Indications and Usage (1.2)</linkHtml><content styleCode=\"xmChange\">]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Following completion of platinum-based chemoradiation therapy, TAGRISSO monotherapy</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">EGFR exon 19 deletions or exon 21 L858R mutations</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Tumor</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC <content styleCode=\"italics\">[see <linkHtml href=\"#_RefID_4798fdab-092e-4687-ad35-867038c9e\">Indications and Usage (1.3)</linkHtml>]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>TAGRISSO monotherapy</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>EGFR exon 19 deletions or exon 21 L858R mutations</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Plasma or tumor </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">First-line Treatment of EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC [see </content><linkHtml href=\"#_RefID_5eb0375b-267a-4a74-8dbd-a74dba7d1\">Indications and Usage (1.4)</linkHtml><content styleCode=\"xmChange\">]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">TAGRISSO in combination with pemetrexed and platinum-based chemotherapy</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">EGFR exon 19 deletions or exon 21 L858R mutations</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Plasma or tumor </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC <content styleCode=\"italics\">[see <linkHtml href=\"#_RefID_48061e06-ad07-4824-9d15-9b6b9f5c1\">Indications and Usage (1.5)</linkHtml>]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>TAGRISSO monotherapy</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>EGFR T790M Mutation</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Plasma or tumor</paragraph></td></tr><tr styleCode=\"Botrule\"><td colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Information on FDA-approved tests for the detection of EGFR mutations is available at <linkHtml href=\"http://www.fda.gov/companiondiagnostics\">http://www.fda.gov/companiondiagnostics</linkHtml>.</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EOIAG\" width=\"100%\"><caption>Table 2. Recommended Dosage of TAGRISSO</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr styleCode=\"Toprule\"><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Indication</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Recommended Dosage of TAGRISSO</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Duration of Treatment</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Adjuvant Treatment of EGFR Mutation-Positive NSCLC</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>80 mg tablet orally once daily with or without food</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>For a total of 3 years or until disease recurrence or unacceptable toxicity</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Following platinum-based chemoradiation therapy, 80 mg tablet orally once daily with or without food</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Until disease progression or unacceptable toxicity</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>80 mg tablet orally once daily with or without food</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Until disease progression or unacceptable toxicity</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">First-line Treatment of EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">80 mg tablet orally once daily with or without food in combination with pemetrexed and platinum-based chemotherapy</content></paragraph><paragraph><content styleCode=\"xmChange\">Refer to the Prescribing Information for pemetrexed and cisplatin or carboplatin for the respective dosing information.</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"xmChange\">Until disease progression or unacceptable toxicity due to TAGRISSO</content></paragraph></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>80 mg tablet orally once daily with or without food</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Until disease progression or unacceptable toxicity</paragraph></td></tr></tbody></table>","<table ID=\"_RefID0EKNAG\" width=\"100%\"><caption>Table 3. Recommended Dosage Modifications for TAGRISSO</caption><col width=\"29%\"/><col width=\"35%\"/><col width=\"35%\"/><thead><tr><th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Target Organ</content></th><th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Adverse Reaction</content><footnote ID=\"_Ref178679949\">Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0).</footnote></th><th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Dosage Modification</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>Pulmonary </paragraph><paragraph><content styleCode=\"italics\">(Patients who have <content styleCode=\"bold\"><content styleCode=\"underline\">not</content></content> received recent definitive platinum-based chemoradiation therapy) [see </content><content styleCode=\"bold\">Error! Hyperlink reference not valid.</content><content styleCode=\"italics\">]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Any Grade </paragraph><paragraph>Interstitial lung disease (ILD)/Pneumonitis</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Permanently discontinue TAGRISSO.</paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Pulmonary </paragraph><paragraph><content styleCode=\"italics\">(Patients who <content styleCode=\"bold\"><content styleCode=\"underline\">have </content></content>received recent definitive platinum-based chemoradiation therapy) [see </content><content styleCode=\"bold\">Error! Hyperlink reference not valid.</content><content styleCode=\"italics\">]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Grade 1</paragraph><paragraph>ILD/Pneumonitis</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Withhold or continue TAGRISSO, as clinically indicated.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Grade &#x2265;2</paragraph><paragraph>ILD/Pneumonitis</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Permanently discontinue TAGRISSO. </paragraph></td></tr><tr><td rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Cardiac</paragraph><paragraph><content styleCode=\"italics\">[see </content><content styleCode=\"bold\">Error! Hyperlink reference not valid.</content><content styleCode=\"italics\">2, </content><content styleCode=\"bold\">Error! Hyperlink reference not valid.</content><content styleCode=\"italics\">]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>QTc<footnote ID=\"_Ref178680062\">QTc = QT interval corrected for heart rate</footnote> interval greater than 500 msec on at least 2 separate ECGs<footnote ID=\"_Ref178680105\">ECGs = Electrocardiograms</footnote></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Withhold TAGRISSO until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec, then resume at 40 mg dose.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>QTc interval prolongation with signs/symptoms of life-threatening arrhythmia</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Permanently discontinue TAGRISSO.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Symptomatic congestive heart failure</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Permanently discontinue TAGRISSO.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Cutaneous</paragraph><paragraph><content styleCode=\"italics\">[see </content><content styleCode=\"bold\">Error! Hyperlink reference not valid.</content><content styleCode=\"italics\">]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Erythema Multiforme Major (EMM), Stevens-Johnson syndrome (SJS), and Toxic Epidermal Necrolysis (TEN)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Withhold TAGRISSO if suspected and permanently discontinue if confirmed.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Blood and bone marrow<content styleCode=\"italics\"> [see </content><content styleCode=\"bold\">Error! Hyperlink reference not valid.</content><content styleCode=\"italics\">]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Aplastic anemia</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Withhold TAGRISSO if aplastic anemia is suspected and permanently discontinue if confirmed.</paragraph></td></tr><tr><td rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Other<content styleCode=\"italics\"> [see <linkHtml href=\"#_RefID_a1f3b98a-9199-4daf-b1ff-4513e5802\">Adverse Reactions (6.1)</linkHtml>]</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Adverse reaction of Grade 3 or greater severity</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Withhold TAGRISSO for up to 3 weeks.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>If improvement to Grade 0-2 within 3 weeks</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Resume at 80 mg or 40 mg daily.</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>If no improvement within 3 weeks</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Permanently discontinue TAGRISSO.</paragraph></td></tr></tbody></table>"],"patient_medication_information_table":["<table width=\"101.04%\"><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PATIENT INFORMATION</content> <content styleCode=\"bold\">TAGRISSO<sup>&#xAE;</sup></content>(tuh-GRISS-oh) <content styleCode=\"bold\">(osimertinib)</content> <content styleCode=\"bold\">tablets</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is the most important information I should know about TAGRISSO?</content></paragraph><paragraph><content styleCode=\"bold\">TAGRISSO may cause serious side effects, including:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Lung problems.</content> TAGRISSO may cause severe lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Heart problems, including heart failure.</content> TAGRISSO may cause heart problems that may lead to death. Your healthcare provider should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Eye problems. </content>TAGRISSO may cause eye problems. Tell your healthcare provider right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Skin problems. </content>TAGRISSO may cause skin problems. Tell your healthcare provider right away if you develop skin reactions that look like rings (target lesions), severe blistering or peeling of the skin.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Inflammation of the blood vessels in your skin</content>. TAGRISSO may cause blood vessel problems in your skin. Tell your healthcare provider right away if you develop purple spots or redness of the skin that does not fade in color when pressed (non-blanching) on your lower arms, lower legs, or buttocks or large hives on the main part of your body (trunk) that do not go away within 24 hours and look bruised.</item></list><paragraph><content styleCode=\"bold\">Blood and bone marrow problems</content>. TAGRISSO may cause a condition where your bone marrow cannot make enough new blood cells (aplastic anemia), and which may lead to death. Your healthcare provider will monitor your blood cell counts before you start and during treatment with TAGRISSO. <content styleCode=\"bold\">Tell your healthcare provider right away</content> if you develop any signs or symptoms of blood and bone marrow problems, including:</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>a new fever or fever that does not go away (temperature 100.4&#xB0;F or higher)</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>easy bruising or bleeding that will not stop</item><item><caption>&#x2022;</caption>unusually pale skin</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>infection</item><item><caption>&#x2022;</caption>tiredness</item><item><caption>&#x2022;</caption>weakness</item></list></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>See <content styleCode=\"bold\">&#x201C;What are the possible side effects of TAGRISSO?&#x201D; </content>for more information about side effects.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is TAGRISSO?</content></paragraph><paragraph>TAGRISSO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s):</paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery, <content styleCode=\"bold\">or</content></item><item><caption>&#x2022;</caption>when your lung cancer has spread to nearby tissues (locally advanced) that is unable to be removed (unresectable) by surgery and has responded or stabilized following chemotherapy and radiation treatment, <content styleCode=\"bold\">or</content></item><item><caption>&#x2022;</caption>as your first treatment when your lung cancer has spread to other parts of the body (metastatic), <content styleCode=\"bold\">or</content></item><item><caption>&#x2022;</caption>in combination with pemetrexed and platinum-based chemotherapy, as your first treatment when your lung cancer has spread to nearby tissues (locally advanced) or to other parts of the body (metastatic).</item><item><caption>&#x2022;</caption>when your lung cancer has spread to other parts of the body (metastatic), and you have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working.</item></list><paragraph>Your healthcare provider will perform a test to make sure that TAGRISSO is right for you.</paragraph><paragraph>It is not known if TAGRISSO is safe and effective in children.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>have lung or breathing problems other than your lung cancer.</item><item><caption>&#x2022;</caption>have heart problems, including a condition called long QTc syndrome.</item><item><caption>&#x2022;</caption>have problems with your electrolytes, such as sodium, potassium, calcium, or magnesium.</item><item><caption>&#x2022;</caption>have a history of eye problems.</item><item><caption>&#x2022;</caption>are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Females</content> who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Males</content> who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO.</item><item><caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time.</item></list><paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Before taking TAGRISSO, tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>have lung or breathing problems other than your lung cancer.</item><item><caption>&#x2022;</caption>have heart problems, including a condition called long QTc syndrome.</item><item><caption>&#x2022;</caption>have problems with your electrolytes, such as sodium, potassium, calcium, or magnesium.</item><item><caption>&#x2022;</caption>have a history of eye problems.</item><item><caption>&#x2022;</caption>are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Females</content> who are able to become pregnant should have a pregnancy test before starting treatment with TAGRISSO. You should use effective birth control (contraception) during treatment with TAGRISSO and for 6 weeks after the last dose of TAGRISSO.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Males</content> who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the last dose of TAGRISSO.</item><item><caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your last dose of TAGRISSO. Talk to your healthcare provider about the best way to feed your baby during this time.</item></list><paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you take a heart or blood pressure medicine.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I take TAGRISSO?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Take TAGRISSO exactly as your healthcare provider tells you to take it.</item><item><caption>&#x2022;</caption>Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TAGRISSO if you have side effects.</item><item><caption>&#x2022;</caption>Take TAGRISSO 1 time each day.</item><item><caption>&#x2022;</caption>You can take TAGRISSO with or without food.</item><item><caption>&#x2022;</caption>If you miss a dose of TAGRISSO, do not make up for the missed dose. Take your next dose at your regular time.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">If you cannot swallow TAGRISSO tablets whole:</content></item><item><caption>&#x2022;</caption>Place your dose of TAGRISSO in a container that contains 60 mL (2 ounces) of water. Do not use carbonated water or any other liquids.</item><item><caption>&#x2022;</caption>Stir the TAGRISSO tablet and water until the TAGRISSO tablet is in small pieces (the tablet will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture.</item><item><caption>&#x2022;</caption>Drink the TAGRISSO and water mixture right away.</item><item><caption>&#x2022;</caption>Add 120 mL to 240 mL (4 to 8 ounces) of water into the container and drink to make sure that you take your full dose of TAGRISSO.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">If you have a nasogastric (NG) tube:</content></item><item><caption>&#x2022;</caption>Follow the same instructions for mixing TAGRISSO tablets in a container that contains 15 mL of water. <content styleCode=\"bold\">Do not</content> use carbonated water or any other liquids.</item><item><caption>&#x2022;</caption>Stir the TAGRISSO tablets and water until the TAGRISSO tablets are in small pieces (the tablets will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture.</item><item><caption>&#x2022;</caption>Add another 15 mL of water into the container to make sure no pieces of TAGRISSO tablet remain.</item><item><caption>&#x2022;</caption>Give the TAGRISSO tablet and water mixture using the NG tube manufacturer instructions within 30 minutes.</item></list><paragraph>Add another 30 mL of water into the syringe and give the water and any remaining TAGRISSO through the NG tube to make sure that all of the medicine is given. Repeat this step until no pieces remain in the syringe. This will help to ensure that the full prescribed dose of the TAGRISSO is given.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the possible side effects of TAGRISSO?</content></paragraph><paragraph><content styleCode=\"bold\">TAGRISSO may cause serious side effects:</content></paragraph><paragraph><content styleCode=\"bold\">&#x2022; See &#x201C;What is the most important information I should know about TAGRISSO?&#x201D;</content></paragraph><paragraph><content styleCode=\"bold\">The most common side effects of TAGRISSO when given alone include:</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>low white blood cell counts</paragraph><paragraph>low platelet counts</paragraph><list listType=\"unordered\"><item><caption> </caption>low red blood cell counts (anemia)</item></list><paragraph>diarrhea</paragraph><paragraph>rash</paragraph></td><td valign=\"top\"><paragraph>muscle, bone, or joint pain</paragraph><paragraph>changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail</paragraph></td><td styleCode=\"Rrule \" valign=\"top\"><paragraph>dry skin</paragraph><paragraph>mouth sores</paragraph><paragraph>tiredness</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">The most common side effects of TAGRISSO when given alone after treatment with platinum-based chemotherapy and radiation treatment include:</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption> </caption><content styleCode=\"bold\">l</content>ow white blood cell counts</item></list><paragraph>lung problems</paragraph><paragraph>low platelet counts</paragraph><paragraph>rash</paragraph><paragraph>diarrhea</paragraph></td><td valign=\"top\"><paragraph>changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail</paragraph></td><td styleCode=\"Rrule \" valign=\"top\"><paragraph>Cough</paragraph><paragraph>COVID-19</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">The most common side effects of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy include:</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>low white blood cell counts</paragraph><paragraph>low platelet counts</paragraph><paragraph>rash</paragraph><paragraph>diarrhea</paragraph><paragraph>mouth sores</paragraph></td><td valign=\"top\"><paragraph>changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed, and shedding of nail</paragraph></td><td styleCode=\"Rrule \" valign=\"top\"><paragraph>dry skin</paragraph><paragraph>increase of a substance in the blood called creatinine</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</paragraph><paragraph>These are not all the possible side effects of TAGRISSO. For more information, ask your healthcare provider or pharmacist.</paragraph><paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I store TAGRISSO?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Store TAGRISSO at room temperature between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item><item><caption>&#x2022;</caption>Safely throw away medicine that is out of date or that you no longer need.</item></list><paragraph><content styleCode=\"bold\">Keep TAGRISSO and all medicines out of the reach of children.</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of TAGRISSO.</content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAGRISSO for a condition for which it was not prescribed. Do not give TAGRISSO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAGRISSO that is written for health professionals.</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the ingredients in TAGRISSO?</content></paragraph><paragraph><content styleCode=\"bold\">Active ingredient:</content> osimertinib</paragraph><paragraph><content styleCode=\"bold\">Inactive ingredients:</content> mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate. Tablet coating contains: polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, ferric oxide yellow, ferric oxide red and ferric oxide black.</paragraph><paragraph>Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850</paragraph><paragraph>&#xA9; AstraZeneca 2024</paragraph><paragraph>For more information, go to <linkHtml href=\"http://www.Tagrisso.com\">www.Tagrisso.com</linkHtml> or call 1-800-236-9933.</paragraph></td></tr></tbody></table>"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Administration of osimertinib resulted in histological findings of lens fiber degeneration in the 2-year rat carcinogenicity study at ≥3 mg/kg/day (exposures 0.2 times the human exposure based on AUC). These findings were consistent with the ophthalmoscopic observation of lens opacities, which were first noted from week 52 and showed a gradual increase in incidence and severity with increased duration of dosing."],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 40 mg NDC 0310- 1349 -30 30 Tablets Tagrisso ® (osimertinib) tablets 40 mg per tablet Rx only AstraZeneca Tagrisso_40_mg_tablet_bottle_label","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 80 mg NDC 0310- 1350 -30 30 Tablets Tagrisso ® (osimertinib) tablets 80 mg per tablet Rx only AstraZeneca Tagrisso 80 mg tablets bottle label","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 0310- 1248 -30 30 Tablets Tagrisso ® (osimertinib) tablets 40 mg per tablet Rx only AstraZeneca 40_mg","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 0310- 1251 -30 30 Tablets Tagrisso ® (osimertinib) tablets 80 mg per tablet Rx only AstraZeneca 80_mg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility A 2-year carcinogenicity was conducted in male and female rats at oral osimertinib doses of 1, 3, and 10 mg/kg/day. Osimertinib increased the incidences of hemangioma and combined hemangioma/hemangiosarcoma in the mesenteric lymph node and whole body at 10 mg/kg/day (0.2 times the human exposure based on AUC at the clinical dose of 80 mg once daily). Administration of osimertinib to male and female rasH2 transgenic mice by oral gavage daily for 26 weeks did not result in an increased incidence of neoplasms at doses up to 10 mg/kg/day. Osimertinib did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in mouse lymphoma cells or in the rat in vivo micronucleus assay. Based on studies in animals, male fertility may be impaired by treatment with TAGRISSO. Degenerative changes were present in the testes in rats and dogs exposed to osimertinib for 1 month or more with evidence of reversibility in the rat. Following administration of osimertinib to rats for approximately 10 weeks at a dose of 40 mg/kg, at exposures 0.5 times the AUC observed at the recommended clinical dose of 80 mg once daily, there was a reduction in male fertility, demonstrated by increased pre-implantation loss in untreated females mated to treated males. Based on studies in animals, female fertility may be impaired by treatment with TAGRISSO. In repeat dose toxicity studies, histological evidence of anestrus, corpora lutea degeneration in the ovaries and epithelial thinning in the uterus and vagina were seen in rats exposed to osimertinib for 1 month or more at exposures 0.3 times the AUC observed at the recommended clinical dose of 80 mg once daily. Findings in the ovaries seen following 1 month of dosing exhibited evidence of reversibility. In a female fertility study in rats, administration of osimertinib from 2 weeks prior to mating through Day 8 of gestation at a dose of 20 mg/kg/day (approximately 1.5 times the C max at the recommended dose of 80 mg once daily) had no effects on estrous cycling or the number of females becoming pregnant, but caused early embryonic deaths. These findings showed evidence of reversibility when females were mated 1 month after treatment discontinuation."]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"10777 reports"},{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"3073 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1521 reports"},{"date":"","signal":"DRUG RESISTANCE","source":"FDA FAERS","actionTaken":"1061 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"905 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"853 reports"},{"date":"","signal":"DECREASED APPETITE","source":"FDA FAERS","actionTaken":"726 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"718 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"688 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"684 reports"}],"drugInteractions":[{"drug":"Strong CYP3A Inducers","action":"Avoid","effect":"Decreased osimertinib exposure"},{"drug":"Strong CYP3A Inducers","action":"Increase TAGRISSO dosage","effect":"Decreased osimertinib exposure"},{"drug":"Moderate and/or weak CYP3A inducers","action":"No dose adjustments required","effect":"No effect on osimertinib exposure"},{"drug":"BCRP or P-gp substrate","action":"Monitor for adverse reactions","effect":"Increased exposure"},{"drug":"Drugs that prolong the QTc interval","action":"Avoid concomitant administration","effect":"Unknown effect on TAGRISSO"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"47%","severity":"mild","_validated":true},{"effect":"Rash","drugRate":"46%","severity":"mild","_validated":true},{"effect":"Musculoskeletal pain","drugRate":"38%","severity":"mild","_validated":true},{"effect":"Nail toxicity","drugRate":"34%","severity":"mild","_validated":true},{"effect":"Dry skin","drugRate":"32%","severity":"mild","_validated":true},{"effect":"Stomatitis","drugRate":"24%","severity":"mild","_validated":true},{"effect":"Fatigue","drugRate":"21%","severity":"mild","_validated":true},{"effect":"Leukopenia","drugRate":"65%","severity":"serious","_validated":true},{"effect":"Lymphopenia","drugRate":"64%","severity":"serious","_validated":true},{"effect":"Thrombocytopenia","drugRate":"53%","severity":"serious","_validated":true},{"effect":"Anemia","drugRate":"52%","severity":"serious","_validated":true},{"effect":"Neutropenia","drugRate":"36%","severity":"serious","_validated":true},{"effect":"Pneumonia","drugRate":"1.5%","severity":"serious","_validated":true},{"effect":"Interstitial lung disease","drugRate":"2.7%","severity":"serious","_validated":true},{"effect":"Cough","drugRate":"19%","severity":"mild","_validated":true},{"effect":"Musculoskeletal Pain","drugRate":"18%","severity":"mild","_validated":true},{"effect":"Nasopharyngitis","drugRate":"14%","severity":"mild","_validated":true},{"effect":"Upper respiratory tract infection","drugRate":"13%","severity":"mild","_validated":true},{"effect":"Urinary tract infection","drugRate":"10%","severity":"mild","_validated":true},{"effect":"Fatigue","drugRate":"13%","severity":"mild","_validated":true}],"contraindications":["None. None."],"specialPopulations":{"Pregnancy":"Based on data from animal studies and its mechanism of action, TAGRISSO can cause fetal harm when administered to a pregnant woman. There are no available data on TAGRISSO use in pregnant women. Administration of osimertinib to pregnant rats was associated with embryolethality and reduced fetal growth at plasma exposures 1.5 times the exposure at the recommended clinical dose. Advise pregnant women of the potential risk to a fetus.","Geriatric use":"Exploratory analysis suggests a higher incidence of Grade 3 or higher adverse reactions and more frequent dosage modifications for adverse reactions in patients 65 years or older as compared to those younger than 65 years. No overall differences in safety or effectiveness were observed between patients 65 years or older and younger patients.","Paediatric use":"The safety and effectiveness of TAGRISSO in pediatric patients have not been established.","Renal impairment":"No dose adjustment is recommended in patients with creatinine clearance (CLcr) 15 - 89 mL/min, as estimated by Cockcroft-Gault. There is no recommended dose of TAGRISSO for patients with end-stage renal disease (CLcr <15 mL/min).","Hepatic impairment":"No dose adjustment is recommended in patients with mild hepatic impairment."}},"trials":[],"aliases":[],"company":"AstraZeneca","patents":[{"source":"DrugCentral Orange Book","expires":"2035-01-02","patentNumber":"10183020"},{"source":"DrugCentral Orange Book","expires":"2032-08-08","patentNumber":"8946235"},{"source":"DrugCentral Orange Book","expires":"2032-07-25","patentNumber":"11524951"},{"source":"DrugCentral Orange Book","expires":"2032-07-25","patentNumber":"9732058"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=osimertinib","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:51:27.907686+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:51:27.907599+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Osimertinib","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:51:34.884408+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:51:33.509088+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:51:27.981042+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:51:26.749101+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=osimertinib","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:51:33.844378+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:51:24.691835+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:51:24.691866+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:51:24.691872+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:51:35.311909+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Epidermal growth factor receptor erbB1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:51:34.884355+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545063/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:51:34.539341+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA208065","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:51:24.691876+00:00"}},"allNames":"azd9291, tagrisso","offLabel":[],"synonyms":["osimertinib","tagrisso","AZD9291","AZD-9291","AZD 9291","osimertinib mesylate","osimertinib mesilate","AZD9291 mesylate","mereletinib"],"timeline":[{"date":"2009-01-01","type":"neutral","_source":"Wikipedia","milestone":"Drug discovery program started","regulator":"none"},{"date":"2012-01-01","type":"neutral","_source":"Wikipedia","milestone":"Osimertinib yielded","regulator":"none"},{"date":"2014-04-01","type":"positive","_source":"Wikipedia","milestone":"Designated as a breakthrough therapy","regulator":"none"},{"date":"2015-11-13","type":"positive","_source":"FDA NDA208065","milestone":"FDA ORIG — ASTRAZENECA","regulator":"FDA","description":""},{"date":"2016-02-01","type":"positive","_source":"Wikipedia","milestone":"EMA provisionally approved osimertinib","regulator":"EMA"},{"date":"2016-02-10","type":"positive","_source":"FDA NDA208065","milestone":"FDA SUPPL — ASTRAZENECA","regulator":"FDA","description":""},{"date":"2017-03-30","type":"positive","_source":"FDA NDA208065","milestone":"FDA SUPPL — ASTRAZENECA","regulator":"FDA","description":""},{"date":"2018-04-18","type":"positive","_source":"FDA NDA208065","milestone":"FDA SUPPL — ASTRAZENECA","regulator":"FDA","description":""},{"date":"2019-12-19","type":"positive","_source":"FDA NDA208065","milestone":"FDA SUPPL — ASTRAZENECA","regulator":"FDA","description":""},{"date":"2020-05-23","type":"positive","_source":"FDA NDA208065","milestone":"FDA SUPPL — ASTRAZENECA","regulator":"FDA","description":""},{"date":"2021-07-26","type":"positive","_source":"FDA NDA208065","milestone":"FDA SUPPL — ASTRAZENECA","regulator":"FDA","description":""},{"date":"2022-01-19","type":"positive","_source":"FDA NDA208065","milestone":"FDA SUPPL — ASTRAZENECA","regulator":"FDA","description":""},{"date":"2023-06-21","type":"positive","_source":"FDA NDA208065","milestone":"FDA SUPPL — ASTRAZENECA","regulator":"FDA","description":""},{"date":"2024-02-01","type":"positive","_source":"Wikipedia","milestone":"FDA approved osimertinib","regulator":"FDA"},{"date":"2024-01-31","type":"positive","_source":"FDA NDA208065","milestone":"FDA SUPPL — ASTRAZENECA","regulator":"FDA","description":""}],"_dailymed":{"setId":"5e81b4a7-b971-45e1-9c31-29cea8c87ce7","title":"TAGRISSO (OSIMERTINIB) TABLET, FILM COATED [ASTRAZENECA PHARMACEUTICALS LP]","labeler":""},"aiSummary":"Tagrisso is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor used to treat non-small-cell lung carcinomas with specific mutations. AstraZeneca developed this medication. It works by inhibiting the activity of EGFR, a protein that promotes cancer cell growth. Tagrisso is indicated for patients with EGFR exon 19 deletions or exon 21 L858R mutations. This medication has shown clinical differentiation in treating NSCLC patients with these specific mutations. Tagrisso has significant commercial value due to its effectiveness and market demand. AstraZeneca continues to develop its pipeline, including potential new indications for Tagrisso.","brandName":"Tagrisso","ecosystem":[],"mechanism":{"target":"ALK tyrosine kinase receptor","novelty":"Best-in-class","targets":[{"gene":"ALK","source":"DrugCentral","target":"ALK tyrosine kinase receptor","protein":"ALK tyrosine kinase receptor","activityType":"IC50"},{"gene":"CARS","source":"DrugCentral","target":"Cysteine--tRNA ligase, cytoplasmic","protein":"Cysteine--tRNA ligase, cytoplasmic","activityType":"Kd"},{"gene":"CTSC","source":"DrugCentral","target":"Dipeptidyl peptidase 1","protein":"Dipeptidyl peptidase 1","activityType":"IC50"},{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor","activityType":"IC50"},{"gene":"INSR","source":"DrugCentral","target":"Insulin receptor","protein":"Insulin receptor","activityType":"IC50"},{"gene":"KDM1A","source":"DrugCentral","target":"Lysine-specific histone demethylase 1A","protein":"Lysine-specific histone demethylase 1A","activityType":"IC50"},{"gene":"PIP4K2C","source":"DrugCentral","target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma","protein":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma","activityType":"Kd"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2","activityType":"IC50"},{"gene":"ERBB2","source":"DrugCentral","target":"Receptor tyrosine-protein kinase erbB-2","protein":"Receptor tyrosine-protein kinase erbB-2","activityType":"IC50"},{"gene":"ERBB3","source":"DrugCentral","target":"Receptor tyrosine-protein kinase erbB-3","protein":"Receptor tyrosine-protein kinase erbB-3","activityType":"IC50"}],"modality":"Small molecule","drugClass":"Kinase Inhibitor [EPC]","explanation":"Osimertinib is a medication that targets the epidermal growth factor receptor (EGFR), a protein that promotes cancer cell growth. By inhibiting EGFR, osimertinib prevents cancer cells from growing and dividing. This mechanism of action is specific to mutant forms of EGFR, making it an effective treatment for non-small-cell lung carcinomas with these specific mutations.","oneSentence":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR.","technicalDetail":"Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that binds irreversibly to mutant forms of EGFR at approximately 9-fold lower concentrations than wild-type. It also inhibits the activity of HER2, HER3, HER4, ACK1, and BLK at clinically relevant concentrations."},"_companyIR":{"url":"https://www.astrazeneca.com/investors","revenueRefs":[],"pipelineRefs":[]},"_wikipedia":{"title":"Osimertinib","extract":"Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.","wiki_history":"==History==\nThe drug discovery program that led to osimertinib started in 2009 and yielded the drug by 2012; the process was structure-driven and aimed to find a third-generation EGFR inhibitor that would selectively target the T790M form of the EGFR receptor.\n\nOsimertinib was designated as a breakthrough therapy in April 2014, based on phase I trial results,\n\nIn February 2016, the EMA provisionally approved osimertinib under an accelerated process—the first approval under the program.\n\nIn February 2024, the FDA approved osimertinib, in combination with platinum-based chemotherapy, for people with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. Efficacy was evaluated in FLAURA 2 (NCT04035486), an open-label, randomized trial of 557 participants with EGFR exon 19 deletion or exon 21 L858R mutation-positive la/mNSCLC and no prior systemic therapy for advanced disease. Participants were randomized 1:1 to receive either osimertinib with platinum-based chemotherapy or osimertinib monotherapy. The application was granted priority review, fast track, breakthrough therapy, and orphan drug designations.","wiki_medical_uses":"==Medical uses==\nOsimertinib is used to treat locally advanced or metastatic non-small-cell lung cancer (NSCLC), if the cancer cells are positive for the T790M mutation in the gene coding for EGFR or for activating EGFR mutations. The T790M mutation may be de novo or acquired following first-line treatment with other EGFR tyrosine kinase inhibitors, such as gefitinib, erlotinib, and afatinib.\n\nIn the US, EGFR exon 19 deletions, exon 21 L858R mutations, or the T790M status of the patient must be detected by a companion diagnostic test before treatment with osimertinib. In Europe and elsewhere, activating EGFR mutations or T790M mutations may be determined by a validated test.\n\nIn February 2024, the FDA approved osimertinib, in combination with platinum-based chemotherapy, for people with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.\n\nIn people treated with osimertinib, resistance usually develops within approximately ten months. Resistance mediated by an exon 20 C797S mutation accounts for the majority of resistance cases, which has resulted in multiple attempts with non-ATP competitive or allosteric inhibitors to try and offset this acquired resistance by targeting other regions of the RTK kinase domain.\n\nIn September 2024, the FDA approved osimertinib for adults with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease h","wiki_society_and_culture":"==Society and culture==\n=== Economics ===\nAt launch, in the United States, AstraZeneca priced the drug at  per month."},"commercial":{"launchDate":"2015","revenueYear":2024,"annualCostUS":"12,000 - 15,000","_launchSource":"DrugCentral (FDA 2015-11-13, ASTRAZENECA PHARMS)","annualRevenue":5800,"revenueSource":"Verified: AstraZeneca AR","currentRevenue":"1.4 billion","revenueCurrency":"USD","patientPopulation":"EGFR+ non-small cell lung cancer (NSCLC) patients","peakSalesEstimate":"3.5 billion","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5062","fields":["approvals","synonyms","ATC","pharmacokinetics","patents","indications","contraindications","interactions","targets"],"source":"DrugCentral"},{"id":2,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=osimertinib","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=osimertinib","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=osimertinib","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":6,"url":"https://en.wikipedia.org/wiki/osimertinib","fields":["history","overview"],"source":"Wikipedia"},{"id":7,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/","fields":["timeline","launchDate"],"source":"FDA Drugs@FDA"},{"id":8,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":9,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":10,"url":"https://www.whocc.no/atc_ddd_index/","fields":["classification"],"source":"WHO ATC/DDD Index"},{"id":11,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_emaChecked":true,"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:38.500632+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Afatinib","company":"Boehringer Ingelheim","advantage":"Irreversible binding and increased potency"},{"name":"Dacomitinib","company":"Boehringer Ingelheim","advantage":"Irreversible binding and increased potency"},{"name":"Gefitinib","company":"AstraZeneca","advantage":"Initial breakthrough in EGFR TKIs"},{"name":"Erlotinib","company":"Roche","advantage":"Targeted agent"},{"name":"Keytruda","company":"Merck","advantage":"Immunotherapy"},{"name":"Opdivo","company":"Bristol-Myers Squibb","advantage":"Immunotherapy"}],"genericName":"osimertinib","indications":{"approved":[{"name":"Adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations","regulator":"FDA"},{"name":"Treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","regulator":"FDA"},{"name":"First-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","regulator":"FDA"},{"name":"First-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, in combination with pemetrexed and platinum-based chemotherapy","regulator":"FDA"},{"name":"Treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy","regulator":"FDA"}]},"_drugCentral":{"patents":[{"number":"10183020","expires":"2035-01-02"},{"number":"8946235","expires":"2032-08-08"},{"number":"11524951","expires":"2032-07-25"},{"number":"9732058","expires":"2032-07-25"}],"targets":[{"gene":"ALK","target":"ALK tyrosine kinase receptor","protein":"ALK tyrosine kinase receptor","activityType":"IC50","activityUnit":"","activityValue":6.75},{"gene":"CARS","target":"Cysteine--tRNA ligase, cytoplasmic","protein":"Cysteine--tRNA ligase, cytoplasmic","activityType":"Kd","activityUnit":"","activityValue":7.92},{"gene":"CTSC","target":"Dipeptidyl peptidase 1","protein":"Dipeptidyl peptidase 1","activityType":"IC50","activityUnit":"","activityValue":4.48},{"gene":"EGFR","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor","activityType":"IC50","activityUnit":"","activityValue":7.824},{"gene":"INSR","target":"Insulin receptor","protein":"Insulin receptor","activityType":"IC50","activityUnit":"","activityValue":6.04},{"gene":"KDM1A","target":"Lysine-specific histone demethylase 1A","protein":"Lysine-specific histone demethylase 1A","activityType":"IC50","activityUnit":"","activityValue":5.4},{"gene":"PIP4K2C","target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma","protein":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma","activityType":"Kd","activityUnit":"","activityValue":5.53},{"gene":"KCNH2","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2","activityType":"IC50","activityUnit":"","activityValue":4.79},{"gene":"ERBB2","target":"Receptor tyrosine-protein kinase erbB-2","protein":"Receptor tyrosine-protein kinase erbB-2","activityType":"IC50","activityUnit":"","activityValue":8.32},{"gene":"ERBB3","target":"Receptor tyrosine-protein kinase erbB-3","protein":"Receptor tyrosine-protein kinase erbB-3","activityType":"IC50","activityUnit":"","activityValue":8.68},{"gene":"NQO2","target":"Ribosyldihydronicotinamide dehydrogenase [quinone]","protein":"Ribosyldihydronicotinamide dehydrogenase [quinone]","activityType":"Kd","activityUnit":"","activityValue":5.44},{"gene":"BTK","target":"Tyrosine-protein kinase BTK","protein":"Tyrosine-protein kinase BTK","activityType":"Kd","activityUnit":"","activityValue":6.28},{"gene":"TEC","target":"Tyrosine-protein kinase Tec","protein":"Tyrosine-protein kinase Tec","activityType":"Kd","activityUnit":"","activityValue":6.49}],"atcCodes":["L01EB04"],"synonyms":["osimertinib","tagrisso","AZD9291","AZD-9291","AZD 9291","osimertinib mesylate","osimertinib mesilate","AZD9291 mesylate","mereletinib"],"approvals":[{"date":"2015-11-13","orphan":false,"company":"ASTRAZENECA PHARMS","regulator":"FDA"},{"date":"2016-02-02","orphan":false,"company":"AstraZeneca AB","regulator":"EMA"},{"date":"2016-03-28","orphan":false,"company":"AstraZeneca K.K.","regulator":"PMDA"}],"properties":{},"drugClasses":[],"identifiers":{"MMSL":"237132","NDDF":"016583","UNII":"3C06JJ0Z2O","CHEBI":"CHEBI:90943","VANDF":"4035124","INN_ID":"10043","RXNORM":"1721559","UMLSCUI":"C4058811","ChEMBL_ID":"CHEMBL3353410","DRUGBANK_ID":"DB09330","PDB_CHEM_ID":" YY3","PUBCHEM_CID":"71496458","SNOMEDCT_US":"716032009","IUPHAR_LIGAND_ID":"7719","SECONDARY_CAS_RN":"1421373-66-1","MESH_SUPPLEMENTAL_RECORD_UI":"C000596361"},"indications":[{"name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","source":"DrugCentral","umlsCui":"C1960925","snomedId":426964009}],"formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","status":"NDA","tradeName":"TAGRISSO"}],"offLabelUses":[],"drugCentralId":5062,"drugInteractions":[],"contraindications":[]},"_drugWebsite":{"url":"https://www.tagrisso.com","content":"SELECT YOUR STAGE\nImportant Safety Information\nPrescribing Information\nPatient Information\nNurse Center\nFor Healthcare Professionals\nprimary navigation\nFinancial Help Video Library Enroll Here\nTAGRIS\nSO\nI can...\nTAGRISSO is approved to treat certain types of EGFR+ non-small cell lung cancer (NSCLC)\nEARLY-STAGE (STAGE 1-3)\nEGFR+ NSCLC\nFollowing tumor removal by surgery (adjuvant)\nLOCALLY ADVANCED UNRESECTABLE\n(STAGE 3) EGFR+ NSCLC\nAfter chemotherapy and radiation therapy for NSCLC that spread to nearby tissues and can't be removed by surgery (unresectable)\nLATE-STAGE EGFR+ NSCLC\nNSCLC that has spread to tissues around the lungs (locally advanced)* or to other parts of the body (metastatic)\n\n*Locally advanced patients who are not eligible for curative surgery or radiation.\n\nEGFR+ is epidermal growth factor receptor mutation-positive.\n\nprimary navigation\nAbout Stage 4 NSCLC\nNSCLC by Stage Biomarker Testing What is EGFR?\n About TAGRISSO\nClinical Trial Results Dosing Information Safety Considerations\n Ask Your Care Team FAQs\nFAQs Glossary\n Support & Resources\nPatient Materials Video Library Caregiver Resources Community & Advocacy\n Financial Help\nAstraZeneca Access 360™ Savings Program\n Enroll Here\nIMPORTANT SAFETY INFORMATION\n\nTAGRISSO may cause serious side effects, including:\n\nLung problems. TAGRISSO may cause severe lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever\nHeart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your healthcare provider should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swellin"},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07491211","phase":"","title":"Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-07-19","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Osimertinib","enrollment":300},{"nctId":"NCT03191149","phase":"PHASE2","title":"Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-25","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7","enrollment":46},{"nctId":"NCT04181060","phase":"PHASE3","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-28","conditions":"Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":300},{"nctId":"NCT06303167","phase":"PHASE2","title":"Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-01-08","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":19},{"nctId":"NCT02503722","phase":"PHASE1","title":"Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-23","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7","enrollment":36},{"nctId":"NCT02496663","phase":"PHASE1","title":"Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-11","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":138},{"nctId":"NCT06538038","phase":"","title":"Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients","status":"RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2024-09-17","conditions":"Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer","enrollment":538},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT05805631","phase":"PHASE2","title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC","status":"RECRUITING","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2024-08-01","conditions":"Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis","enrollment":23},{"nctId":"NCT07486648","phase":"PHASE1, PHASE2","title":"Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Province Cancer Hospital","startDate":"2026-05-15","conditions":"Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell), Advanced Non-small-cell Lung Cancer","enrollment":53},{"nctId":"NCT07185997","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","status":"RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2025-12-17","conditions":"Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer","enrollment":480},{"nctId":"NCT07005102","phase":"PHASE2, PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-08-03","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":854},{"nctId":"NCT07485452","phase":"PHASE2","title":"Boosting Osimertinib Blood Brain Barrier Penetration","status":"NOT_YET_RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2026-04","conditions":"Non-Small Cell Lung Cancer","enrollment":7},{"nctId":"NCT06726720","phase":"","title":"UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-16","conditions":"Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance","enrollment":300},{"nctId":"NCT05801029","phase":"PHASE2","title":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-18","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":60},{"nctId":"NCT07100080","phase":"PHASE2, PHASE3","title":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-05","conditions":"Non-Small Cell Lung Cancer","enrollment":596},{"nctId":"NCT07279935","phase":"PHASE4","title":"Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-05-31","conditions":"Non-small Cell Lung Cancer","enrollment":100},{"nctId":"NCT02971501","phase":"PHASE2","title":"Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-27","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8","enrollment":7},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT06618287","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-04","conditions":"Lung Cancer, Breast Cancer","enrollment":416},{"nctId":"NCT05663866","phase":"PHASE2","title":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":68},{"nctId":"NCT05388669","phase":"PHASE3","title":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-05","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":418},{"nctId":"NCT06525246","phase":"PHASE1","title":"Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-08-06","conditions":"Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":78},{"nctId":"NCT05364073","phase":"PHASE1","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2022-06-30","conditions":"Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer","enrollment":160},{"nctId":"NCT03381274","phase":"PHASE1, PHASE2","title":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2018-05-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":43},{"nctId":"NCT04285671","phase":"PHASE1, PHASE2","title":"Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-01-29","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":30},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT07458919","phase":"EARLY_PHASE1","title":"Therapy for Advanced NSCLC With EGFR 19delins Mutation","status":"NOT_YET_RECRUITING","sponsor":"Fuzhou General Hospital","startDate":"2026-03-30","conditions":"Lung Cancer","enrollment":94},{"nctId":"NCT06194448","phase":"PHASE2","title":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-21","conditions":"Lung Cancer","enrollment":76},{"nctId":"NCT05166616","phase":"PHASE1","title":"Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-03-07","conditions":"Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":8},{"nctId":"NCT05526755","phase":"PHASE2","title":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-06","conditions":"Stage II-IIIB Non-small Cell Lung Carcinoma","enrollment":188},{"nctId":"NCT05401110","phase":"PHASE1","title":"Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Karen Reckamp, MD, MS","startDate":"2023-09-15","conditions":"Non Small Cell Lung Cancer, Lung Cancer","enrollment":60},{"nctId":"NCT07028489","phase":"","title":"Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"N-Power Medicine","startDate":"2025-06-05","conditions":"Non Small Cell Lung Cancer","enrollment":130},{"nctId":"NCT06068049","phase":"","title":"OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-28","conditions":"Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT06417814","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-04","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":744},{"nctId":"NCT04606771","phase":"PHASE2","title":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-09-28","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03521154","phase":"PHASE3","title":"A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-07-19","conditions":"Non Small Cell Lung Cancer (Stage III)","enrollment":216},{"nctId":"NCT03940703","phase":"PHASE2","title":"A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-09-19","conditions":"Non-small Cell Lung Cancer","enrollment":140},{"nctId":"NCT05647122","phase":"PHASE1","title":"First in Human Study of AZD9592 in Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-21","conditions":"Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms","enrollment":403},{"nctId":"NCT04868877","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merus B.V.","startDate":"2021-04-28","conditions":"Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma","enrollment":194},{"nctId":"NCT06741085","phase":"PHASE2","title":"A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-13","conditions":"Non Small Cell Lung Cancer Metastatic","enrollment":56},{"nctId":"NCT07363252","phase":"","title":"Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2026-02","conditions":"EGFR-mutated NSCLC","enrollment":100},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT07379476","phase":"PHASE2","title":"Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-02-11","conditions":"Lung Cancer (NSCLC)","enrollment":64},{"nctId":"NCT06970639","phase":"PHASE3","title":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-09-26","conditions":"NSCLC Patients With Brain Metastasis","enrollment":380},{"nctId":"NCT03778229","phase":"PHASE2","title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-01-09","conditions":"Carcinoma","enrollment":367},{"nctId":"NCT07398599","phase":"NA","title":"Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2026-02-15","conditions":"Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07375316","phase":"PHASE2","title":"A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy","status":"RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-12-15","conditions":"Non Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT02917993","phase":"PHASE1, PHASE2","title":"An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-12-20","conditions":"Lung Cancer","enrollment":59},{"nctId":"NCT06507306","phase":"PHASE1","title":"A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Kumquat Biosciences Inc.","startDate":"2024-06-03","conditions":"Solid Tumor, Adult","enrollment":100},{"nctId":"NCT03133546","phase":"PHASE2","title":"Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2017-05-31","conditions":"Non Small Cell Lung Cancer Metastatic","enrollment":155},{"nctId":"NCT04988295","phase":"PHASE3","title":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-17","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":776},{"nctId":"NCT04487080","phase":"PHASE3","title":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-30","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1074},{"nctId":"NCT04184921","phase":"PHASE2","title":"Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2019-01-01","conditions":"Lung Cancer Non-small Cell Stage IV","enrollment":216},{"nctId":"NCT07376382","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-03-03","conditions":"NSCLC","enrollment":450},{"nctId":"NCT03040973","phase":"PHASE2","title":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-23","conditions":"Advanced Solid Tumors Which Are cMET-dependent","enrollment":29},{"nctId":"NCT06296745","phase":"PHASE2","title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2025-09-01","conditions":"Leptomeningeal Metastasis","enrollment":36},{"nctId":"NCT02143466","phase":"PHASE1","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-08-05","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":344},{"nctId":"NCT06675695","phase":"","title":"Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-10-30","conditions":"Non Small Cell Lung Cancer","enrollment":4864},{"nctId":"NCT05546866","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-02-09","conditions":"Non-small Cell Lung Cancer","enrollment":51},{"nctId":"NCT05816252","phase":"PHASE2","title":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klus Pharma Inc.","startDate":"2023-04-19","conditions":"Non-small Cell Lung Cancer","enrollment":356},{"nctId":"NCT03833154","phase":"PHASE3","title":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-03-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":724},{"nctId":"NCT07361705","phase":"PHASE1","title":"Zorifertinib With Osimertinib for NSCLC With Meningeal Progression","status":"NOT_YET_RECRUITING","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2026-01-31","conditions":"Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment","enrollment":42},{"nctId":"NCT03392246","phase":"PHASE2","title":"A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-01-31","conditions":"Non-small Cell Lung Cancer","enrollment":25},{"nctId":"NCT07174388","phase":"","title":"A Study in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"N-Power Medicine","startDate":"2026-01-07","conditions":"Non Small Cell Lung Cancer","enrollment":550},{"nctId":"NCT07213076","phase":"","title":"Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-07-04","conditions":"Non-small Cell Lung Cancer","enrollment":350},{"nctId":"NCT04486833","phase":"PHASE1, PHASE2","title":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","status":"RECRUITING","sponsor":"Genprex, Inc.","startDate":"2021-09-03","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":158},{"nctId":"NCT04743505","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-01-18","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":27},{"nctId":"NCT02411448","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2015-05-06","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":545},{"nctId":"NCT05089916","phase":"PHASE2","title":"Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"AIO-Studien-gGmbH","startDate":"2022-01-20","conditions":"NSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression","enrollment":42},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT07338396","phase":"","title":"A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":3000},{"nctId":"NCT04765059","phase":"PHASE3","title":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-09-12","conditions":"Non-small Cell Lung Cancer","enrollment":98},{"nctId":"NCT04769388","phase":"PHASE2","title":"Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Cancer Prevention & Treatment Society","startDate":"2021-12-28","conditions":"Non Small Cell Lung Cancer","enrollment":80},{"nctId":"NCT05120349","phase":"PHASE3","title":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-02-21","conditions":"Non-Small Cell Lung Cancer","enrollment":390},{"nctId":"NCT02296125","phase":"PHASE3","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-03","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer","enrollment":674},{"nctId":"NCT07329322","phase":"PHASE2","title":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2026-02-01","conditions":"Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT02442349","phase":"PHASE2","title":"Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-06-22","conditions":"Non-Small Cell Lung Cancer","enrollment":171},{"nctId":"NCT04563871","phase":"PHASE2","title":"Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2020-11-17","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":73},{"nctId":"NCT06376084","phase":"","title":"Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-23","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms","enrollment":532},{"nctId":"NCT07322783","phase":"PHASE2","title":"Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification","status":"RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2025-01-01","conditions":"EGFR Positive Non-small Cell Lung Cancer, MET Amplification","enrollment":60},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT07323641","phase":"PHASE2","title":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-02-01","conditions":"Lung Non-Small Cell Carcinoma","enrollment":60},{"nctId":"NCT02511106","phase":"PHASE3","title":"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-10-21","conditions":"Stage IB-IIIA Non-small Cell Lung Carcinoma","enrollment":682},{"nctId":"NCT07315113","phase":"PHASE1","title":"Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nuvectis Pharma, Inc.","startDate":"2025-12-18","conditions":"EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients","enrollment":18},{"nctId":"NCT07303218","phase":"","title":"The HER Project: HRD in EGFR-mutated NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2025-12-01","conditions":"EGFR, Non Small Cell Lung Cancer, Homologous Recombination Deficiency","enrollment":100},{"nctId":"NCT07073365","phase":"PHASE2","title":"Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)","status":"RECRUITING","sponsor":"Pusan National University Hospital","startDate":"2025-07-01","conditions":"Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor","enrollment":70},{"nctId":"NCT03410043","phase":"PHASE2","title":"Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-01-17","conditions":"Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8","enrollment":173},{"nctId":"NCT07079475","phase":"PHASE1, PHASE2","title":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","status":"RECRUITING","sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","startDate":"2025-07-31","conditions":"Non-Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT05629234","phase":"PHASE3","title":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-05-08","conditions":"Cancer","enrollment":37},{"nctId":"NCT03810807","phase":"PHASE1","title":"Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-01-17","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":22},{"nctId":"NCT07295821","phase":"PHASE2","title":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-09","conditions":"Lung Cancer","enrollment":60},{"nctId":"NCT07153055","phase":"PHASE1, PHASE2","title":"Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Misty Shields","startDate":"2026-05","conditions":"Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer","enrollment":16},{"nctId":"NCT07285148","phase":"PHASE1, PHASE2","title":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2026-06","conditions":"Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer","enrollment":253},{"nctId":"NCT05256290","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Black Diamond Therapeutics, Inc.","startDate":"2022-03-31","conditions":"Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma","enrollment":200},{"nctId":"NCT07271446","phase":"PHASE1","title":"An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer","status":"COMPLETED","sponsor":"Precision Biotech Taiwan Corp.","startDate":"2018-09-01","conditions":"Non-small Cell Lung Cancer","enrollment":8},{"nctId":"NCT04780568","phase":"PHASE1","title":"Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2022-01-18","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":24},{"nctId":"NCT05642572","phase":"PHASE2","title":"Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-05-05","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":66},{"nctId":"NCT06670196","phase":"PHASE3","title":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2024-11-27","conditions":"Non-Small Cell Lung Cancer","enrollment":420},{"nctId":"NCT07267247","phase":"","title":"Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2022-06-01","conditions":"Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor","enrollment":100}],"_emaApprovals":[{"date":"17/02/2016","name":"Tagrisso","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[{"role":"Manufacturer","site":"AstraZeneca Pharmaceuticals LP","location":"","operator":"AstraZeneca Pharmaceuticals LP"}],"molecularData":{"oral":true,"chemblId":"CHEMBL3545063","moleculeType":"Small molecule","molecularWeight":"595.73"},"administration":{"route":"Oral","formulation":"osimertinib 40 MG Oral Tablet [Tagrisso]; osimertinib 80 MG Oral Tablet [Tagrisso]; osimertinib 40 MG Oral Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","tradeName":"TAGRISSO"}]},"_patentsChecked":true,"_warningLetters":[{"date":"08/15/2023","subject":"08/04/2023\tAstraZeneca Pharmaceuticals LP\tThe Office of Prescription Drug Promotion (OPDP)\tFalse & M"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"MMSL":"237132","NDDF":"016583","UNII":"3C06JJ0Z2O","CHEBI":"CHEBI:90943","VANDF":"4035124","INN_ID":"10043","RXNORM":"1721559","UMLSCUI":"C4058811","chemblId":"CHEMBL3545063","ChEMBL_ID":"CHEMBL3353410","DRUGBANK_ID":"DB09330","PDB_CHEM_ID":" YY3","PUBCHEM_CID":"71496458","SNOMEDCT_US":"716032009","IUPHAR_LIGAND_ID":"7719","SECONDARY_CAS_RN":"1421373-66-1","MESH_SUPPLEMENTAL_RECORD_UI":"C000596361"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"2009-2012","_source":"Wikipedia","companyName":"AstraZeneca","relationship":"Originator"}],"pharmacokinetics":{"tmax":"Not specified in text","halfLife":"Not specified in text","metabolism":"Metabolized to two pharmacologically-active metabolites (AZ7550 and AZ5104) circulating at approximately 10% of parent drug concentration. AZ7550 shows similar potency to osimertinib; AZ5104 shows greater potency against exon 19 deletion and T790M mutants (approximately 8-fold) and wild-type EGFR (approximately 15-fold).","elimination":"Not explicitly specified in text. Linear pharmacokinetics observed with approximately 3-fold accumulation at steady-state after 15 days of daily dosing.","bioavailability":"Not specified in text"},"publicationCount":4098,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:57:02.300738+00","atcClassification":{"atcCode":"L01EB04","atcName":"osimertinib"},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 27","pmid":"41904893","title":"BMP4-driven morphogenetic reprogramming sustains EGFR-TKI resistance via SOX2 suppression and EMT activation.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2026 Mar 28","pmid":"41904352","title":"Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models.","journal":"Therapeutic innovation & regulatory science"},{"date":"2026 Mar 28","pmid":"41902997","title":"The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression.","journal":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico"},{"date":"2026 Mar 23","pmid":"41899369","title":"Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand.","journal":"Journal of clinical medicine"},{"date":"2026 Mar 16","pmid":"41898563","title":"MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy.","journal":"International journal of molecular sciences"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"2015","enrichmentLevel":4,"visitCount":3,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-08-28T00:00:00.000Z","mah":"ASTRAZENECA","brand_name_local":null,"application_number":"NDA208065"},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"9732058","territory":"US","patent_type":null,"expiry_date":"2032-07-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11524951","territory":"US","patent_type":null,"expiry_date":"2032-07-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8946235","territory":"US","patent_type":null,"expiry_date":"2032-08-08T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10183020","territory":"US","patent_type":null,"expiry_date":"2035-01-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":9,"withResults":4},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:38.500632+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}